Investigation of inducible nitric oxide synthase in an experimental model of chronic heart failure by Miller, Alyson Anne
Investigation of inducible nitric oxide





I dedicate this thesis to my sister
Gillian with love
Declaration
I hereby declare that the work described in this thesis was performed entirely by




I would first of all like to thank my principal supervisor Dr. Gillian Gray for her
continual advice and encouragement throughout my PhD. To Dr. Ian Megson, my
second supervisor, I am thankful for his presence and source of motivation
throughout my PhD, and not to forget his humour and vitality, not only in the
laboratory but in the pub as well. Thank you to the Medical Research Council for
their financial support. There are a number of people who I have worked within the
laboratory that I would like to acknowledge, these include Pauline McEwan, Mark
Miller, Isam Sharif, Mark Patrizio and Manuela Reicht, who have all helped in their
special ways. Of course, my biggest thanks must go to Lorcan Sherry for his charm,
wit and most importantly, his steadfast support over the past three years. Thank you
to Darren Downing for his computing expertise and for all those Jack Daniels he
bought me over the past three years.
Thank you to all my friends in Edinburgh and those who are no longer here. Eilis,
Ian and Heather were always a source of distraction in those early days, thanks guys.
A special thank you must go to my flatmate Hazel and to Catherine, Gillian, Elaine
and Derek who have helped me through the past few months by simply being there.
Finally, I would like to say thanks to my parents and sister for their constant support
throughout my university career.
II
Abstract
Impaired nitric oxide (NO)-mediated vasodilatation has been implicated in the
increased peripheral vascular resistance (PVR) associated with chronic heart failure
(CHF). However, there is evidence that basal synthesis of NO may be preserved or
even enhanced in CHF, perhaps due to the expression of the inducible NO synthase
(iNOS). Increased superoxide production has been demonstrated in CHF and, since
superoxide destroys NO, a reduction in NO bioavailability may be responsible for
impaired NO-mediated relaxations and may also explain why PVR remains elevated
despite increased NO production. Therefore, the aims of this thesis were to
investigate the expression of iNOS in the cardiovascular system in rats with CHF
following coronary artery ligation, to determine the functional significance of this
potential source of NO on responsiveness of the peripheral vasculature and to
investigate the role that superoxide plays in modulating vascular function.
Immunohistochemical studies revealed that iNOS was expressed in all cell types of
small mesenteric arteries and in thoracic aortae from CHF rats. iNOS was also
identified in coronary vascular and endocardial endothelial cells in hearts from CHF
rats. Intense immunoreactive iNOS was also found throughout the viable left
ventricular myocardium of hearts from CHF rats. No staining was found in arteries
or hearts from sham-operated rats.
Prior to commencing functional studies, the pharmacological properties of the novel
iNOS inhibitor, V-(3-(Aminomethyl) benzyl) acetamidine dihydrochloride (1400W),
and the cell permeable superoxide dismutase mimetic, Mn [III] tetrakis [l-methyl-4-
pyridyl] porphyrin (MnTMPyP) were investigated. Experiments revealed that 1400W
was a selective iNOS inhibitor and that MnTMPyP was an effective SOD mimetic.
Despite the presence of iNOS, endothelium-intact small mesenteric arteries
(300 - 350 pm) from CHF rats were hyperesponsive to phenylephrine (PE). Both
1400W and MnTMPyP reversed the hyperesponsiveness. Furthermore, the NOS
substrate, L-arginine reduced responsiveness to PE of endothelium-denuded arteries
III
from CHF rats. None of these drugs altered responses to PE in arteries from sham-
operated rats. Endothelium-dependent relaxations were impaired in arteries from
CHF rats but were restored by MnTMPyP. These results suggest that substrate
deficient, iNOS-derived superoxide may be responsible for this vascular dysfunction
of small mesenteric arteries in this model of CHF.
In endothelium-intact thoracic aortic rings from CHF rats, 1400W has no significant
effect on vascular responsiveness to norepinephrine (NE). Supplementation of
endothelium-denuded aortic rings from CHF rats but not sham-operated rats with
F-arginine, resulted in a significant reduction in responsiveness to NE. However,
MnTMPyP had no significant effect on responsiveness of endothelium-intact aortic
rings from CITF rats. These results suggest that despite being substrate deficient,
iNOS plays no role in modulating vascular responsiveness in conductance arteries in
this model of CHF.
The salient finding of this thesis is that iNOS is expressed in the peripheral
vasculature and in the heart in this model of CHF. However, in small mesenteric
arteries, which play a pivotal role in determining PVR, substrate deficient
iNOS-derived superoxide is responsible for increased responsiveness of these
arteries. In the thoracic aortae, however, iNOS appears to play no role in modulating
vascular function. In conclusion, the findings of this thesis may represent an





Miller, A.A., megson, I.L. & Gray, G.A. (1998). Vascular reactivity in
conductance and resistance arteries in septic shock. Poster presentation at the
'Scottish Cardiovascular Forum', 2nd annual meeting, Edinburgh, September, 1998.
Miller, A.A., Megson, I.L. & gray, G.A. (1999). Increased vascular
responsiveness in a rat model of chronic heart failure, Acta Physiologica
Scandinavia, 167, Suppl 645. Poster presentation at the 'Biology of Nitric Oxide', 6th
International Meeting, Stockholm, September 1999.
Miller, A.A., Megson, I.L. & Gray, G.A. (1999). Vascular Nitric Oxide System
during Chronic Heart Failure. Oral presentation at the Scottish Nitric Oxide
Workshop, 2nd Annual Meeting, St. Andrews, November 1999.
Full Paper
MILLER, A.A., Megson, I.L. & Gray, G.A. (1999). Inducible nitric oxide synthase-
derived superoxide contributes to hyporeactivity in small mesenteric arteries from a
rat model of chronic heart failure, British Journal ofPharmacology, 131 (1), 29 - 36
Paper in Preparation
Miller, A.A., Reicht, M., Megson, I.L. & Gray, G.A. (2001). Investigation of








LIST OF FIGURES XII
LIST OF ABBREVIATIONS XVI
CHAPTER 1 1
General Introduction 1
1.1 The heart 2
1.1.1 Overview of Anatomy 2
1.1.2 The cardiac cycle 3
1.1.3 Control of the heart 4
1.2 The circulation 6
1.2.1 Overview of anatomy 6
1.2.2 The arterial circulation 8
1.2.3 Control of blood pressure 8
1.2.4 The vascular endothelium 10
1.3 Nitric oxide 12
1.3.1 Discovery 12
1.3.2 Nitric oxide synthases 12
1.3.3 Synthesis of nitric oxide 13
1.3.4 Role of calmodulin and tetrahydrobiopterin in the synthesis of nitric
oxide 17
1.3.5 Regulation of nitric oxide synthases 18
1.3.6 Cellular interactions of nitric oxide 20
1.3.6.1 Metal-containing proteins 20
1.3.6.2 Molecular oxygen 21
1.3.6.3 Superoxide 22
1.4 Nitric oxide and the cardiovascular system 23
1.4.1 Vascular tone 23
1.4.1.1 Cellular effects of nitric oxide in the vasculature 23
1.4.1.2 Basal release of nitric oxide 25
1.4.1.3 Agonist-stimulated release of NO 26
1.4.2 Heart 26
1.4.2.1 Introduction 26
1.4.2.2 Regulation of nitric oxide release in the heart 27
1.4.2.3 Cellular effects of nitric oxide in the heart 28
1.4.2.4 Effect of nitric oxide on systolic and diastolic function 28
1.4.2.5 Interaction with the ^-adrenergic pathway 30
1.5. Heart Failure 32
1.5.1 Introduction 32
VI
1.5.2 Chronic heart failure following myocardial infarction 33
1.5.3 Acute response to cardiac injury 34
1.5.4 Chronic heart failure 36
1.5.5 Role of compensatory mechanisms in chronic heart failure 38
1.5.5.1 Cardiac remodelling 38
1.5.5.2 Sympathetic nervous system 39
1.5.5.3 Renin-angiotensin-aldosterone system 41
1.5.5.4 Arginine vasopressin 42
1.5.5.5 Natriuretic peptides 43
1.5.6 Other mechanisms 44
1.5.6.1 Endothelin-1 44
1.5.6.2. Proinflammatory cytokines 47
1.5.6.3 Superoxide 49
1.5.7 Nitric oxide and chronic heart failure 50
1.6 General aims of thesis 54
CHAPTER 2 56
Methods 56
2.1 Animal models used 57
2.1.1 Rat model of septic shock 57
2.1.1.1 Introduction 57
2.1.1.2 Induction of endotoxic shock 59
2.1.1.3 Tissue harvesting and plasma sampling 60
2.1.2 Rat coronary artery ligation model of CHF 60
2.1.2.1 Introduction 60
2.1.2.2 Coronary artery ligation surgery 61
2.1.2.3 Haemodynamic measurements 63
2.1.2.4 Tissue harvesting 64
2.1.2.5 Measurement of infarct size 65
2.2 Functional pharmacological studies of isolated thoracic aorta 67
2.2.1 Preparation of aortic rings 67
2.2.2 General protocol 67
2.3 Functional pharmacological studies of isolated small mesenteric arteries
using perfusion myograph 69
2.3.1 Introduction to technique 69
2.3.2 Preparation of small mesenteric arteries 72
2.3.3 Mounting of arteries in the myograph 74
2.3.4 Protocol for addition of drugs to the perfusion myograph 75
2.3.5 General protocol 76
2.4 Drugs used in functional studies 78
2.5 Immunohistochemistry 79
2.5.1 Introduction 79
2.5.2 Production of Antibodies for Immunohistochemistry 79
2.5.3 Methods used in Immunohistochemistry 80
2.5.4 Preparation of tissues for Immunohistochemistry 81
2.5.5 Protocol for Immunohistochemistry 82




2.6.3 Experimental protocol 87
2.7 Data Analyses 88
CHAPTER 3 89
Investigation of the pharmacological selectivity of the novel inducible
nitric oxide synthase inhibitor 1400W 89
3.1 Introduction 90
3.2 Methods 92
3.2.1 Model of endotoxic shock 92
3.2.1.1 Induction of endotoxic shock, plasma sampling and tissue
harvesting 92
3.2.1.2 Localisation of iNOS by immunohistochemistry 93
3.2.1.3 Measurement of nitric oxide production 93
3.2.1.4 Functional studies in thoracic aortae 93
3.2.2 Investigation of the pharmacological selectivity of 1400W 94
3.2.3 Preparation of drugs 95
3.2.4 Data Analysis 95
3.3 Results 97
3.3.1 Investigation of the expression of iNOS during endotoxic shock 97
3.3.1.1 Immunohistochemical localisation of iNOS 97
3.3.1.2 Plasma nitrite concentrations 97
3.3.1.3. Effect of lipopolysaccharide administration on vascular
responsiveness 97
3.3.2 Investigation of the pharmacological selectivity of 1400W 101
3.3.2.1 KC1, norepinephrine maximal constrictions and endothelial
integrity 101
3.3.2.2 Effect of 1400W on vascular responsiveness in aortic rings from
LPS-treated rats 101
3.3.2.3 Effect of 1400W on basal and agonist-stimulated release of nitric
oxide from eNOS 105
3.4 Discussion 108
CHAPTER 4 113




4.2.1 Tissue harvesting and preparation of aortic rings 116
4.2.2 Experimental protocols 116
4.2.2.1 Model of oxidative stress 116
4.2.2.2 Effects ofMnTMPyP on the activity of eNOS-derived nitric oxide
in pyrogallol-treated aortic rings 119
4.2.2.3 Effect ofMnTMPyP on the synthesis of nitric oxide by eNOS ...119
4.2.2.4 Effect ofMnTMPyP on the synthesis of nitric oxide by iNOS....120
4.2.3 Preparation of drugs 120
4.2.4 Data Analysis 121
4.3 Results 122
VIII
4.3.1 Effects of superoxide generation on the activity of eNOS-derived nitric
oxide 122
4.3.1.1 Basal activity of nitric oxide 122
4.3.1.2 Agonist-stimulated activity of nitric oxide 123
4.3.2 Effects of MnTMPyP on the activity of eNOS-derived nitric oxide in
pyrogallol-treated aortic rings 125
4.3.2.1 Basal activity of nitric oxide 125
4.3.2.2 Agonist-stimulated activity of nitric oxide 126
4.3.3 Effect ofMnTMPyP on eNOS-derived nitric oxide 128
4.3.4 Effect ofMnTMPyP on iNOS-derived nitric oxide 129
4.4 Discussion 131
CHAPTER 5 136
Investigation of the distribution of immunoreactive inducible nitric




5.2.1 Rat coronary artery ligation model of chronic heart failure 139
5.2.2 Haemodynamic measurements, plasma sampling and tissue harvesting
139
5.2.3 Measurement of infarct size 139
5.2.4 Immunohistochemistry 140
5.2.5 Data Analysis 140
5.3 Results 141
5.3.1 Effect of left coronary artery ligation 141
5.3.2 Localisation of inducible nitric oxide synthase in the heart 144
5.3.3 Localisation of inducible nitric oxide synthase in small mesenteric
arteries and thoracic aortae 151
5.4 Discussion 154
CHAPTER 6 160
Investigation of the role of inducible nitric oxide synthase and
superoxide in modulating vascular function of small arteries from rats
with chronic heart failure 160
6.1 Introduction 161
6.2 Methods 163
6.2.1 Tissue harvesting and preparation of arteries from mesenteric bed ....163
6.2.2 Experimental protocols 163
6.2.2.1 Vascular responsiveness of arteries from coronary artery ligation
and sham-operated rats 163
6.2.2.2 Effect of inducible nitric oxide synthase inhibition on vascular
responsiveness 164
6.2.2.3 Effect of superoxide quenching on vascular responsiveness 164
6.2.2.4 Effect of combined inducible nitric oxide inhibition and superoxide
quenching on vascular responsiveness 165
6.2.2.5 Effect of nitric oxide synthase substrate on vascular responsiveness
165
IX
6.2.2.6 Assessment of endothelium-dependent and endothelium-
independent vascular relaxations in arteries from coronary artery ligation
and sham-operated rats in the presence and absence of the SOD mimetic,
MnTMPyP 165
6.2.3 Preparation of drugs 166
6.2.4 Data Analysis 166
6.3 Results 167
6.3.1 Effect of left coronary artery ligation 167
6.3.2 KC1, phenylephrine maximal constrictions and endothelial integrity .167
6.3.3 Assessment of vascular responsiveness to adrenoceptor stimulation in
coronary artery ligation and sham-operated rats 168
6.3.4 Effect of 1400W and MnTMPyP on vascular responsiveness 172
6.3.5 Effect of L-arginine on vascular responsiveness 175
6.3.6 Assessment of endothelium-dependent and endothelium-independent
vascular relaxations in coronary artery ligation and sham-operated rats. Effect
of superoxide quenching 177
6.4 Discussion 183
CHAPTER 7 189
Investigation of the role of inducible nitric oxide synthase and
superoxide inmodulating vascular function of conductance arteries
from rats with chronic heart failure 189
7.1 Introduction 190
7.2 Methods 192
7.2.1 Rat coronary artery ligation model of chronic heart failure 192
7.2.2 Haemodynamic measurements, plasma sampling and tissue harvesting
192
7.2.3 Measurement of infarct size 192
7.2.4 Preparation of aortic rings 193
7.2.5 Experimental protocols 193
7.2.5.1 Vascular responsiveness of aortic rings from coronary artery
ligation and sham-operated rats 193
7.2.5.2 Effect of inducible nitric oxide synthase inhibition on vascular
responsiveness 193
7.2.5.3 Effect of superoxide quenching on vascular responsiveness 194
7.2.5.4 Effect of combined inducible nitric oxide inhibition and superoxide
quenching on vascular responsiveness 194
7.2.5.5 Effect of nitric oxide synthase substrate on vascular responsiveness
194
7.2.5.6 Assessment of endothelium-dependent vascular relaxations in
aortic rings from coronary artery ligation and sham-operated rats in the
presence and absence of the SOD mimetic, MnTMPyP 195
7.2.6 Preparation of drugs 195
7.2.7 Data Analysis 195
7.3 Results 197
7.3.1 Effect of left coronary artery ligation 197
7.3.2 KC1, norepinephrine maximal constrictions and endothelial integrity 198
X
7.3.3 Assessment of vascular responsiveness to adrenoceptor stimulation in
coronary artery ligation and sham-operated rats 199
7.3.4 Effect of 1400W and MnTMPyP on vascular responsiveness 202
7.3.5 Effect of L-arginine on vascular responsiveness 206
7.3.6 Assessment of endothelium-dependent vascular relaxations in coronary





8.2 Future studies 222








Figure 1.1 Diagram of the heart showing major coronary blood 3
vessels
Figure 1.2 Diagram showing the relationship between ventricular 5
end-diastolic volume and stroke volume
Figure 1.3 Diagram showing the morphological characteristics of 7
a blood vessel
Figure 1.4 Endothelium-derived vasoactive factors 11
Figure 1.5 Diagram showing the nitric oxide synthase catalysed 14
reaction of L-arginine to nitric oxide
Figure 1.6 General model of domain organisation of nitric oxide 15
synthase subunits
Figure 1.7 Schematic diagram representing the proposed Frank- 37
Starling relationship in the chronically failing heart
CHAPTER 2
Figure 2.1 Effects of lipopolysaccharide 58
Figure 2.2 A representative pressure-transducer reading of arterial 64
blood pressures and left ventricular end-diastolic
pressures in a coronary artery ligation rat
Figure 2.3 Computer generated image of a longitudinal section of 66
a heart from a rat six weeks post coronary artery
ligation
Figure 2.4 Schematic diagram of a wire and perfusion myograph 71
Figure 2.5 Anatomical selection of third order mesenteric arteries 73
from the rat mesenteric bed
Figure 2.6 Immunohistochemical methods 81
Figure 2.7 Diagram of immunohistochemical method used in this 84
thesis
Figure 2.8 Summary of assay for the measurement of nitrite 86
plasma concentrations
Figure 2.9 Example of a standard nitrite curve 88
CHAPTER 3
Figure 3.1 Localisation of iNOS by immunohistochemistry in 98
thoracic aortae from lipopolysaccharide (LPS)-treated
and control rats
Figure 3.2 Cumulative concentration response curves (CRC) 100
showing contractile responses to norepinephrine (NE)




















Cumulative CRCs to NE in endothelium-intact aortic
rings from LPS-treated rats in the presence of 10"6 M
1400W
Cumulative CRCs to NE in endothelium-intact aortic
rings from LPS-treated rats in the presence of 10~5 M
1400W
Cumulative CRCs to NE in endothelium-intact aortic
rings from LPS-treated rats in the presence of 10"4 M
1400W
Cumulative CRCs to NE in endothelium-intact aortic
rings from control rats in the presence of 1400W
(10"6-10"4M)
Cumulative CRCs to acetylcholine (ACh) in
endothelium-intact aortic rings from control rats in the
presence of 1400W (10" 10"4 M)
An experimental trace showing the effect of pyrogallol
on NE-induced tone in endothelium-intact rat aortic
rings
The effect of pyrogallol on NE-induced tone in
endothelium-intact rat aortic rings
Cumulative CRCs to ACh in endothelium-intact rat
aortic rings in the presence and absence of pyrogallol
The effect of pyrogallol on NE-induced tone in
endothelium-intact rat aortic rings in the presence of
MnTMPyP
Percentage increases in NE-induced tone in pyrogallol
treated endothelium-intact aortic rings in the presence
and absence ofMnTMPyP
Cumulative CRCs to ACh in endothelium-intact rat
aortic rings treated with MnTMPyP in the presence and
absence of pyrogallol
Cumulative CRCs to NE in endothelium-intact rat
aortic rings in the presence and absence of MnTMPyP
Cumulative CRCs to ACh in endothelium-intact rat
aortic rings in the presence and absence of MnTMPyP
Cumulative CRCs to ACh in endothelium-intact aortic
rings from LPS-treated rats in the presence and absence
of MnTMPyP
Images of heart sections from coronary artery ligation




















Figure 5.2 Immunohistochemical localisation of iNOS in heart 145
sections from coronary artery ligation rats six weeks
post-ligation
Figure 5.3 Immunohistochemical localisation of iNOS in heart 146
sections from coronary artery ligation rats six weeks
post-ligation
Figure 5.4 A representative image showing absense of iNOS 147
immunoreactivity in hearts from sham-operated rats
Figure 5.5 Immunohistochemical localisation of iNOS in 149
intramyocardial blood vessels in hearts from coronary
artery ligation rats six weeks post-ligation
Figure 5.6 Immunohistochemical localisation of iNOS in 150
endocardial endothelial cells in hearts from coronary
artery ligation rats six weeks post-ligation
Figure 5.7 Images of representative sections of small mesenteric 152
arteries from coronary artery ligation and sham-
operated rats
Figure 5.8 Images of representative sections of thoracic aortae 153
from coronary artery ligation and sham-operated rats
CHAPTER 6
Figure 6.1 Cumulative CRCs to phenylephrine (PE) in 169
endothelium-intact small mesenteric arteries from
coronary artery ligation and sham-operated rats
Figure 6.2 Cumulative CRCs to PE in endothelium-denuded small 170
mesenteric arteries from coronary artery ligation and
sham-operated rats
Figure 6.3 Effect of 1400W and MnTMPyP on their own or 173
together on cumulative CRCs to PE in endothelium-
intact small mesenteric arteries from coronary artery
ligation rats
Figure 6.4 Effect of 1400W and MnTMPyP on their own or 174
together on cumulative CRCs to PE in endothelium-
intact small mesenteric arteries from sham-operated
rats
Figure 6.5 Effect of L-arginine on cumulative CRCs to PE in 175
endothelium-denuded small mesenteric arteries from
coronary artery ligation rats
Figure 6.6 Effect of L-arginine on cumulative CRCs to PE in 176
endothelium-denuded small mesenteric arteries from
sham-operated rats
Figure 6.7 Cumulative CRCs to ACh in endothelium-intact small 178




Figure 6.8 Cumulative CRCs to ACh in endothelium-intact small 180
mesenteric arteries from coronary artery ligation rats in
the presence and absence of MnTMPyP
Figure 6.9 Cumulative CRCs to ACh in endothelium-intact small 181
mesenteric arteries from sham-operated rats in the
presence and absence of MnTMPyP
Figure 6.10 Cumulative CRCs to sodium nitroprusside (SNP) in 182
endothelium-intact small mesenteric arteries from
coronary artery ligation and sham-operated rats
CHAPTER 7
Figure 7.1 Cumulative CRCs to NE in endothelium-intact and 201
endothelium-denuded aortic rings from coronary artery
ligation and sham-operated rats
Figure 7.2 Effect of 1400W on cumulative CRCs to NE in 202
endothelium-intact aortic rings from coronary artery
ligation rats
Figure 7.3 Effect of MnTMPyP on its own or in combination with 203
1400W on cumulative CRCs to NE in endothelium-
intact aortic rings from coronary artery ligation rats
Figure 7.4 Effect of 1400W on cumulative CRCs to NE in 204
endothelium-intact aortic rings from sham-operated
rats
Figure 7.5 Effect of MnTMPyP on its own or in combination with 205
1400W on cumulative CRCs to NE in endothelium-
intact aortic rings from coronary artery ligation rats
Figure 7.6 Effect of L-arginine on cumulative CRCs to PE in 206
endothelium-denuded aortic rings from sham-operated
rats
Figure 7.7 Effect of L-arginine on cumulative CRCs to PE in 207
endothelium-denuded aortic rings from sham-operated
rats
Figure 7.8 Cumulative CRCs to ACh in endothelium-intact aortic 209
rings from coronary artery ligation and sham-operated
rats
Figure 7.9 Cumulative CRCs to ACh in endothelium-intact aortic 210
rings from coronary artery ligation rats in the presence
ofMnTMPyP
Figure 7.10 Cumulative CRCs to ACh in endothelium-intact aortic 211







ANOVA analysis of variance
ACE angiotensin converting enzyme
ACh acetylcholine
ANP atrial natriuretic peptide
AVP arginine vasopressin
BH4 (6R)-5,6,7,8-tetrah ydrobiopterin
BNP brain natriuretic peptide
BSA bovine serum albumin
cAMP cyclic 3', 5' adenosine monophosphate
CAD coronary artery disease
CAL coronary artery ligation
CHF chronic heart failure
CRC concentration response curve
cGMP cyclic 3', 5' guanosine monophosphate
DETCA detca diethyldithocarbamate
EDHF endothelium-derived hyperpolarizing factor
EDRF endothelium-derived relaxing factor
EDV end-diastolic volume
eNOS endothelial nitric oxide synthase
XVI
ET-1 endothelin-1
FAD flavin adenine dinucleotide
FMN flavin monophosphate
SGC soluble guanylate cyclase
GTP guanosine triphosphate
H202 hydrogen peroxide








MAP mean arterial blood pressure
MI myocardial infarction
MnTMPyP Mn[III]tetrakis[l-methyl-4-pyridyl]porphyrin
NADP nicotinamide adenine dinucleotide phosphate
NADPH reduced nicotinamide adenine dinucleotide phosphate






NYHA New York Heart Association
ONOO" peroxynitrite
PBITU S'S'-(l,3-phenylenebis(l,2 ethanediyl)bisisothiourea
PBS phosphate buffered saline
pD2 negative logarithm of the agonist concentration that
results in a half maximal constriction or relaxation
PE phenylephrine
PGI2 prostacyclin
PKA protein kinase A
PKB protein kinase B
PKC protein kinase C
PVR peripheral vascular resistance
RAAS renin-angiotensin-aldosterone system
TBS tris-buffered saline
TGF-[3 transforming growth factor-(3
SNP sodium nitroprusside
TNF-cc tumour necrosis factor-a








1.1.1 Overview of Anatomy
The wall of the heart is composed of three layers, the inner endocardium which
consists of a layer of endothelial cells, the middle layer, myocardium, which consists
of cardiac muscle, and finally the pericardium, a two layered serous membrane
enclosing the the whole heart. The myocardium is composed of various cells types
including myocardial cells, specialised 'conducting' cells, endothelial cells, vascular
smooth muscle (VSM) cells and connective tissue. The heart is divided into four
chambers: the right and left ventricles and the right and left atria, with the right side
of the heart being separated from the left side by a muscular wall called the
interventricular septum. It is the myocardial cells in the ventricles that are
responsible for pumping blood throughout the body.
Collagen is found in the extracellular space of the myocardium, and serves to support
and align myocytes, blood vessels and lymphatic vessels, preserving the architecture
of the myocardium. The network of collagen also prevents cardiac myocyte slippage
and over stretching. The cardiac connective tissue also includes fibroblasts, which
produce components of the extracellular matrix, namely collagen and fibronectin.
The blood being pumped through the heart chambers does not exchange nutrients
and metabolic waste products with the myocardial cells. They, like the cells of all
other organs, receive blood via arteries that branch off the aorta. Two major coronary
arteries run from the base of the aorta to the left and right ventricles, respectively.
These arteries then branch into smaller arteries, which run down the surface of the
heart towards the apex. The major branch of the left coronary artery, which supplies
blood to the left ventricle, is called the left anterior descending coronary artery
(Figure 1.1). The control of the myocardial oxygen supply lies in the coronary
arterioles, which keep branching until the very small, thin-walled capillaries are
formed. It is here that transfer of oxygen from oxygenated arterial blood to the
myocardial tissues occurs. Endothelial cells in the atrial and ventricular myocardium
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form the lining of both coronary vessels and the fine coronary capillary network that
runs throughout the myocardium, these endothelial cells being termed
myoendothelial cells. At the level of the coronary microvasculature, there is close
contact between endothelial cells and cardiac myocytes throughout the heart, with no
cardiac myocyte being more that 2-3 pm from a coronary vascular endothelial cell




Figure 1.1 Diagram of the heart showing major coronary blood vessels of the
myocardium, including right coronary artery, left anterior descending coroanry
artery and circumflex artery.
1.1.2 The cardiac cycle
The cardiac events occurring from the beginning of one heartbeat to the beginning of
the next constitute the cardiac cycle. In terms ofmechanics, the cycle is divided into
two major phases, both named after the events that occur in the ventricles: the period
of ventricular contraction and blood ejection, systole, followed by a period of
ventricular relaxation and blood filling, diastole. Each cycle is initiated by the








potential travels through the atrium, resulting in both atria contracting almost
simultaneously. The action potential then travels through the atrioventricular (AV)
node, the bundle of His and eventually via the Purkinje fibres. The Purkinje fibres
rapidly distribute the impulse to the ventricles more or less simultaneously, ensuring
a single coordinated contraction.
1.1.3 Control of the heart
Cardiac output is determined by the heart rate multiplied by the stroke volume. Heart
rate is closely controlled by the autonomic nervous system; stimulation of the
sympathetic nervous system increases heart rate, whereas the parasympathetic
nervous system decreases heart rate. The stroke volume is regulated primarily by two
opposing factors: the force with which the myocytes contract and the arterial
pressure (afterload) against which they have to expel the blood.
The force of contraction of the myocyte is a variable, regulated quantity, and can be
increased by two processes. Firstly, Frank-Starling's law states that the more a
myocardial cell is stretched during diastole the greater the energy of the ensuing
contraction. Thus, the amount of blood within the ventricle at the end of diastole
(preload) will determine the force of contraction and hence stroke volume. The
relationship between stroke volume and end-diastolic volume (EDV) is known as
Starling's law of the heart. The physiological significance of this law is that venous
return is an important determinant of stroke volume and hence cardiac output. The
second mechanism for controlling stroke volume is the strength with which a
myocyte contracts from a given initial stretch, 'or inotropic state'. This can be
increased by the sympathetic nervous system and by hormonal influences (Figure
1.2).
The afterload has a negative effect on the stroke volume. This is because the
immediate effect of contraction of the myocardium is not to produce ejection of
blood but to raise the pressure within the ventricle. Ejection of blood can only occur
when the pressure within the ventricle is greater than the pressure in the periphery,
4
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and this consumes a substantial part of the energy available for each contraction.
Therefore, if afterload is increased, more contractile energy is used to raise










Figure 1.2 Diagram showing the relationship between ventricular end-diastolic
volume and stroke volume (Frank-Starling mechanism). Also shown is the effect of




1.2.1 Overview of anatomy
Blood vessels form a tubular network that permits blood to flow from the heart to all
the living cells of the body and then back to the heart. The circulation is divided into
the pulmonary and systemic circulation. In both the pulmonary and systemic
circulation, arteries are responsible for the transportation of blood away from the
heart, whereas veins are responsible for returning blood to the heart. Arteries, leaving
the heart, branch extensively to form smaller microscopic vessels called arterioles,
which subsequently branch into capillaries. Capillaries are the thinnest and most
numerous of blood vessels and it is here that fluids, nutrients and waste products are
exchanged between blood and tissue. Capillaries join with microscopic-sized veins,
called post-capillary venules and venules, which deliver blood into the larger veins,
which in turn return the blood to the heart.
On the basis of strictly morphological characteristics, and excluding capillaries,
blood vessel anatomy is divided into three components (Figure 1.3). The tunica
intima (endothelium) is the innermost layer of blood vessels and consists of flat
endothelial cells adhering to an underlying layer of connective tissue. The
endothelium acts as physical barrier to plasma proteins and cells, and also releases
paracrine substances that modulate blood vessel tone (see Section 1.2.4). The tunica
media (VSM) is the middle layer of the blood vessel and is made up of spindle-
shaped smooth muscle cells, embedded in matrix of elastin and collagen. The media
provides mechanical strength and contractile power. The outermost layer is called the
tunica adventitia (adventitia). The adventitia is a connective tissue sheath
containing various cell types, including fibroblasts, tissue macrophages and Schwann
cells (Rhodin et al., 1980). In addition, the adventita of larger arteries contain small
blood vessels called vasa vasorum, which serve to nourish the thick media. Initially,
it was thought that the adventitia served to hold the blood vessel loosely in place,
however, it is now thought that the adventitia and its cellular components plays a role

















1.2.2 The arterial circulation
The arterial circulation is constructed on the sound principal that each blood vessel
must fulfil at least one other function in addition to the conduction of blood
throughout the body. As a result the structure of blood vessels vary considerably to
meet their functional roles. There are three main types of blood vessels in the arterial
circulation: 1. Elastic arteries (eg aorta, carotid artery) have very distensible walls
as a result of their media being rich in elastin, allowing them to expand an
accomidate the blood from the heart (see Section 1.2.3), 2. Muscular arteries are
characterised by a thicker tunica media layer relative to the lumen diameter, and act
as low-resistance conduits, 3. Resistance arteries have the thickest walls of all
vessel types relative to their lumen. Their narrow lumens and thick muscular walls
make these blood vessels the chief resistance to blood flow (see Section 1.2.3),
1.2.3 Control of blood pressure
Arterial blood pressure is determined by the cardiac output multiplied by the total
peripheral vascular resistance (PVR). As discussed in Section 1.1.3, cardiac output
can be altered by changes in heart rate and stroke volume. Total PVR is the sum of
all the vascular resistances within the systemic circulation. The resistance to laminar
flow arises exclusively from the internal friction between adjacent laminae of fluid
and has nothing to do with friction between the tube and fluid. Nevertheless,
resistance is greatly affected by tube geometry because the radius of the tube affects
the rate of shear (sliding) of the laminae. The properties which determine resistance
were elucidated in 1840 by Jean Leonard Marie Poiseuille. Poiseuille established that
the resistance (R) to the steady laminar flow of fluid along a straight cyclindrical
tube was proportional to tube length (L) and fluid viscosity (r|); and inversely
proportional to tube radius raised to the fourth power (r4):
R oc Lr|/ r4
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When physical constants are added to this relationship, rate of blood flow can now be
calculated according to Poiseuille's law:
Blood Flow = AP r4 (71)/ r\ L (8)
Where: AP = driving force, ie. the difference in pressure between one end of the
tube and the other
The physiological significance of this law is that resistance to blood flow is greatest
in the arteries with the smallest diameter, ie small arteries and arterioles, and as a
censequence these are the most important blood vessels in determining arterial blood
pressure. The radius of arterioles is actively controlled by the tension of smooth
muscle cells in its wall. Owing to the fourth-power effect on resistance, active
changes in radius constitute an extremely powerful mechanism for regulating both
the local blood flow downstream of the arteriole and the arterial pressure.
Larger arteries, while imposing little resistance to blood flow, serve two important
functions in the arterial system. First, these arteries serve a conduit function,
delivering an adequate supply of blood to smaller arteries and arterioles. The second
important role of these arteries, which is complementary to the first, is to transform
pulsatile flow generated by contraction of the ventricles into a continuous flow of
blood in the periphery, sometimes referred to as a cushioning function. In this
cushioning role, larger arteries play an important role in modulating arterial blood
pressure (reviewed by London & Guerin, 1999). Briefly, large arteries distend to
accomidate the entire blood volume ejected from the heart during systole. Arteries
store part of the stroke volume and drain it during diastole. This transforms the
pulsatile flow into an almost continuous blood flow in downstream arteries.
Furthermore, it keeps the rise in arterial blood pressure to a minimum during systole
thus protecting peripheral arteries from high pressures. In addition to their role in
modulating arterial blood pressure, these arteries play an important role in the
effciciency of the heart (Bank et al., 1994). In particular, if the large arteries were not
elastic then the heart would have to accelerate the entire volume of blood in the left
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ventricle to the resistance arteries during early systole. Consequently, the heart would
have to expend more energy in a shorter time. It is clear, therefore, that these arteries
play an important role in the overall efficiency of the cardiovascular system.
1.2.4 The vascular endothelium
As described in Section 1.2.1, the endothelium comprises the innermost layer of all
blood vessels. Initially, it was thought that the endothelium served as physical barrier
to plasma proteins and cells. However, it has been widely demonstrated that the
endothelium plays a pivotal role in the regulation of vascular tone and in the
modulation of various physiological processes, including inflammatory responses,
mitogenesis, fibrinolysis, lipid transport and angiogenesis. The endothelium
modulates the tone of underlying smooth muscle cells, and therefore blood flow and
pressure, by producing a variety of paracrine substances that have vasoactive
properties. Among these are endothelium-derived relaxing factor (EDRF),
endothelin-1 (ET-1), prostacyclin (PGI2), endothelium-derived hyperpolarizing
factor (EDHF) and cyclooxygenase-derived contracting factors (Figure 1.4).
Numerous stimuli can elicit the release of endothelium-derived factors, these include
autocoids released from the tissue, circulating hormones, neurotransmitters, platelet









Figure 1.4 Endothelium-derived vasoactive substances. The endothelium is a source
of relaxing (right) and contracting factors (left). All, angiotensin; ACh,
acetylcholine; ADP, adenosine diphosphate; ATi, angiotensin receptor 1; Bk,
bradykinin; IF, bradykinin receptor 2; cAMP/cGMP, cyclic adnosine/guanosine
monophosphate; ECE, endothelin converting enzyme; EDHF, endothelium-derived
hyperpolarizing factor; 5-HT, 5-hydroxytryptamine; bET-1, big endothelin-1; ET-1,
endothelin-1; ET\, endothelin receptor A; ETb, endothelin receptor B; L-Arg,
L-arginine; M, muscarinic receptor; NO, nitric oxide; NOS, nitric oxide synthase; P,
purinoceptor, PGlh, prostaglandin Hi; PGF, prostacylin; TGFfi, transforming
growth factor /3/; Si, serotonin receptor; T, thrombin receptor; Thr, thrombin; TX,
thromboxane receptor; TXA2, thromboxane /C. Modified from The Endothelium in





The role of the endothelium as the source of a novel 'relaxing factor', EDRF, was
first advanced by in 1980 by Furchgott and Zawadzki when they demonstrated that
the vasorelaxant action of acetylcholine in isolated blood vessels was mediated by a
diffusible factor released from the endothelium (Furchgott & Zawadzki, 1980). Early
studies suggested that EDRF might be a product of the arachidonate pathway (Singer
& Peach, 1983) or the cytochrome P-450 enzyme system (Pinto et al., 1986).
Flowever, six years after his initial discovery, based on the similarities in the
pharmacological properties of EDRF and nitric oxide (NO) generated from acidified
N02", Furchgott suggested that EDRF might be NO. Within one year of this
suggestion two groups had confirmed that the release of NO from the vascular
endothelium accounts for the biological activity of EDRF (Ignarro et al., 1987;
Palmer et al., 1987). It is still uncertain whether EDRF is free NO or labilie nitroso
compound(s) from which NO is liberated, or both (see Section 1.3.6.2; Myers et al.,
1990; Rubanyi et al., 1991; Stamler et al., 1992).
1.3.2 Nitric oxide synthases
Since the discovery of NO, it has been established that many cell types, besides
endothelial cells, are capable of synthesizing NO. The enzymes responsible for the
synthesis of NO are known as the nitric oxide synthases (NOS). In humans, three
isoforms have been identified, neuronal NOS (nNOS), inducible NOS (iNOS) and
endothelial (eNOS). Each isoform is the product of a separate gene and enzymes
share 52% to 58% amino acid homology (Forstermann et al., 1994). In general, the
synthases are grouped into two broad categories: Ca2+/calmodulin-dependent
constitutive type (nNOS and eNOS) and an inducible isoform that is not dependent
on Ca2+/calmodulin (iNOS). Although, recent studies suggest that eNOS can also be




nNOS was the first isoform to be purified and cloned from rat and porcine
cerebellum (Bredt & Snyder, 1990; Mayer et al., 1990). nNOS has since been
localised to tissues and cells other than the brain, including, certain areas of the
spinal cord, peripheral vasomotor nerves, skeletal muscle and cardiac neurons
(Forstermann et al., 1994). NO produced by this isoform of NOS has numerous roles
throughout the nervous system, these include the regulation of synaptic plasticity
(Schuman & Madison, 1991) and central and peripheral nervous control of the
cardiovascular system (Cederqvist et al., 1991; Huang et al., 1995).
iNOS was first purified and cloned from an immunoactivated murine macrophage
cell line (Lowenstein et al., 1992; Xie et al., 1992). The expression of iNOS in
macrophages, and the subsequent production of large quantities of NO, plays a major
role in the immunological defence against infection. (Nathan, 1992). Its expression
can also be induced in almost any cell type, including vascular endothelial and
smooth muscle cells (Schulz et al., 1991; Balligand et al., 1995; Fleming et al.,
1991) and cardiomyocytes (Brady et al., 1992; Balligand et al., 1994), by bacterial
lipopolysaccharide (LPS) and inflammatory cytokines, such as tumour necrosis
factor-a (TNF- a).
eNOS was originally purified and cloned from bovine vascular endothelial cells
(Nishida et al., 1992). In addition to its constitutive expression in arterial and venous
vascular endothelial cells, eNOS is also expressed in cardiac myocytes (Seki et al.,
1996) and endocardial endothelial cells (Schulz et al., 1991). eNOS-derived NO
plays an important role in the control of the cardiovascular system (see Section 1.4).
1.3.3 Synthesis of nitric oxide
The three isoforms of NOS exhibit a similar catalytic profile and composition. Each
isoform of NOS catalyses the five-electron oxidation of the terminal guanido
nitrogen of the amino acid, L-arginine, to form NO and L-citrulline, via the
formation of A^-Hydroxyguanidine (NOHA) as an intermediate (Stuehr & Griffith,
1992; Figure 1.5). The reaction is complex, involving oxygen and nicotanamide
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adenine dinucleotide phosphate (NADPH) as co-substrates, and numerous other
cofactors/coenzymes, including flavins, calmodulin and (6R)-5,6,7,8-
tetrahydrobiopterin (BH4).
H2N^NH2 HjNyj-OH oyNH2
NH ^NHy 1 NADPH r 0-5 NADPH
w. i —— N-0
H3N COO* HgN^COO H3N COO
O? 1 °?2
0 i 0 ® JL 0
L-Arginine N^-Hydroxyguanidine L-citrulline Nitric
Oxide
Figure 1.5 Diagram showing the nitric oxide synthase catalysed reaction of L-
arginine to nitric oxide
All three isoforms of NOS consist of an active homodimer ranging in size from 130 -
162 kDa (Nathan & Xie, 1994). Each inactive monomer is made up of two parts, a
C-terminal flavin-containing reductase domain and a N-terminal haem-containing
oxygenase domain (.Figure 1.6). The reductase domain contains regions that bind
flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD) as prosthetic
groups, as well as a binding site for NADPH. Furthermore, a site for phosphorylation
by cAMP-dependent protein kinase A (PKA) is found in the reductase domain
(Knowles & Moncada, 1994). The oxygenase domain contains a region for the
binding of iron protoporphyrin IX (haem) as a prosthetic group, a binding site for L-
arginine and BH4. The binding site for calmodulin is generally thought to exist
somewhere between the two domains (Bredt et al., 1991; Ghosh & Stuehr, 1995;
Gachhui et al., 1996), although, a recent study demonstrated that eNOS also binds





Figure 1.6 General model ofdomain organisation ofNOS subunits. Each subunit of
NOS contains a reductase and oxygenase domain. Within the reductase domain
binding sites for NADPH, flavin adenine dinucleotide (FAD), flavin mononucleotide
(FMN), whereas the oxygenase domain contains sites for L-arginine (ARG), haem
(Fe) and tetrahyrobiopterin (H4B). Although the diagram shows the binding site for
calmodulin (CAM) to be on the reductase domain, it is thought to be located
somewhere between the two domains. During activation, the subunits are thought to
be aligned head to head at the oxygenase domains, with the reductase domains
attached as independent extensions. Modified from Stuehr: Annual Reviews of
Pharmacology and Toxicology, 1997, 37: 339 - 359.
Despite the structural similarities between the three isoforms, some differences exist.
In contrast to nNOS and eNOS, where calmodulin binding is reversible, iNOS binds
calmodulin extremely tightly (Cho et al., 1992). Indeed, calmodulin remains bound
to iNOS even after denaturing, suggesting that calmodulin is a constitutive part of
this isoform (Cho et al., 1992). The N-terminus of eNOS differs from both nNOS
and iNOS, in that it is dually acylated by the fatty acids myristate and palmitate
(Michel et al., 1997). Both myristoylation (irreversible) and palmitylation
(reversible) are required for targeting of eNOS to specialized plasmalemmal
microdomains called caveolae (Feron et al., 1998). Caveolin, the structural coat
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protein of calveolae, interacts with eNOS and is thought to inhibit the enzyme in a
reversible manner (Michel et al., 1997; Ghosh et al., 1998).
The detailed mechanism by which NOS synthesises NO remains to be established.
However, a unified model has been proposed (Stuehr, 1999). The activity of all three
isoforms is dependent on the dimerisation of the two monomers (Stuehr, 1999) and,
in the case of eNOS, this dimerisation is preceded by its dissociation from caveolin
in the caveolae (Michel et al., 1997). Only the oxygenase domains appear necessary
to form the dimer (McMillan & Masters, 1995). The precise mechanism by which
dimerisation is induced is unclear. Studies suggest that Ca2+/calmodulin binding to
the oxygenase domain is essential for dimerisation of eNOS (Hellermann &
Solomonson, 1997) and for its dissociation from caveolin in the caveolae (Feron et
al., 1998). Ca2+/calmodulin is less important in the dimerisation of nNOS and plays
no role in the dimerisation of iNOS. This is not surprising considering the
constitutive manner in which calmodulin is bound to iNOS. The dimerisation of
iNOS is dependent on the incorporation of haem, and the binding of L-arginine and
BH4 (Baek et al., 1993). In nNOS and eNOS, haem incorporation is also important
but BH4 may not be an absolute requirement despite its ability to stabilise the dimers
once they are formed (Klatt et al., 1995; Venema et al., 1997). A general model for
the structure and domain composition of the dimeric form of NOS is shown in
Figure 1.6. It is has been postulated that the two subunits of NOS align head-to-
head, with the oxygenase domains of each subunit interacting to form the dimer, and
the reductase domains attached as independent extensions (Stuehr, 1999).
The flavin containing-reductase domain exhibits 56% homology to the dual-flavin
enzymes NADPH-cytochrome P-450 reductase and the bacterial sulfite reductase
(Bredt et al., 1992). Because these enzymes all function to transfer electrons from
NADPH to an endogenous or associated haem group, it is thought that the C-terminal
reductase domain of NOS serves to transfer electrons from NAPDH to haem in the
oxygenase domain (Stuehr, 1999). Therefore, the proposed model is as follows;
NADPH-derived electrons, are transferred in a linear sequence across the two
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domains, first entering the flavins and then passing to the haem in the oxygenase
domain. Recent evidence suggests that this transfer of electrons may actually occur
from the reductase domain in one monomer to the oxygenase domain in the other
(Siddhanta et al., 1998). Reduction of the haem moiety allows oxygen to bind and be
reduced. Oxygen is then incorporated into the guanido group of L-arginine giving
rise to the intermediate species, NOHA, which is then oxidised to give NO and L-
citrulline.
1.3.4 Role of calmodulin and tetrahydrobiopterin in the synthesis of
nitric oxide
Calmodulin is a Ca2+-activated regulatory protein that binds to and regulates a
number of enzymes known to respond to changes in intracellular [Ca2+], Calmodulin
is considered to be one of the most important regulatory cofactors in the synthesis of
NO by NOS. In addition to playing an allosteric role in synthesis of NO from eNOS,
calmodulin also plays a catalytic role in all three isoforms. Indeed, Ca2+/calmodulin
is required for maximal activation of nNOS and eNOS. On the basis of electron flow
studies, calmodulin is thought to act as a hinge between the reductase and oxygenase
domains in each monomer (Abu-Soud et al., 1994). When Ca2+/calmodulin is not
bound, the domains are not aligned, and the reductase domain cannot supply
electrons to the haem. When Ca2+/calmodulin is bound, the domains align and the
enzyme is active. The precise mechanism by which Ca2+/calmodulin activates
electron transfer remains to be established, but, a recent study suggested that
Ca2+/calmodulin might induce a conformational change in the reductase domain that
promotes electron transfer (Gachhui et al., 1996). In addition to providing an electron
'bridge', it is thought that calmodulin may also promote electron transfer into the
flavin domain from NADPH (Abu-Soud et al., 1994).
The allosteric and catalytic roles of calmodulin in the synthesis of NO from nNOS
and eNOS account for the Ca2+ dependence of these isoforms and also the
insensitivity of iNOS to calcium. In iNOS, calmodulin is always bound, therefore the




Tetrahydrobiopterin (BH4) is a co-factor of many aromatic amino acid mono-
oxygenases. BH4 is an essential cofactor in the synthesis of NO by all isoforms of
NOS (Mayer et al., 1990). The precise role of BH4 in NO synthesis is not fully
understood. It has been suggested that cooperation exists between the binding sites of
BH4 and L-arginine, with BH4 binding positively modulating the binding of L-
arginine and vice versa (Klatt et al., 1994; McMillan & Masters, 1995). Furthermore,
recent studies reveal that BH4 may play a crucial role in the coupling of electrons
from the flavins to L-arginine (Xia et al., 1998b). Haem-iron is approximately 80%
reducible in the presence of NADPH and L-arginine (Siddhanta et al., 1996), and
reduction is further enhanced in the presence of BH4 (Presta et al., 1998). Binding of
L-arginine to the oxygenase domain of NOS shifts the iron in haem from its low
electron spin state to its higher spin state (McMillan & Masters, 1993). When BH4
binds, the number of iron molecules with their electrons in high-spin state is
increased further (Rodriguez-Crespo et al., 1996; Salerno et al., 1996). Therefore,
BH4 is probably not acting as an electron donor, but is acting with L-arginine to
increase the reduction potential of the iron relative to the flavins and thus make
electron transfer to the haem more thermodynamically favourable (Rodriguez-Crespo
et al., 1996).
1.3.5 Regulation of nitric oxide synthases
The generation of NO from eNOS and nNOS is generally assumed to be dependent
on the binding of calmodulin to the enzyme, which is in turn dependent on the
intracellular concentration of Ca2+. Indeed, many receptor-dependent and -
independent agonists stimulate the release of NO from eNOS and nNOS by elevating
intracellular [Ca2+], However, it is now clear that eNOS and nNOS are also regulated
by a Ca2+/calmodulin-independent mechanism. For example, basal eNOS activity in
native endothelial cells has been reported to occur at Ca2+ concentrations as low as
10 nM (Mulsch et al., 1989). Furthermore, mechanical factors, such as fluid shear
stress, and some receptor-dependent agonists are thought to increase the synthesis of
NO from eNOS, in a Ca2+/calmodulin-independent manner (Ayajiki et al., 1996;
Fisslthaler et al., 2000, see Section 1.4.1.2). It is postulated that the Ca2+/calmodulin-
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independent activation of eNOS is mediated by direct phosphorylation of eNOS. The
precise mechanism by which phosphorylation of eNOS is induced is poorly
understood. However, a number of phosphorlyating kinases have been implicated in
the Ca2+/calmodulin-independent activation of eNOS, including tyrosine kinases,
PKA, cGMP-dependent protein kinases (PKG) and protein kinase B (PKB; Butt et
al., 2000; Fisslthaler et al., 2000). Purified nNOS can also be phosphorylated by
kinases. However, in contrast to eNOS, the activity of nNOS is downregulated by
phosphorylation, suggesting a possible negative feedback regulatory mechanism
(Bredt et al., 1992).
In addition to the acute regulation of eNOS activity, NO production from eNOS can
be modified chronically by altering the expression of the enzyme itself. An increase
in shear stress within a blood vessel, not only increases endothelial release of NO
acutely, but also upregulates the expression of eNOS (Miller & Vanhoutte, 1988).
Indeed, a putative shear stress-responsive element has been described in the
promotor sequence of eNOS (Marsden et al., 1993). The inflammatory cytokine,
tumour necrosis factor-a (TNF-a), down regulates the expression of eNOS in human
umbilical vein endothelial cells (Yoshizumi et al., 1993; Nathan & Xie, 1994). The
mechanism of action of TNF-a has been ascribed to a destabilisation of mRNA for
eNOS (Yoshizumi et al., 1993).
iNOS is not constitutively expressed, but, its expression is transcriptionally regulated
by various inflammatory cytokines and by bacterial LPS. Its activity is not dependent
on Ca2+/calmodulin. Therefore, once it is expressed, there are no regulatory
mechanisms known for the activity of this enzyme.
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NO is capable of interacting with a variety of cellular molecules, including transition
metals, molecular oxygen and superoxide (Stamler et al., 1992). Each of the products
of these reactions - metal-NO adducts, NOx and peroxynitrite (ONOO) respectively -
support additional nitrosative reactions, including S-nitrosation of thiol-containing
proteins and the nitration of tyrosine residues. Not surprisingly, metal and thiol-
containing proteins serve as major target sites for NO. Among these are signalling
proteins (Lander et al., 1993), ion channels receptors (Bolotina et al., 1994) and
enzymes (Gopalakrishna et al., 1993; Stone & Marietta, 1994).
1.3.6.1 Metal-containing proteins
The interaction of NO with haem-containing proteins has been widely studied. The
principal, but by no means exclusive, target for NO is iron in the haem group of
soluble guanylate cyclase (sGC; Stone & Marietta, 1994). Indeed, many of the
physiological effects of NO in the cardiovascular system, such as vasorelaxation and
platelet inhibition, are mediated, in part, by the activation of sGC (see Section
1.4.1.1), By binding to the haem group (Craven & DeRubertis, 1978), NO is thought
to displace the trans-imidazole ligand, which attaches the haem to the enzyme
(Traylor & Sharma, 1992). It is speculated that by displacing the trans-imidazole
ligand for haem, sGC becomes free to undergo conformational changes that in
essence, activate the enzyme (Traylor & Sharma, 1992). It is clear, however, that
further studies are required to establish the precise mechanism by which sGC is
activated. In addition to the activation of haem-containing proteins, NO can inhibit
the activity of enzymes that use a haem prosthetic group as part of their catalysis.
Examples include the cytochrome P-450 reductase enzymes (Stamler et al., 1992).
As discussed in Section 1.3.3, the NOS family of isoenzymes contain haem as a
prosthetic group. Therefore, it is not surprising that the haem of NOS readily binds
NO. Binding of NO to the haem inhibits the activity of NOS in a reversible manner
(Buga et al., 1993), presumably by forming an iron-NO haem adduct and inhibiting
the activity of the oxygenase domain. Thus, the interactions of NO with haem in
NOS may serve as important autoregulatory feedback mechanism for NO synthesis.
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Other haem containing proteins that are thought to be targets of NO include catalase
(Brown, 1995) and cytochrome C (Giulivi, 1998).
NO also forms complexes with non-haem transition metal containing proteins. In
particular, NO forms adducts with the iron-sulphur centres of the mitochondrial
electron transport chain (complex I and complex II), which inhibits their activities
(Clementi et al., 1998).
1.3.6.2 Molecular oxygen
NO is vulnerable to oxidation by molecular oxygen, which results in the production
of various nitrosating species, nitrogen dioxide (NO2), dinitrogen trioxide (N2O3) and
dinitrogen tetraoxide (N204) (collectively called NOx). All three compounds are
capable of nitrosating thiols, resulting in the formation of S-nitrosothiols. Thiol
groups are found in many biological active compounds. The reaction of NOx with
cysteinyl sulhydryl moieties is now appreciated to be responsible for a wide range of
protein modifications (Gaston, 1999). S-nitrosothiols, for example S-
nitrosoglutathione, S-nitrosoalbumin and S-nitrosohaemoglobin, have been
postulated to be putative intermediates of NO, some of which might be present in
sufficient quantities to exert biological effects in their own right (Stamler et al.,
1992; Mayer et al., 1998). S-nitrosothiols have been shown to be potent vasodilators
and inhibitors of platelets (Ignarro et al., 1981; Mellion et al., 1983), and are
considerably more stable than NO (Ignarro et al., 1981). Furthermore, S-nitrosothiols
may mediate some of their effects through activation of sGC (Mayer et al., 1998). It
is postulated that the production of S-nitrosothiols as intermediates of NO, serves to
accentuate the biological effects of NO (Stamler et al., 1992).
S-Nitrosation is thought to regulate the function of many other proteins. Examples
include the down-regulation of Ca2+ currents through the NMDA glutamate receptor
(Lipton et al., 1993), inhibition of the activity of protein kinase C (Gopalakrishna et
al., 1993) and the opening of calcium-dependent potassium channels (Bolotina et al.,
1994). In a similar fashion to NOx, S-nitrosothiols can readily transnitrosoate thiols




As discussed, NO is vulnerable to oxidation by molecular oxygen, however, this
reaction is much slower than its reaction with superoxide. Indeed the reaction of NO
with superoxide occurs at a diffusion-limited rate. The main source of superoxide in
healthy cells is the mitochondrial electron transport chain, but most is inactivated by
the family of isoenzymes, superoxide dimutase (SOD). However, in circumstances
where cells produce increased amounts of superoxide production or have a decreased
antioxidant capacity, NO will react with superoxide, under physiological pH
conditions, to form peroxynitrite (ONOO). ONOO may isomerise to yield NO3




1.4 Nitric oxide and the cardiovascular system
1.4.1 Vascular tone
1.4.1.1 Cellular effects of nitric oxide in the vasculature
NO diffuses from the endothelium to underlying VSM cells where it causes smooth
muscle relaxation. It is generally accepted that NO mediates smooth muscle
relaxation via activation of the sGC/cGMP pathway, but, recent studies suggest that
cyclic guanosine 3', 5' monophosphate (cGMP)-independent mechanisms may also
be involved (Bolotina et al., 1994; Gupta et al., 1994; Mistry & Garland, 1998;
Homer & Wanstall, 2000). Binding to sGC in VSM cells results in the conversion of
guanosine triphosphate (GTP) to cGMP. It is generally accepted that cGMP triggers
relaxation of VSM cells by initiating an intracellular cascade, which is ultimately
dependent on the activation of cGMP-dependent protein kinases (PKG; Carvajal et
al., 2000). The precise mechanism by which PKG mediates VSM relaxation is poorly
understood, however, two mechanisms have been proposed (Carvajal et al., 2000).
The first is a reduction in intracellular [Ca2+] and the second is the reduction in the
sensitivity of the contractile apparatus of VSM cells to Ca2+.
Several investigators have shown in rat mesenteric artery, guinea pig and human
trachea, isolated porcine tracheal smooth muscle cells and the Chinese Hamster
ovary that activation of the cGMP-PKG pathway increases the activity
Ca2+-activated K+ channels by phosphorylation of either the channel protein or a
regulatory protein (Yamakage et al., 1996; Zhou et al., 1996; Mikawa et al., 1998;
Tanaka et al., 1998). Similarly, studies have shown that PKG may activate the
plasmalemmal and sacroplasmic reticulum (SR) Ca2+/ATPase pump (Comwell et al.,
1991; Rashatwar et al., 1987; Furukawa et al., 1988). Activation of Ca2+-activated
K+ channels and the plasmalemmal Ca2+/ATPase pump serve to increase Ca2+ efflux
from the cell, whereas SR Ca2+/ATPase pump increases the uptake of Ca2+ into the
SR. Membrane voltage-dependent Ca2+ channels, which normally open in response
to membrane depolarisation, can also be regulated by various protein kinases (Tewari
& Simard, 1997). It has been suggested that PKG can phosphorylate the Ca2+ channel
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or a closely associated regulatory protein, reducing the possibility that the channel
remains in its open state (Tewari & Simard, 1997). Further to its effects on channels
there is evidence to suggest that PKG can inhibit inositol triphosphate and its
receptor (Lincoln & Cornwell, 1993; Komalavilas & Lincoln, 1996), which
ultimately decrease the efflux of Ca2+ from the SR.
The mechanism of PKG-induced Ca2+ desensitisation is unknown, although several
theories have been proposed. Studies using isolated smooth muscle cells have
demonstrated that cGMP-PKG pathway results in an increase in the activity of
myosin light chain phosphatase (MCLP; Wu et al., 1996; Lee et al., 1997). This is
thought to decrease the phosphorylation of the contractile apparatus, resulting in a
decrease in its sensitivity to Ca2+. In cultured rat aortic smooth muscle cells, the
cGMP-PKG pathway has been shown to inhibit protein kinase C (PKC) activation
induced by angiotensin II and ET-1 (Kumar et al., 1997). This supports a role for
PKC inhibition as part of the decrease in Ca2+ sensitivity induced by cGMP (Kumar
et al., 1997), especially in those muscles in which PKC plays a role in smooth
muscle contraction.
The cGMP-independent component of NO-induced smooth muscle relaxation is less
well defined. Numerous studies have demonstrated that NO activates Ca2+-dependent
K+ channels in a manner that is independent of the sGC/cGMP pathway (Bolotina et
al., 1994; Mistry & Garland, 1998). In isolated rabbit aorta, NO stimulated Na+/K+-
ATPase by a mechanism that was not blocked by a GC inhibitor (Gupta et al., 1994).
Furthermore, a recent study demonstrated that the NO donor, spermine NONOate,
resulted in cGMP-independent relaxation of isolated pulmonary arteries by a
mechanism that involves activation of Na+/K+-ATPase, SR Ca2+-ATPase and Ca2+-
activated K+ channels (Homer & Wanstall, 2000). It is unclear if cGMP-independent
mechanisms of NO-induced smooth muscle relaxation involve upstream secondary
messengers. Interestingly, Bolotina et al. (1994) demonstrated that cGMP-
independent activation of Ca2+-dependent K+ channels was dependent on the
modification of sulphydryl groups within the channel, suggesting that NO-mediated
S-nitrosation may be involved in the activation of these channels.
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1.4.1.2 Basal release of nitric oxide
Mechanical forces are amongst the most important stimuli determining the release of
NO. The endothelium is continuously exposed to shear stress, or viscous drag, from
the blood and pulsatile stretching due to the beating of the heart. It has been widely
demonstrated that these physical forces stimulate the release of NO from vascular
endothelial cells (Hutcheson & Griffith, 1991; Ayajiki et al., 1996; Fisslthaler et al.,
2000). The mechanisms by which the endothelium is able to sense changes in shear
stress/pulsatile stretch on its luminal surface remain obscure. However, mechanical
disruption/deformation of the endothelial cytoskeleton and subsequent transmission
of the force from the cell surface to intracellular compartment has been suggested as
a possible mechanism (Ingber, 1997).
There is some evidence that shear stress can increase intracellular [Ca2+] by opening
ion channels (Mo et al., 1991). However, basal release of NO from the endothelium
is evident in native endothelial cells at Ca2+ concentrations as low as 10 nM (Mialsch
et al., 1989). It has been suggested that shear stress/pulsatile stretch activates eNOS
in a Ca2+/calmodulin-independent manner, possibly by inducing phosphorylation of
eNOS (Ayajiki et al., 1996; Fisslthaler et al., 2000; Nakano et al., 2000).
As a result of the assiduous exposure of blood vessels to mechanical stress, NO is
released from the endothelium in a continuous, basal fashion. Indeed, inhibition of
eNOS reduces blood flow in virtually every arterial bed studied, including
pulmonary and cardiac, demonstrating that NO plays an important role in
maintaining blood flow through tissues (Lefroy et al., 1993; Stamler et al., 1994).
Not surprisingly, the release of NO from resistance arteries plays a pivotal role in the
regulation of total PVR and hence systemic arterial blood pressure. Indeed, systemic
blockade of NO generation in humans using non-selective inhibitors of NOS, e.g.
A^-monomethyl-L-arginine (L-NMMA), results in an immediate rise in systemic
arterial blood pressure (Haynes et al., 1993; Stamler et al., 1994). Knocking out the
gene encoding eNOS in mice results in a significant hypertension (Huang et al.,
1995). Furthermore, the importance of eNOS-derived NO in the regulation of blood
pressure and vascular homeostasis was further highlighted by the observation that a
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missense variant of eNOS (Glu289Asp) in exon 7 of the eNOS gene is positively
associated with essential hypertension and myocardial infarction (Miyamoto et al.,
1998).
As discussed in Section 1.2.3, the main functional role of conductance arteries is to
dampen the pressure oscillations that are caused by the intermittent nature of
ventricular ejection. This cushioning effect is determined by the elastic properties of
arterial walls (London & Guerin, 1999). There is substantial evidence that VSM tone
plays a role in modulating the elastic properties of conductance arteries (Dobrin &
Rovick, 1969; Wilson et al., 1995; Bank, 1997; Joannides et al., 1997). Furthermore,
evidence suggests that the basal release of NO from the endothelium serves to
increase arterial compliance (Bank et al., 1994; Joannides et al., 1997).
1.4.1.3 Agonist-stimulated release of NO
Many endogenous agonists can increase the release of NO from the endothelium,
these include histamine, ADP, bradykinin, ET-1, thrombin and norepinephrine. It is
generally accepted that these agonists act through specific receptors on the
endothelial cell surface, to increase intracellular [Ca2+] and thus activate eNOS.
However, recent studies suggest that the effects of these agonists on eNOS, may be
mediated, in part, by a Ca2+/calmodulin-independent mechanism (Butt et al., 2000).
In a similar fashion to the effects of mechanical forces on eNOS activity, it is
proposed that agonists, such as bradykinin, can also induce phosphorylation of eNOS
and subsequent activation (Butt et al., 2000).
1.4.2 Heart
1.4.2.11ntroduction
NO derived from the endothelium has the potential to indirectly influence cardiac
function secondary to alterations in 1) arterial tone 2) venous return and hence left
ventricular (LV0 filling volume, thereby modulating the cardiac output via the
Frank-Starling mechanism and 3) coronary vascular tone and perfusion. In addition
to these indirect effects, NO has direct actions on the functioning of cardiomyocytes.
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Over the past decade, it has become apparent that complex, paracrine interactions
exist between endothelial cells and cardiomyocytes in the heart, analogous to the
paracrine crosstalk between endothelial cells and VSM cells. Two types of
endothelial cells exist in the heart, namely endocardial endothelial cells
(endocardium) and endothelial cells of the coronary vasculature. eNOS is expressed
in the endocardium, the coronary endothelium (Schulz et al., 1991), and at a much
lower level in cardiomyocytes (Seki et al., 1996). Furthermore, eNOS is expressed in
the conducting system of the heart (Han et al., 1996). In the intact mammalian heart,
it is likely that NO released from the vascular endothelial cells is of greater
physiological importance than the NO released from the endocardium. This is
because no cardiac myocyte is more than 2-3 pm from a vascular endothelial cell,
contrasting with the endocardium which lines the inner cavity surfaces, and is
therefore likely to only influence subjacent myocytes (Shah & MacCarthy, 2000).
1.4.2.2 Regulation of nitric oxide release in the heart
Specific studies for eNOS activation in cardiomyocytes, coronary vascular
endothelial cells and endocardial endothelial cells are lacking. However, as with the
vascular endothelium, the most relevant physiological stimuli for the release of
eNOS-derived NO in the heart are likely to be physical forces, i.e. flow-induced
shear stress and mechanical deformation (stretch). During the cardiac cycle, these
physical forces will oscillate, and it has been suggested that the release and action of
NO in the heart may also be cyclic. Indeed, with the use of an NO sensor, Pinsky et
al. (1997), demonstrated that there is a cyclical release of NO in the beating heart.
Furthermore, there is a sharp rise in the release of NO during diastole. Conceivably,
changes in workload of the heart, possibly even beat to beat, may be reflected in
changes in the release of NO.
As with the vascular endothelium, the coronary vasculature and the endocardium are
continuously exposed to the blood. Therefore, the activity of eNOS will be
susceptible to regulation by circulating humoral factors. Furthermore, factors




1.4.2.3 Cellular effects of nitric oxide in the heart
The effects of NO on cardiomyocytes are complex. A number of studies have been
published concerning the cellular effects of NO on the heart, and multiple and
complex contradictory actions have been reported. As in VSM cells, many of the
cardiac effects of NO have been attributed to the elevation of intracellular cGMP,
secondary to the activation of sGC. However, cGMP-independent mechanisms may
also contribute. The main targets for cGMP are PKG and cGMP-stimulated and -
inhibited cyclic nucleotide phosphodiesterases (cGsPDE and cGiPDE, respectively).
However, it is possible that cGMP-activated phosphatases and cGMP-regulation of
ion channels may be important. Reported actions of cGMP on cardiac myocytes
include, 1) modulation of sacrolemmal Ca2+ influx through voltage-gated Ca2+
channels, 2) reduction in the sensitivity of the contractile apparatus to Ca2+, 3) altered
release of Ca2+ from SR, 4) changes in the action potential, 5) modulation of the cell
volume, and 6) reduction in oxygen consumption (Shah & MacCarthy, 2000).
Some of the actions of NO in the myocardium may be mediated by cGMP-
independent mechanisms. A recent study demonstrated that NO stimulates cyclic
adenosine monophosphate (cAMP) in cardiomyocytes (Vila-Petroff et al., 1999).
Other possible cGMP-independent mechanisms include S-nitrosation of thiol groups
and the formation of adducts with iron-sulphur containing proteins (see Section
1.3.6). However, cGMP-independent effects may be more relevant when large
amounts of NO are produced, for example as a result of iNOS expression (Shah &
MacCarthy, 2000).
1.4.2.4 Effect of nitric oxide on systolic and diastolic function
While the role of NO in control vasomotor tone is well established, the physiological
significance of eNOS-derived NO on the functioning of the heart is not fully
understood. Many studies that have investigated the effects of NO on myocardial
function have focused in the modulation of systolic function, i.e. inotropic state.
However, in studies where full analysis of myocardial performance have been
undertaken, NO has also been shown to exert significant effects on myocardial
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relaxation and diastolic properties, often in the absence of changes in systolic
function.
Using NO donors, recent studies have demonstrated that submicromolar
concentrations of NO have a small positive inotropic effect on the basal contractile
function of cultured rat myocytes (Kojda et al., 1996; Vila-Petroff et al., 1999).
Similarly, in isolated human atrial myocytes, an NO donor (sodium nitroprusside;
SNP) exerted positive inotropic effects (Kirstein et al., 1995). In anaesthetised dogs,
intra-aortic infusion of NOS-inhibitors induced a significant inotropic effect, despite
an only moderate increase in mean aortic pressure and a lack of reduction of
coronary blood flow (Klabunde et al., 1991). This was interpreted as endogenous NO
having a positive inotropic effect. A possible subcellular mechanism for the positive
inotropic effects of NO may be via cGiPDE and a subsequent rise in intracellular
cAMP levels (Kirstein et al., 1995; Kojda et al., 1996; Vila-Petroff et al., 1999). In
contrast to the effects of low concentrations of NO, higher (micromolar and above)
doses of NO donors have been reported to induce negative inotropic effects (Brady et
al., 1993; Mohan et al., 1996). Inhibition of endogenous NOS in isolated
cardiomyocytes has been shown to have no effect on function, suggesting a lack of
effect of NO on basal myocardial function and that endogenous myocardial NO may
be derived from the endocardium and vascular endothelial cells.
In the isolated ferret papillary muscle preparation, exogenous donors of NO,
substance P and a cGMP-analogue all resulted in an earlier and faster onset of LV
relaxation and a reduction in the peak tension developed before systole (Smith et al.,
1991). An effect of NO and cGMP on twitch relaxation and diastolic properties has
also been reported in isolated cardiac myocytes. In adult rat ventricular myocytes, a
cGMP analogue caused an earlier onset of relaxation and an increase in diastolic cell
length (Shah et al., 1994). Furthermore, this effect was mediated without altering the
intracellular [Ca2+], It was concluded that the effects of NO were mediated by a
reduction in the sensitivity of the contractile apparatus (myofilaments) to Ca2+
probably via PKG (Shah et al., 1994).
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Daring diastole, filling of the LV with blood stretches the myofilaments of the
myocytes, which ultimately determines the amount of blood that is ejected from the
ventricle. It has been postulated that stretching of myocytes may be mediated by
changes in myofilament responsiveness to Ca2+ (Shah & MacCarthy, 2000). Thus it
is conceivable that the release of NO during diastole, serves to increase diastolic
distensibilty by reducing Ca2+ sensitivity, and thus facilitate the Frank-Starling
response of the whole heart. Furthermore, since the release of NO may be dependent
on the amount of stretch imposed on the cardiac endothelium, NO may provide an
acute autoregulatory feedback mechanism between LV workload and diastolic LV
performance, thus optimising overall pump function. For example, during periods of
increased LV workload, such as during exercise, the accompanying increases in heart
rate, preload, contractility and coronary flow would result in increased stimuli for
NO release (eg. increased fluid shear stress in the coronary vasculature and increased
stretching of the endocardium and myocytes). The subsequent increase in NO
synthesis could hasten LV relaxation, thus prolonging diastolic filling time and
coronary perfusion. Furthermore, NO may increase the distensibility of the left
ventricle, thus improving LV filling and, therefore, cardiac output. Indeed,
intracoronary infusion of SNP in patients with angiographically normal coronary
arteries and normal LV function resulted in: 1) an earlier onset of LV relaxation; 2) a
concomitant reduction in peak and end-systolic LV pressure; 3) a fall in LV
minimum diastolic pressure and LV end-diastolic pressure, with a rise in LV end-
diastolic volume; and 4) a downward and rightward displacement of the LV diastolic
pressure-volume relationship (Paulus et al., 1994). Furthermore, a subsequent study
by Paulus et al. (1995) reported similar effects of bicoronary infusion of substance P
on LV relaxation and diastolic function in subjects with normal cardiac function.
Thus, both exogenous and endogenous NO modulates myocardial relaxation and
diastolic properties.
1.4.2.5 Interaction with the (3-adrenergic pathway
Numerous studies have been carried out to investigate a possible role for NO in
modulating (3-adrenergic responses (Balligand et al., 1993). Balligand et al. (1993)
were the first to report that the inotropic response of adult rat ventricular myocytes to
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the ^-adrenergic agonist isoprenaline was enhanced by approximately 30% following
application of an NOS inhibitor. However, these findings have not been universally
confirmed. In isolated rat perfused hearts, the inotropic response to isoprenaline was
unaffected by infusion of a NOS inhibitor (Ebihara & Karmazyn, 1996). In contrast
to these studies with NOS inhibitors, most investigators have been able to
demonstrate interactions between exogenous NO and (3-adrenergic responses. For
example, in isolated rat perfused hearts, the inotropic response to dobutamine was
reduced by NO donors (Ebihara & Karmazyn, 1996). An interaction between
endocardium-derived NO and (3-adrenergic stimulation has also been demonstrated
(Bartunek et al., 1997). It is clear, therefore, that more research is needed to elucidate





The understanding, investigation and treatment of chronic heart failure (CHF) in the
medical profession, has improved substantially in the last 20 years. However, CHF is
still a major cause of cardiovascular mortality and morbidity, accounting for 5% of
acute hospital admissions in the UK (Sutton et al., 1997). Furthermore, in USA it is
the most common hospital-discharge diagnosis among patients older that 65 years
(Lenfant, 1994). Once a patient has developed CHF, the quality of life and life
expectancy is markedly reduced. Indeed, a recent study estimated a 6 year mortality
rate of 84% for men and 77% for women (Croft et al., 1999). The life expectancy of
the population has increased substantially over the past 50 years, and it is projected
that as the population ages, the incidence of CHF, and its resulting mortality, will
markedly rise over the next decade. It is clear, therefore, that there is a need for
extensive research into the pathogenesis of CHF and the development of novel
therapeutic tools.
Traditionally, CHF is defined as a clinical syndrome typified by the inability of the
heart to meet the metabolic requirements of the body. For the past 50 years the
pathophysiology of this disease has largely been described in haemodynamic terms.
According to this model, CHF follows damage to the heart, eg. after myocardial
infarction (MI), which impairs its ability to eject blood; renal blood flow is reduced
and subsequent sodium retention leads to pulmonary and peripheral oedema. Indeed,
this focus on haemodynamics led to an increase in the use of digitalis to increase the
inotropic state of the heart, and diuretics in the treatment of CHF (Packer, 1992).
However, it is now well established that CHF is a disorder of the circulation, not
merely a disease of the heart. For example, many patients have structural cardiac
damage that adversely affects systolic and diastolic function, but they do not have
CHF because compensatory mechanisms maintain cardiac output and peripheral
perfusion. Therefore, CHF is not exlusively linked to heart damage but also requires
failure of compensatory mechanisms that usually maintain cardiovascular
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homeostasis. Indeed, it is now established that these compensatory mechanisms play
a pivotal role in the pathophysiology of CHF (Packer, 1992). The progression from a
compensated state to overt CHF, and the factors that are involved in this progression
remains an important focus for medical research in the 21st century.
1.5.2 Chronic heart failure following myocardial infarction
CHF may occur as the result of myocardial damage caused by a number of disease
processes such as coronary artery disease (CAD), hypertension, valvular disease,
alcohol misuse and viral infection (myocarditis; Cowie et al., 1997). Each disease
holds its own complex pathology, but, they all result in irreversible impairment of
myocardial function. Furthermore, impairment of LV function is the main cause of
CHF, although right ventricular dysfunction also occurs. Impaired LV function may
be global, as in hypertension, valvular disease, alcohol misuse and myocarditis, or
regional as result of MI following CAD.
The most common cause of CHF in Western society is MI secondary to CAD
(McMurray et al., 1992). CAD most often results from atherosclerosis, where fat
deposits on the inside of the coronary artery and leads to the formation of a plaque.
The initial stage of this disease consists of an asymptomatic period where the non¬
obstructive plaque is formed with further progression dependant on associated risk
factors. The obstructive stage, however, involves rapid rupturing of the plaque,
thrombogenesis and the development of an occlusive or near occlusive thrombus
(Falk et al., 1996).
The size of the MI is dependent on the extent of the occlusion, its position within the
coronary vasculature, the duration in which the artery remains occluded, LV oxygen
consumption and collateral blood flow (Maroko et al., 1971; Schaper & Pasyk,
1976). Initially, impaired coronary blood flow and oxygen supply to the affected area
of the myocardium results in extensive biochemical and morphological changes in
the myocardial cells (Poole-Wilson, 1989). Acute deprivation of oxygen to
myocardial cells will, after 10-15 seconds, lead to a rapid decrease in oxygen and
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high-energy phosphates, which ultimately result in a shift from aerobic to anaerobic
metabolism. After a prolonged period of ischaemia, the accumulation of anaerobic
waste products and a reduction in energy stores results in irreversible myocardial cell
damage and death. In addition, there is experimental and clinical evidence that
programmed cell death or apoptosis is a major source of myocardial cell death during
myocardial ischaemia (Kajstura et al., 1996; Saraste et al., 1997).
Necrosis and/or apoptosis are followed by a process of degradation and clearance of
damaged myocardial cells. This is thought to involve a complex interplay of
inflammatory cells, such as neutrophils and macrophages (reviewed by Entman et
al., 1991). A scar, composed principally of collagen, then replaces the damaged
myocardium (reviewed by Weber, 1997).
1.5.3 Acute response to cardiac injury
After MI, the heart is unable to sustain stroke volume due to a loss in myocardial cell
mass and as result cardiac output falls. A complex interplay of haemodynamic and
neurohormonal mechanisms are activated to maintain cardiovascular homeostasis.
Decreased stimulation of baroreceptors in the aortic arch, carotid sinus and the left
ventricle, as a result of a reduced cardiac output, leads to an increase in sympathetic
outflow from the autonomic nervous system. Increased sympathetic activation
enhances the force and frequency of contraction of the non-injured myocardium and
causes systemic vasoconstriction. Subsequent hypoperfusion and direct sympathetic
innervation of the kidney activate the renin-angiotensin-aldosterone system (RAAS).
Furthermore, stimulation of baroreceptors in the aortic arch and left ventricle
promotes the release of arginine vasopressin (AVP) from the pituitary gland. All
three systems serve to increase blood volume, total PVR and thus aid perfusion of
organs.
Increased blood volume also results in an augmentation in venous return to the heart.
As discussed in Section 1.1.3, the stroke volume is dependent on the stretch of the
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myofilaments, which in turn is dependent of the EDV. Therefore, during the acute
response to cardiac injury, a greater EDV, as a result of increased venous return, will
impose more stretch on the myocardium, resulting in an increase in the contractile
state of the myocardium. This effectively shifts the Frank-Starling curve to the right,
resulting in increased cardiac output.
In addition to the rapid activation of haemodynamic and neurohormonal
compensatory mechanisms, the heart itself undergoes structural changes to
compensate for the loss of viable myocardial cells. Increased total PVR and EDV
increases the internal stretch exerted on the heart wall during diastole. This can
dramatically distort its architecture and accelerate its energy expenditure. To prevent
such adverse structural and functional effects, the heart undergoes a process called
hypertrophy. The hypertrophied response is characterised by increased
cardiomyocyte cell volume, proliferation of non-myocyte cells and increased
myofibrillar protein expression (Rumberger, 1994). Stretching of cultured cardiac
myocytes increased protein content by approximately 30% (Sadoshima et al., 1992).
Furthermore, analysis of cell signalling mechanisms shows that physical stress
activates multiple signal transduction pathways, similar to those activated by growth
factors (Swynghedauw, 1999). Indeed, a recent study provided evidence that cardiac
hypertrophy in vivo is regulated by the stress-activated protein kinases, which belong
to the mitogen-activated protein kinase family (Gabriel et al., 1999). Although
mechanical stretch is possibly the most common stimulus for hypertrophy, the
sympathetic nervous system and RAAS may also play a role (Colucci, 1997). The
subsequent increase in wall thickness reduces ventricular stress and restores the




1.5.4 Chronic heart failure
Compensatory mechanisms serve to restore cardiovascular homeostasis, and may be
sufficient for the patient to remain asymptomatic for some time. In general, however,
with time these compensatory mechanisms appear to fail and may even become
detrimental to the diseased heart. As a result, myocardial function declines further,
cardiovascular homeostasis is no longer maintained and the patient develops
symptoms of CHF. The pathological development of CHF translates into distinct, if
overlapping, stages in clinical presentation and can be classified according to the
New York Heart Association (NYHA) scaling system. Patients are categorised as
NYHA Class I, II, III or IV (see Table 1). Classes II, III and IV are regarded as mild,
moderate and severe CHF respectively, while patients in Class I are regarded as very
mild (Timms & Davies, 2000).
Class Symptoms
I Cardiac disease but without resulting limitation of physical activity.
II Cardiac disease but with slight limitation of physical activity, comfortable at rest.
Ordinary physical activity results in fatigue, palpitation, dyspnoea or anginal pain.
III Cardiac disease resulting in marked limitation of physical activity but comfortable
at rest.
Less than ordinary physical activity causes fatigue, dyspnoea or anginal pain.
IV Cardiac disease resulting in the inability to perform any physical activity without
discomfort, often discomfort at rest.
If any physical activity is undertaken, discomfort is increased.
Table 1 NYHA classification ofchronic heartfailure
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In practice, CHF may be diagnosed whenever a patient develops signs or symptoms
of low cardiac output, pulmonary congestion and/or systemic venous congestion.
Where increases in EDV restore cardiac output in the acute response to cardiac
injury, in the chronic state a progressive decline in the functioning of the
myocardium requires even higher volumes to maintain cardiac output. As a
consequence of working with higher EDVs, with time the heart is left with little or
no reserve. As a result, it becomes insensitive to changes in venous return. It is
proposed that in CHF the Frank-Starling curve is shifted to the right and becomes
flatter ( Figure1.7). The physiological consequence of this decline in LV
performance is that the heart is unable to match cardiac output to the needs of the
body. In cases of severe CHF, the heart may even fail to maintain cardiac output at
rest. Furthermore, an inability of the heart to eject all the blood in the left ventricle
into the periphery, results in an accumulation of fluid in the pulmonary circulation,
which results in pulmonary congestion.
Figure 1.7 Schematic diagram representing the proposed Frank-Starling
relationship in the chronically failing heart (CHF; red line), compared with a








The precise mechanism responsible for the progressive decline in LV function is not
well defined. Research suggests that it is likely to involve a complex interplay of
multiple systems including failure of compensatory mechanisms, adverse effects of
long-term activation of compensatory mechanisms and the activation of other
potentially adverse systems, possibly as a consequence of the disease progression.
The role of such mechanisms is discussed in Sections 1.5.5 and 1.5.6,
1.5.5 Role of compensatory mechanisms in chronic heart failure
1.5.5.1 Cardiac remodelling
During CHF, the left ventricle experiences changes in structure and function that are
referred to as remodelling. This process of remodelling is characterised by further
hypertrophy, changes in extracellular matrix composition and loss of myocardial
cells either by necrosis or apoptosis (Colucci, 1997).
As discussed in Section 1.5.3, hypertrophy is an important compensatory
mechanism; reducing internal stress and helping to restore cardiac output. However,
there is a downside to this altered geometry. In the long term, an increase in
ventricular size requires the heart to contract even more to expel the blood, as
explained by Laplace's Law (Julian & Cowan, 1992). This law states that the tension
of the myocardium is proportional to the intraventricular pressure multiplied by the
radius of the ventricular chamber. This need for a higher contractile state increases
internal stress within the LV, promoting further hypertrophy and ventricular
enlargement. Furthermore, numerous neurohumoral factors are believed to play a
role in promoting hypertrophy, these include cq-adrenoceptor agonists (Knowlton et
al., 1993), angiotensin-II (Gray et al., 1998) and ET-1 (Mullan et al., 1997).
Therefore, although appropriate hypertrophy of the myocardium compensates for
myocardial loss in the acute state, excessive hypertrophy is believed to be
maladaptive and to be associated with the progressive decline in the functioning of
the non-infarcted myocardium (Sakai et al., 1998).
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In addition to hypertrophy, CHF often results in changes in the extracellular matrix
of the heart. Indeed, the chronically failing human heart is characterised by increased
collagen synthesis in the infarcted and noninfarcted myocardium of both right and
left ventricles (Beltrami et al., 1994). An accumulation of collagen is believed to
increase the stiffness of the failing heart, which may impair the contractility and/or
relaxation of the myocardium. In a rat model of CHF, myocardial fibrosis and
stiffness impaired the diastolic properties of the heart (Conrad et al., 1995).
Numerous factors have been implicated in fibrosis, including angiotensin II
(McEwan et al., 1998) inflammatory cytokines (Castagnoli et al., 1993; Bryant et al.,
1998; Ono et al., 1998), transforming growth factor-(3 (TGF-(3; Parker et al., 1990)
andET-1 (Mullan et al., 1997).
Narula et al. (1996) and Olivetti et al. (1997) were the first to demonstrate that
apoptosis occurs in the myocardium of patients with end-stage dilated
cardiomyopathy. In the study by Olivetti et al. (1997), CHF was characterised by an
approximate 250-fold increase in the number of apoptotic myocytes. In addition,
findings from several in vitro studies and animal models suggest that apoptosis can
occur in response to a variety of insults, many of which are present within the failing
heart including mechanical stretch (Cheng et al., 1995), (3-adrenergic stimulation,
release of inflammatory cytokines and oxidative stress (Colucci, 1997). Therefore, a
progressive loss of myocardial cells by apoptosis may contribute to the myocardial
dysfunction associated with CHF. However, the ultimate outcome may depend on its
balance with hypertrophy. Therefore, although this evidence is persuasive, the
precise role of apoptosis in the LV remodelling associated with the progression of
CHF remains to be defined.
1.5.5.2 Sympathetic nervous system
Activation of the sympathetic nervous system improves the inotropic state of the
non-infarcted myocardium and also helps redistribute blood flow to pulmonary,
coronary and cerebral vascular beds. In addition, vasoconstriction helps maintain




However, with time, the heart loses its ability to respond to endogenous
catecholamines. This attenuation is thought to occur as a result of changes in the
cardiac (3-adrenergic pathway, including down-regulation of (31-receptors, which
mediate the inotropic effects of catecholamines, and uncoupling of the receptors
from their effector enzyme, adenylate cyclase (Krum, 1997). This impaired response
to catecholamines is relatively specific to the heart with the sympathetic innervation
of the kidneys and vasculature remaining intact. Indeed, there appears to be an
enhanced responsiveness of the peripheral vasculature to a-adrenergic stimulation
(Elborn et al., 1989). This effect is enhanced further by a depression in the baroreflex
parasympathetic nervous system (Floras, 1993), which normally serves as a
physiological antagonist mechanism against the sympathetic nervous system.
Excess catecholamines may have direct pathological effects on the myocardium, but
substantial evidence to support this hypothesis is still lacking. Although (3i-receptors
are downregulated, (32 and ai-receptors become more prominent and may be
responsible for mediating adverse effects of catecholamines (Deisher et al., 1995). In
vitro, norepinephrine stimulates the growth of cardiac myocytes, possibly through
both (32 and ai-receptors (Knowlton et al., 1993). Furthermore, (3-adrenergic
stimulation has been shown to cause cardiac myocyte cell death (Mann et al., 1992)
and induce DNA and protein synthesis in cardiac fibroblasts in vitro (Calderone et
al., 1998). Thus, there is convincing evidence that the sympathetic nervous system
may play an important role in the LV remodelling associated with CHF.
In conclusion, a decreased inotropic response in combination with enhanced
peripheral vasoconstriction increases the cardiac workload, which in turn accentuates
the internal stress on the LV. In addition to the effects of increased LV stress, direct




In response to a decrease in perfusion or sympathetic stimulation, the
juxtaglomerular cells of the kidney secrete renin into the circulation. Renin is a
proteolytic enzyme which converts angiotensinogen, a circulating plasma globulin,
into angiotensin I. Angiotensin I is then cleaved by angiotension converting enzyme
(ACE) to the active peptide angiotensin II (Cockcroft et al., 1995). Angiotensin II
mediates its effects through angiotensin receptors, of which two have been cloned
and defined: ATi and AT2. The majority of the effects of angiotensin II are mediated
via the AT] receptor, although recent studies are defining roles for the AT2 receptor
(Matsusaka & Ichikawa, 1997). At normal plasma concentrations the main role of
angiotensin II is to stimulate the secretion of the mineralcorticosteroid, aldosterone,
from the adrenal glands. The principal and most well characterised action of
aldosterone is the reabsorption of sodium and water from the kidney, resulting in an
increase in blood volume. At higher concentrations, angiotensin II is a potent
vasoconstrictor and is believed to enhance the release of norepinephrine from
sympathetic nerve fibres and it can also penetrate the blood-brain barrier to directly
stimulate sympathetic activity.
The RAAS plays an important role in maintaining PVR and tissue perfusion in the
face of reduced cardiac output after damage to the heart, as well as helping restore
cardiac output. However, it is now widely accepted that sustained activation of the
RAAS plays a pivotal role in the progression of CHF. Indeed, the degree of
activation of the RAAS is often used as prognostic index in patients with CHF
(Francis et al., 1990). Furthermore, the importance of the RAAS in the pathogenesis
of CHF is emphasised by the success of ACE inhibitors in the treatment of CHF. In
large randomised clinical trial, ACE inhibitors have been shown to improve LV
function, prolong survival and reduce the need for hospital admissions in patients
with CFfF (reviewed by Lonn & McKelvie, 2000).
Like the sympathetic nervous system, a sustained increase in blood volume and PVR
as a result of persistent activation of the RAAS will accentuate the workload and
stress within the heart. Furthermore, this stress will be potentiated by increases in
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EDV. Presumably, these mechanical influences will contribute to LV remodelling
and the progressive decline in myocardial function. Therefore, in areas where RAAS
serves as an important compensatory mechanism in the acute response to cardiac
injury, long-term activation may actually be detrimental to the heart. Furthermore,
the combination of increased systemic blood volume and reduced cardiac output,
results in peripheral oedema.
Studies implicate a tissue-based RAAS within the heart (reviewed by Danser et al.,
1999), suggesting that components of the RAAS may be synthesised and act locally
within the heart. Furthermore, there is evidence that myocardial expression of ACE
is upregulated in experimental CHF and in patients with end-stage CHF (Danser et
al., 1999). Fike catecholamines, angiotensin II has the potential to have direct effects
on the functioning of cardiac cells, independent of its vascular and metabolic effects.
Angiotensin II promotes hypertrophy of cultured neonatal rat myocytes (Gray et al.,
1998). This effect was shown to be mediated by ET-1 and TGF-(3 released from
fibroblasts. Both ET-1 and TGF-[3 have been shown to promote hypertrophy of
cultured myocytes in vitro (Parker et al., 1990; Mullan et al., 1997). In addition, a
recent study demonstrated that angiotensin II promoted the proliferation of rat
fibroblasts (McEwan et al., 1998) suggesting a role for angiotensin II in cardiac
fibrosis.
1.5.5.4 Arginine vasopressin
AVP or anti-diuretic hormone is synthesised by the posterior pituitary gland. Its
release is primarily controlled by the hypothalamus, which senses changes in blood
osmolarity via osmoreceptors. In addition, afferent signals from baroreceptors in the
aortic arch, carotid sinus and LV can also stimulate its release. Recent evidence
suggests that AVP is also synthesised in blood vessels and the heart where it may act
locally (Simon & Kasson, 1995; Hupf et al., 1999). AVP is considered to be a major
hormone in the body responsible for salt and water homeostasis (Phillips et al.,
1995). Other effects of AVP include contraction of VSM cells, platelet aggregation,
mitogenesis, central regulation of blood pressure and the baroreflex response
(Phillips et al., 1995; Sampey et al., 1999).
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The release of AVP in response to reduced cardiac output promotes the reabsorption
of water from the kidney, which as in the case of the RAAS helps to maintain PVR
and restore cardiac output. Acting through vasopressin receptors (V2) expressed on
the collecting duct of the kidney, AVP initiates an intracellular cascade, which leads
to the translocation of water channels from cytoplasmic vesicles to the apical surface
of the collecting duct (Nielsen et al., 1995). This effectively increases the
permeability of the ducts to water.
The precise role of AVP in the progression of CHF is unclear, however, circulating
levels of AVP are elevated in CHF (Naitoh et al., 1998). Furthermore, recent studies
using novel non-peptide vasopressin receptors support a role for AVP in the
pathogenesis of CHF (reviewed by Burred et al., 2000). Continuous release of AVP
will clearly contribute to the effects of the RAAS and sympathetic nervous system on
cardiac workload and peripheral oedema. Indeed, Burrell et al. (2000) demonstrated
that administration of a novel V2 antagonist to sheep with pacing-induced heart
failure, increased water excretion as well as having favourable effects on cardiac
output and myocardial contractility. Water retention in excess of sodium retention
may occur in CHF and lead to hyponatremia. Indeed, hyponatremia is believed to be
a very ominous prognostic indicator in patients with CHF (Lee & Packer, 1986). In
patients with CHF and hyponatremia, hypo-osmolarity, which inhibits the release of
AVP in healthy humans, is associated with persistently high plasma concentrations
of AVP (Szatalowicz et al., 1981), suggesting a pivotal role for AVP in
hyponatremia. In addition to its effects on sodium and water homeostasis, AVP may
directly increase PVR. Indeed, in dogs with pacing-induced heart failure, a Vt
receptor antagonist decreased systemic vascular resistance and increased cardiac
output (Naitoh et al., 1994).
1.5.5.5 Natriuretic peptides
Atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) are
predominantly synthesised in the atria and ventricles, respectively. ANP and BNP are
released into the circulation in response to stretch where they have profound
natriuretic, diuretic and vasodilating properties.
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Both ANP and BNP are elevated in patients with CHF (Saito et al., 1987; Boland &
Abraham, 1998). Increased ANP and BNP secretion from the heart may serve as an
important inhibitory pathway for the RAAS, sympathetic nervous system and the
effects of AVP. In addition, there is evidence that the natriuretic peptides may
directly inhibit fibroblast proliferation and myocardial fibrosis (Itoh et al., 1990; Cao
& Gardner, 1995). However, in CHF it is generally accepted that the beneficial
effects of these peptides will be overcome by the powerful nature of the RAAS and
sympathetic nervous system. Furthermore, patients with CHF appear to be resistant
to the natriuretic effects of exogenously administered ANP and BNP (Cody et al.,
1986). This resistance may be due to down-regulation of renal natriuretic peptide
receptors, increased degradation of natriuretic peptides by neutral endopeptidases in
kidney or decreased sodium delivery to the site of action of the peptides (Schrier &
Abraham, 1999). Furthermore, there is evidence that the atrial stretch receptors
involved in the secretion of ANP may be down-regulated during CHF, as well as
there being a reduction in the sensitivity of its vascular receptors (Ferrari &
Agnoletti, 1989; Matsumoto et al., 1999).
1.5.6 Other mechanisms
Exciting new observations suggest that there may be other factors that play a role in
the progression of CHF. Among the growing list of possibilities are ET-1,
inflammatory cytokines, superoxide and NO. The role of NO is pathogenesis of CHF
is discussed in Section 1.5.7.
1.5.6.1 Endothelin-1
The existence of a potent endothelium-derived vasoconstrictor was first
demonstrated in 1985 (Hickey et al., 1985), but the peptide responsible was not
identified until 1988 (Yanagisawa et al., 1988). ET-1 is a 21 amino acid peptide,
which elicits a slow onset and extremely potent contraction of VSM cells. There are
at least three different ET-receptors, of which two (ETA and ETb) are well
characterised. ETA receptors are expressed exclusively on VSM cells, whereas ETB
receptors are found expressed on both VSM cells and endothelial cells. Stimulation
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of ETa and ETB on VSM cells results in vasoconstriction, whereas stimulation of
endothelial ETB receptors results in vasodilataion via the release of NO and PGI2
from the endothelium. Mickley et al. (1997) demonstrated the relative role of ETB -
mediated vasoconstriction in rat small mesenteric arteries is greater when the ETA-
mediated effect is blocked, suggesting the presence of a possible 'crosstalk'
mechanism existing between the receptors. It is now established that ET-1 and its
receptors are also expressed in the heart. Synthesis of ET-1 has been reported in
cultured neonatal rat cardiac myocytes (Suzuki et al., 1993b). ET receptors have
been detected within the heart in various cells, including myocardial cells,
specialised 'conducting' cells (Molenaar et al., 1993), fibroblasts (Katwa et al.,
1993) and within the coronary vasculature (Saetrum Opgaard et al., 1996).
The physiological importance of endogenous ET-1 in the maintenance of basal
vascular tone and blood pressure in healthy humans has been demonstrated by local
and systemic (Haynes et al., 1996) vasodilatation in response to inhibitors of the ET
system. More recently, Spratt et al. (1999) demonstrated that systemic blockade of
the ETa receptor inhibited the agonist-induced vasoconstriction and decreased PVR,
suggesting that ETA-mediated vascular tone contibutes to the maintenance of basal
systemic vascular resistance and blood pressure. The physiological role of ET-1 in
the functioning of the heart is less well defined. Studies suggest that ET-1 may have
an indirect effect on myocardial function through modulation of coronary tone
(Wang et al., 1994). Furthermore, recent studies suggest that ET-1 may act directly
on the cardiac myocytes and specialised 'conducting' cells, and may play a role in
modulating heart rate, cardiac output and contractility (Kusumoto et al., 1996; Meyer
et al., 1996; Spratt et al., 1999; MacCarthy et al., 2000).
Patients with CHF have higher plasma ET-1 concentrations when compared with
healthy individuals (McMurray et al., 1992). Furthermore, high concentrations are
associated with increased severity and mortality of CHF (Wei et al., 1994). The
source of elevated plasma ET-1 concentrations is unclear, but, at least two
mechanisms may be responsible. Both angiotensin II and AVP can stimulate the
release of ET-1 from the endothelium, and thus may serve as a stimulus in CHF
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(Rubanyi & Polokoff, 1994). Another possible explanation is decreased clearance of
ET-1 from the circulation (Cavero et al., 1990). In addition to increased plasma
concentrations of ET-1, there is some evidence that ET receptor number and
sensitivity may also be altered in CHF. In a rat model of CHF, both ET-1 and ETA
receptor subtype expression were increased in the failing heart (Brown et al., 1995).
McEwan et al. (2001) revealed an upregulation of ETB receptors in the non-infarcted
myocardium of hearts from rats with CHF, 12 weeks after coronary artery ligation.
Furthermore, Gray et al. (2000) recently reported specific upregulation of ETB
receptor immunoreactivity within the media of small mesenteric arteries from rats
with CHF.
The precise role for ET-1 in the pathogenesis of CHF remains to be established. The
vasoconstrictor effects of ET-1 may contribute to the increase in PVR associated
with C1TF. In addition, ET-1 has been shown to have direct effects on the functioning
of the myocardium, including promotion of myocardial Ca2+ overload, direct toxic
effects and an increase in contractility (Sakai et al., 1996a). ET-1 has been shown to
induce hypertrophy in cultured neonatal rat cardiac myocytes (Itoh et al., 1990) and
ventricular cardiac myocytes from adult rabbits (Mullan et al., 1997), suggesting a
role for ET-1 in LV remodelling. Understanding the actions of the ET system during
CHF has been aided by the development of compounds that block ET receptors.
Sakai et al (1996a) found that administration of the ETA receptor antagonist, BQ-
123, to rats for 12 weeks after coronary artery ligation markedly increased the
survival of rats, while improving LV function and preventing LV remodelling.
Preliminary studies using a mixed ET antagonist called bosentan demonstrated an
improvement in LV performance, together with a reduction in mean arterial blood
pressure and systemic vascular resistance in patients with severe CHF (Kiowski et
al., 1995). Furthermore, recent clinical research in CHF has identified a therapeutic
role for ET antagonism during CHF. The REACH-1 trial (reviewed by Mylona &
Cleland, 1999) reported improvements in symptoms using bosentan (500 mg BID),
though an increase in hepatic transaminases led to a premature halt in the study.
However, a follow-up study found that a lower concentration of bosentan (125 mg
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BID, Krum et al., 1999) was well tolerated and maintained the clinical improvements
observed in REACH-1.
1.5.6.2. Proinflammatory cytokines
Cytokines are a group of low molecular weight proteins secreted primarily by
polymorphonuclear cells and are responsible for orchestrating immunological
responses to pathogenic infection as well as initiating the repair of tissue after injury.
So far, the main cytokines that have been implicated in the pathogenesis of CHF are
TNF-a, interleukin 1 (IL-1) and IL-6 (Shan et al., 1997).
Plasma concentrations of TNF-a are increased in patients with CHF, and correlate
with severity of symptoms (Fevine et al., 1990; Torre-Amione et al., 1996a).
Furthermore, TNF-a is found expressed in the failing human myocardium but not in
healthy hearts (Torre-Amione et al., 1996a). TNF-a mediates its effects through two
membrane bound receptor subtypes, namely Type 1 (TNFR1) and Type 2 (TNFR2),
both of which are expressed in the failing human heart (Torre-Amione et al., 1995).
After exposure to TNF-a these receptors can be cleaved from the membrane and
circulate as soluble receptors, which may bind and neutralise TNF-a (Ferrari et al.,
1995). However, there is some evidence that binding of TNF-a to soluble receptors
also act to stabilise TNF-a, thereby potentiating its actions (Bozkurt et al., 1996).
TNF-a is known to have negative inotropic effects on isolated cardiomyocytes
(Yokoyama et al., 1993; Ferrari et al., 1995; Miiller-Werdan et al., 1997).
Furthermore, TNF-a has been shown to promote fibrosis of the heart (Castagnoli et
al., 1993) as well as apoptosis of cultured cardiac myocytes (Krown et al., 1996).
Artificially raising TNF-a activity can mimic many of the hallmarks of CHF.
Infusion of TNF-a at levels found in clinical CHF resulted in LV remodelling and
dysfunction in normal rats (Bozkurt et al., 1998). Cardiac contractility was depressed
within five days of starting the infusion and recovered on cessation. Consistent these
findings, transgenic mice overexpressing TNF-a in the heart develop a condition
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similar to CHF, characterised by reduced cardiac output, hypertrophy, myocyte
apoptosis and fibrosis (Bryant et al., 1998).
Further to its potential role in myocardial dysfunction, TNF-a may have other
adverse effects. Patients with severe CHF often develop a wasting condition known
as cardiac cachexia. Administration of recombinant TNF-a to healthy rats over a
sustained period of time precipitates symptoms analogous to cachexia (Fong et al.,
1989). Furthermore, TNF-a levels are markedly increased in cachetic patients with
CHF and these levels are found to be the strongest predictors of the degree of weight
loss (Anker et al., 1997).
IL-1(3 is found expressed in the coronary arteries and myocardium of patients with
cardiomyopathy, whereas patients with CHF of ischaemic origin appear to express
less IL-lp (Francis et al., 1998). In a rat model of CHF, the expression of IL-1(3 was
increased in the non-infarcted myocardium when compared with the myocardium
from sham-operated rats (Ono et al., 1998). Furthermore, this expression correlated
with LV end-diastolic diameter and collagen deposition in the non-infarcted
myocardium, suggesting a role for IL-1 (3 in LV remodelling. In a similar fashion to
TNF-a, IL-ip has the potential to reduce contractility of the heart (Balligand et al.,
1994).
Elevated levels of IL-6 have been reported in patients with CHF, and are associated
with a worsening of NYHA functional class, increased hospital stay, and poorer LV
function (Sharma et al., 2000). The precise role of IL-6 in the pathogenesis of CHF
remains to be established.
It is unclear if proinflammatory cytokines mediate their effects directly or indirectly.
As mentioned in Section 1.3.2, inflammatory cytokines can induce the expression of
iNOS in almost any cell type, including VSM cells and cardiac myocytes. Therefore,
NO may well be responsible for mediating the effects of cytokines in CHF.
Furthermore, cytokines increase the synthesis of eicosanoids, superoxide, other
inflammatory cytokines and they also activate inflammatory cells.
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It is clear, therefore, that there is an abundance of evidence to suggest that
proinflammatory cytokines may play an important role in the pathogenesis of CHF.
Indeed, the emergence of such findings has led to the development of treatments that
directly or indirectly reduce their availability within the heart and systemic
circulation.
The main stimulus for the immune activation in CHF is not known. In many disease
states the activated macrophage is the major source of TNF-a, however, in CHF
cardiomyocytes are capable of producing TNF-a (Torre-Amione et al., 1996b;
Kapadia et al., 1997). Kapadia et al. (1997) demonstrated that mechanical stretch
might be the physiological stimuli for the release of TNF-a from the myocardium. In
this study, haemodynamic overloading of the isolated perfused feline heart resulted
in increased de novo synthesis of TNF-a mRNA after only 30 minutes, and de novo
synthesis of TNF-a protein after 60 minutes. Furthermore, simple passive stretch
was a sufficient stimulus for TNF-a biosynthesis in isolated feline papillary muscles
(Kapadia et al., 1997).
Oedema of the bowel wall and subsequent bacterial translocation has been postulated
as a possible stimulus for immune activation (Anker et al., 1997). Bacterial
translocation would result in the release of endotoxin and subsequent immune
activation.
1.5.6.3 Superoxide
Plasma malondialdehyde-like activity (MDA), a marker of oxidative stress, is
increased in patients with CHF (Belch et al., 1991; Diaz-Velez et al., 1996).
Furthermore, levels of oxidative stress appear to correlate with severity and
chronicity of symptoms, and inversely with cardiac output and exercise capacity
(Diaz-Velez et al., 1996). Moreover, pericardial levels of 8-iso-prostaglandin F2a, a
specific and quantitative marker of oxidant stress positively correlated with the
functional severity of CHF (Mallat et al., 1998).
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Although the source of elevated superoxide in CHF is unclear, at least two
mechanisms may be responsible. Some studies suggest that a deficiency in
antioxidant systems is responsible. Several studies have demonstrated a reduction in
antioxidants, such as glutathione peroxidase, vitamin E, catalase and SOD, both in
the failing heart (Hill & Singal, 1996; Prasad et al., 1996) and the systemic
circulation (Nishiyama et al., 1998; Yucel et al., 1998). In a rat model of CHF, levels
of endogenous antioxidant pathways are progressively reduced in the heart between 1
and 16 weeks post MI (Hill & Singal, 1996). The precise reason for a reduced
antioxidant reserve is unclear. Other studies suggest that increased synthesis of
superoxide is responsible. In cultured VSM cells, angiotensin II stimulates
NADH/NADPH oxidase activity (Griendling et al., 1994). As mentioned in Section
1.5.6,2, TNF-a increases superoxide production from cultured cells (Hennet et al.,
1993). Other possible sources include, autoxidation of catecholamines and increased
arachidonate metabolism (Givertz & Colucci, 1998).
Increased superoxide production during CHF may have a wide range of effects,
superoxide has been shown to induce apoptosis of cardiac myocytes, while
stimulating the proliferation of fibroblasts and inducing the expression of TGF-(3 (Li
et al., 1999b). Depressed contractility, impaired energy production and a rise in
diastolic tension have all also been demonstrated in various cardiac preparations
exposed to superoxide (reviewed by Singal et al., 1998).
1.5.7 Nitric oxide and chronic heart failure
In general, the NO system is assessed by measuring vascular relaxations to the
muscarinic receptor agonist, acetylcholine. In rats with CHF following coronary
artery ligation (CAL), relaxations of isolated conductance arteries to acetylcholine
are impaired when compared with sham-operated control rats (Teerlink et al., 1994;
Baggia et al., 1997; Bauersachs et al., 1999). These experimental findings have also
been demonstrated in conductance arteries in patients with CHF with varying
pathologies (Bank et al., 1994; Ramsey, 1994).
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Impaired peripheral vasodilator responses to acetylcholine have also been observed
by several laboratories in the forearm and leg resistance vessels of patients with CHF
(Drexler et al., 1992; Kubo et al., 1991; Katz et al., 1992; Carville et al., 1998).
Furthermore, this impairment appears to correlate with disease severity (Carville et
al., 1998). Hindquarter quarter resistance arteries in rats with large infarctions
following CAL were less responsive to acetylcholine than control rats (Drexler & Lu,
1992). Furthermore, the reduction in PVR to acetylcholine in the pacing canine
model of CHF was shown to be attenuated (Kiuchi et al., 1993).
In a similar manner to agonist-stimulated release of NO, there is evidence that flow-
dependent increases in NO-mediated vasodilatation of conductance and resistance
arteries are also attenuated in CHF. A recent study demonstration that flow-mediated
dilatation skeletal muscle resistance arteries was abolished in rats with CHF
following CAL (Varin et al., 1999). Similarly, Hirai et al. (1995) found that
hyperaemic response of hindquarter resistance arteries was impaired in rats with
CHF. Impaired flow-mediated NO-mediated dilatation of conductance and resistance
arteries has also been demonstrated in patients with CHF (Hayoz et al., 1993; Katz et
al., 1996; Hornig et al., 1996; Mohri et al., 1997; Hornig et al., 1998).
Taken together these experimental and clinical studies provide convincing evidence
that the release of NO from the endothelium in resistance and conductance arteries,
either in response to agonists or mechanical influences, is impaired in CHF. As
discussed, increased blood volume and PVR as a result of activation of
neurohormonal mechanisms play an important role in the progression of CHF,
contributing to increased internal LV stress and thus LV remodelling. Therefore,
impaired release of NO from the vascular endothelium in resistance arteries may
contribute to this raised PVR. Dysfunction of the endothelial-NO system in
conductance arteries may also have functional consequences. There is evidence that
the release of NO from the endothelium serves to increase arterial compliance of
conductance arteries (see Section 1.4.1.2; Bank et al., 1994; Joannides et al., 1997).
Therefore, impaired release of NO in CHF may result in a decrease in arterial
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compliance, resulting in increased impedence of the failing left ventricle and
consequently impairing LV ejection (see Section 1.2.3).
Somewhat paradoxically, studies have demonstrated that plasma concentrations of
nitrate, the stable end product of NO, are elevated or preserved in patients with CHF
(Kubo et al., 1994; Winlaw et al., 1994; Carville et al., 1998). Furthermore, there is
some functional evidence that basal release of NO from the vasculature is enhanced
or preserved in CF1F. Drexler et al. (1992a) demonstrated that vasoconstrictor
responses to L-NMMA in the forearm were exaggerated in patients with CHF when
compared with healthy individuals. In the same study group this increase in basal NO
release contrasted with impaired dilatory responses to acetylcholine. Habib et al.
(1994) and Winlaw et al. (1994) observed that increases in systemic vascular
resistance in response to L-NMMA were enhanced in patients with CHF. Some
studies fail to corroborate these findings, however, and instead document a decrease
in basal NO release (Baggia et al., 1997). It is clear, therefore, that additional studies
are required to elucidate whether basal release of NO is increased in CHF.
Furthermore, more research is needed to elucidate why this facet of the vascular NO
system remains intact in the face of impaired agonist and/or mechanical induced
release of NO. Some investigators have postulated that iNOS might be expressed in
the vasculature during CHF (Carville et al., 1998; Drexler & Hornig, 1999), since
circulating levels of inflammatory cytokines are elevated in CHF (see Section
1.5.6.2), and thus may be responsible for the paradoxical increase in basal NO
production in CHF. Furthermore, numerous studies have demonstrated that iNOS is
expressed in the heart during CHF (de Belder et al., 1993; Haywood et al., 1996).
However, the expression of iNOS and its functional significance on vascular function
in CHF has not been addressed. Irrespective if basal NO is derived from eNOS or
iNOS, one would expect this source of NO to counteract compensatory constrictor
mechanisms associated with CHF and thus lower PVR. It is unclear why this
counter-regulatory mechanism fails to reduce PVR.
The underlying mechanisms responsible for impaired NO release in CHF may be
complex and have not yet been clarified. However, potential mechanisms have been
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suggested, these include down regulation of eNOS (Comini et al., 1996; Smith et al.,
1996; Wang et al., 1997; Varin et al., 1999), increased release of endothelium-
dependent constriction factors (Kaiser et al., 1989; Varin et al., 1999) and impaired
endothelial receptor-signal transduction pathways, ie. dysfunctional muscarinic
receptor (Hirooka et al., 1992). In other cardiovascular diseases, such as
hypercholestrolemia and hypertension, compelling evidence suggests that the
endothelial dysfunction results from increased vascular production of superoxide
(Ohara et al., 1993; Grunfeld et al., 1995). As discussed in Section 1.5.6.3, CHF is
associated with increased superoxide production. Because superoxide rapidly
scavenges NO within the vascular wall, a reduction the bioavailability of NO may be
responsible for impaired endothelium-dependent relaxations associated with CHF.
Furthermore, this may explain why PVR remains elevated in CHF despite increased
basal production of NO. The role of superoxide in modulating the vascular NO
system in CHF has not been fully addressed.
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As discussed in Section 1.5.7, evidence suggests that the release of NO from the
endothelium in resistance and conductance arteries, either in response to agonists or
mechanical influences, is impaired in CHF. However, somewhat paradoxically, there
is some evidence that basal release of NO may be preserved or even enhanced. Some
investigators have suggested that iNOS may be expressed in the peripheral
vasculature, since circulating levels of inflammatory cytokines are elevated in CHF,
and may be responsible for the paradoxical increase in basal NO production in CHF.
Furthermore, there is substantial evidence that iNOS is expressed in the heart during
CHF. The expression of iNOS and the functional significance of this potential source
of NO in the peripheral vasculature in CHF have not been addressed.
The localisation of iNOS in the peripheral vasculature would be an intriguing finding
itself, but its expression would pose some interesting questions. In particular, why
does this potential source of NO fail to counteract compensatory constrictor
mechanisms and thus lower PVR? As discussed in Section 1.5.7, increased
scavenging of endothelium-derived NO by superoxide has been implicated in the
endothelial dysfunction associated with other cardiovascular diseases. Increased
superoxide production has been demonstrated in CHF, however, its role in
modulating the bioavailability of NO has not been fully addressed.
Therefore, this thesis set out to investigate following hypothesis:
1. iNOS is expressed in throughout the cardiovascular system in CHF
2. iNOS-derived NO is responsible for increased basal production of NO associated
with CHF
3. Increased scavenging of NO by superoxide is responsible for the vascular
dysfunction associated with CHF
The primary aim of thesis was therefore to determine whether iNOS was expressed
in the cardiovascular system in rats with CHF following CAL and subsequent MI. In
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particular, the aim of these experiments was to investigate its expression within the
heart, small mesenteric arteries (internal diameters, 300 - 350 pm) and thoracic
aortae. After establishing whether iNOS was expressed in small mesenteric arteries
and thoracic aortae from rats with CHF, the aim of future experiments was to
investigate the functional significance of iNOS on vascular function. The final of aim
of this thesis was to examine the role of superoxide in modulating vascular NO
bioavailabilty in this model of CHF.
Investigations into the role of iNOS and superoxide in the pathogenesis of
cardiovascular diseases have in the past been hampered by the lack of suitable
pharmacological tools. The aim of preliminary experiments in this thesis were to
investigate the pharmacological properties of the novel iNOS inhibitor, N-(3-
(Aminomethyl) benzyl) acetamidine dihydrochloride (1400W), and the cell








This chapter describes the experimental techniques used in one or more chapters of
this thesis. Specific experimental protocols for each group of experiments are given
in the relevant chapters. All experiments using animals were carried out in
accordance with the Animals (Scientific Procedures) Act 1986.
2.1 Animal models used
2.1.1 Rat model of septic shock
2.1.1.11ntroduction
Despite extensive research and development of modern therapeutic tools, septic
shock remains a complex disease with high mortality. Septic shock results from
spread and expansion of an initially localized infection, eg peritonitis, meningitis,
into the bloodstream. It is characterised by systemic hypotension, loss of
responsiveness to vasoconstrictors, diminished myocardial contractility, activation of
the coagulation system and widespread endothelial cell injury (Mitchell & Cotran,
1999). The hypoperfusion resulting from the effects of widespread vasodilatation,
myocardial pump failure and disseminated intravascular coagulation results in
multiple organ failure. If the underlying infection is not brought under control, septic
shock is usually fatal. The pathogenesis of septic shock is complex and not fully
understood. However, the most common cause of septic shock is the contamination
of the blood with Gram-negative bacilli (Titheradge, 1999). It is now widely
accepted that endotoxin, a lipopolysaccharide (LPS) component of the bacteria cell
wall, is the major mediator of Gram-negative septic shock (endotoxic shock;
Titheradge, 1999). The release of endotoxin induces a cascade of self-perpetuating


















Figure 2.1 Effects of lipopolysaccharide (LPS). LPS initiates a cytokine cascade,
tumour necrosis factor-a, (TNF); interleukin-1, (IL-1); interleukin-6, (IL-6) and
interleukin-8 (IL-8). In addition, LPS can directly stimulate down-stream cytokine
production and the release of secondary mediators such as nitric oxide (NO) and
platelet-activating factor (PAF). DIC, disseminated intravascular coagulation;
ARDS, adult respiratory distress syndrome. Modified from Abbas et al., (1994),
Cellular and Molecular Immunology.
A number of mediators have been implicated in the pathogenesis of endotoxic shock,
including inflammatory cytokines, platelet activating factor (PAF) and nitric oxide
(NO) (Figure 2.1). LPS and cytokines can induce expression of the inducible
isoform of NO synthase (iNOS) in almost any cell type, including vascular
endothelial and smooth muscle cells (Schulz et al., 1991; Balligand et al., 1995;
Fleming et al., 1991) and cardiac myocytes (Brady et al., 1992; Balligand et al.,
1994). In endotoxic shock, the expression of iNOS throughout the cardiovascular
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system and the subsequent production of large quantities of NO is thought to play an
important role in the cardiovascular dysfunction associated with this disease (for
review see Titheradge, 1999).
Animal models have been used extensively to investigate the pathogenesis of
endotoxic shock and also in the development of pharmacological agents for both the
treatment and investigation of the disease. Administration of LPS to rats reproduces
many of the features of endotoxic shock in humans, including hypotension (Gray et
al., 1991; Pedoto et al., 1998) and myocardial dysfunction (Schulz et al., 1995; Sun
et al., 1997). Endothelium-intact and endothelium-denuded blood vessels from rats
treated with LPS, show hyporesponsiveness to a variety of vasoconstrictors (Julou-
Schaeffer et al., 1990; Weigert et al., 1995). Furthermore, inhibition of NO synthesis
using non-selective inhibitors of NOS reverses this hyporesponsiveness irrespective
if the endothelium is intact or not, suggesting that enhanced formation from iNOS
accounts for this vascular hyporeactivity. It is not the purpose of this thesis to
investigate the pathogenesis of endotoxic shock. However, the expression of iNOS in
the vasculature during experimental endotoxic shock provides an ideal model for the
establishment of techniques and provides positive controls for the investigation of the
expression of iNOS in the cardiovascular system of rats with CHF following
coronary artery ligation (CAL). Furthermore, blood vessels isolated from rats treated
with LPS should provide an acceptable model to examine the pharmacological
selectivity of the novel iNOS inhibitor, A-(3-(Aminomethyl)benzyl) acetamidine
dihydrochloride (1400W; see Chapter 3).
2.1.1.2 Induction of endotoxic shock
Endotoxic shock was induced in male Wistar rats (250 - 350 g, Charles River, U.K.)
by injection of LPS. Rats were injected with LPS (30mgkg_1, i.p., suspended in 0.1ml
saline/lOOg rat body weight) derived from Escherichia Coli (Serotype 055:B5,
Sigma, U.K.) and subsequently left for 5 h to develop endotoxic shock.
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2.1.1.3 Tissue harvesting and plasma sampling
Where blood samples were required, LPS-treated and control rats were anaesthetised
with sodium pentobarbitol (60 mgkg"1, i.p. Sagatal). A plastic cannula (2.10mm
diameter, Portex Ltd.) was then introduced into the abdominal aorta. Blood was
collected (~ 5 ml) into a syringe pre-rinsed with heparin (100 U ml"1, Multiparin, CP
Pharmaceuticals, Wrexham, U.K.). Samples were immediately transferred into pre¬
cluded Eppendorph sample tubes containing 50 pi of 10mmol/l
ethylenediaminetetraacetic acid (EDTA; Sigma, U.K.). The blood was fractioned by
centrifugation at 2000 revolutions per minute at 4 °C for 20 min. The cell free
plasma was collected and stored at - 20°C until use.
Following exsanguination, the thoracic aortae was removed and placed in cold,
oxygenated (95% 02, 5% C02), Krebs Henseleit solution (see Appendix) for
functional studies (see Section 2.2). Sections of the thoracic aortae from both
LPS-treated and control rats were fixed in 10% neutral buffered formalin (24 h,
Sigma) for immunohistochemical staining (see Section 2.3).
2.1.2 Rat coronary artery ligation model of CHF
2.1.2.11ntroduction
In cardiovascular research, animal models have facilitated the investigation and
treatment of cardiovascular disease. An ideal animal model should, for any
cardiovascular disease have five characteristics, 1) mimic the human disease, 2)
allow studies in chronic, stable disease, 3) produce symptoms which are predictable
and controllable, 4) satisfy economic, technical and animal welfare considerations
and 5) allow measurement of relevant cardiac, biochemical and haemodynamic
parameters (Doggrell & Brown, 1998). Experimental heart failure can be induced by
a variety of techniques in a range of species (for reviews see Doggrell & Brown,
1998; Hasenfuss, 1998). It is acknowledged, however, that no single model is able to
completely mimic the complex alterations during heart failure in man. The most
common model of heart failure, which is used in this thesis, is the rat coronary artery
ligation (CAL) model. In the first instance, rat models of heart failure have a clear
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advantage over other species with respect to cost, sample size, gestation period and
life span (Hasenfuss, 1998). In 1960, Seyle et al. were the first to describe the
technique of CAL in the rat (Seyle et al., 1960). However, Pfeffer et al. were the first
to characterise this model (Pfeffer et al., 1979). Occlusion of the coronary artery was
found to induce left ventricular (LV) infarctions that were histologically similar to
those in man and impairment of LV performance was directly related to the size of
the infarct. Furthermore, CAL was associated with LV dilatation, reduced systolic
function and increased LV end-diastolic pressures (LVEDP; Pfeffer et al., 1979;
Litwin et al., 1994). Further studies have since shown that the progression of
myocardial failure after CAL is associated with neurohormonal activation similar to
that seen in the human (Hodsman et al., 1988).
Despite the obvious advantages of this model it has disadvantages. Pfeffer et al.
(1979) acknowledged that CAL in the rat is not analogous to the pathogenesis of
coronary artery disease or infarction in humans since surgery is carried out on
essentially healthy coronary arteries and myocardium. Furthermore, problems exist
with high mortality, variation in infarction size and lack of progression from
compensation to end-stage heart failure. Despite these disadvantages, in balance, the
rat CAL model of CHF has proven to be a useful and appropriate model in the
investigation of CHF. Indeed, the therapeutic potential of angiotensin converting
inhibitors (ACE) inhibitors was first realised using this model (Pfeffer & Pfeffer,
1988). It is for this and the aforementioned reasons that the CAL rat model of CHF
was used in this thesis.
2.1.2.2 Coronary artery ligation surgery
Myocardial infarction was induced in male Wistar rats (250 - 300 g, Charles River,
U.K.) by occlusion of the left anterior descending coronary artery according to the
method described by Seyle et al. (1960) and modified by Pfeffer et al. (1979). Rats
were maintained on standard rat chow and tap water ad libitum for at least one week
prior to surgery. On the day of surgery, rats were weighed before being anaesthetised
with sodium pentobarbital (60 mgkg"1, i.p. Sagatal, Rhone Merieux Ltd., Essex,
U.K.). Prior to surgery, the left side of the chest was shaved and sterilised using 70%
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alcohol. Once fully unconscious, rats were placed on a thermostatically controlled
heating blanket (37°C) and intubated with a plastic cannula (2.10 mm diameter,
Portex Ltd., Kent, U.K.) using a guide wire. Mechanical ventilation (02 enriched air)
was achieved using a small rodent ventilator (Harvard Apparatus Ltd., Kent, U.K.) at
a rate of 60 cycles/minute and a tidal volume of 1 ml/lOOg body weight.
After a period of stabilisation, an incision (~ 2 cm), parallel to the direction of the
ribs, was made into the left side of the chest. Underlying muscle layers were
carefully separated and held in position with metal clips to expose the ribs. An
incision (~ 1.5 cm) was made in between the 4th and 5th ribs again running parallel
with the ribs. Care was taken not to damage the lungs when making this incision. To
protect the lungs during exteriorisation of the heart, a piece of sterilised gauze was
used to collapse the left lung. The lung was then gently pushed down and away from
the heart. Using a pair of blunt scissors, a hole was made in the pericardium, after
which the heart was gently and rapidly manipulated out of thoracic cavity. Once the
heart was in position, a silk suture (10 mm round bodied, Ethicon Ltd., Edinburgh,
U.K.) was positioned around the left descending coronary artery, after which the
heart was swiftly returned to the chest. The rat was left for 10 min to allow recovery
from exteriorisation before the suture was tied. A plastic cannula (0.75 mm diameter,
Portex Ltd.), attached to a 1ml syringe, was then carefully placed in the thoracic
cavity and the gauze used to collapse the lung removed. The chest wall was closed
using a 16 mm round bodied suture (Ethicon Ltd.). Before tying the last suture, the
chest was gently squeezed to remove air from thoracic cavity. The overlying muscles
were returned to their original position. Any remaining air within the thoracic cavity
was removed by means of the cannula and syringe. The cannula was removed before
suturing the skin with a 25 mm round bodied suture (Ethicon Ltd.). Rats were
maintained on the ventilator for a further 15 min. After this period rats were taken off
the ventilator, placed on a thermostatically controlled heating blanket and left to
recovery with 100% oxygen. The tracheal cannula was removed when rats showed
signs of recovery from anaesthesia. Rats were returned to their cages when fully
recovered from anaesthesia and maintained on standard rat chow and tap water ad
libitum. All rats were given buprenorphine hydrochloride (0.05 ml, Vetergesic, 0.3
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mg/ml; Redout & Colman, U.K.) subcutaneously upon recovery from anaesthesia
and the following morning for analgesia.
For sham-operated control rats, the same procedure was applied except the coronary
suture (10 mm round bodied, Ethicon Ltd.) was not tied but pulled under the artery.
2.1.2.3 Haemodynamic measurements
Six weeks after CAL or sham-operation, rats were anaesthetised with sodium
pentobarbitol (60 mgkg"1, i.p. Sagatal). The right carotid artery was isolated and a
fluid-filled (heparin; 100 U ml"1, Multiparin, CP Pharmaceuticals, Wrexham, U.K,
diluted in 0.95 saline) cannula (0.75 mm internal diameter, Portex, Ltd.) was
introduced into the artery. After a stabilisation period (~ 5 min), arterial blood
pressure was analysed using a MacLab (version 3.4/e) data analysis system (AD
Instruments, Hastings, U.K.) and recorded on an Apple Mac computer. The catheter
was then carefully advanced into the left ventricle for measurement of LVEDP as an
index of LV function. A representative trace of arterial blood pressure and LVEDP
measured from a CAL rat is shown in Figure 2.2. From Figure 2.2 we can see that
as the catheter is advanced into the left ventricle there is an increase in the pressure
pulse. The peaks and troughs of this part of the trace represent the LV systolic
pressure and LVEDP respectively. LVEDP was measured as an average of ~ 30
















Figure 2.2 A representative pressure-transducer reading of arterial blood pressures
and left ventricular pressures from within the carotid artery and left ventricle,
respectively, in a coronary artery ligation rat.
2.1.2.4 Tissue harvesting
Following exsanguination, the mesenteric bed and thoracic aortae were removed and
placed in cold, oxygenated (95% O2, 5% C02), Krebs Henseleit solution for
functional studies (see Sections 2.2 and 2.3). Before storage of mesenteric bed the
jejunum was removed and the remaining vascular bed returned to Krebs Henseleit
solution. Sections of the mesenteric bed and thoracic aortae from both CAL and
sham-operated rats were fixed in 10% neutral buffered formalin (24 h, Sigma.) for
immunohistochemical staining (see Section 2.3). The heart, lungs and kidneys were
also removed, washed in saline (0.9%) and weighed. Hearts were bisected from apex
to base and placed in formalin as above.
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2.1.2.5 Measurement of infarct size
Occlusion of the left coronary artery results in the development of a collagen rich
scar in the infarcted zone of the LV (see Section 1.5.2), Therefore, using a
histological stain for collagen, infarct size in relation to the LV free wall can be
measured. Formalin fixed hearts from both CAL and sham-operated rats were
processed in alcohol (to replace the formalin), infiltrated and embedded in molten
paraffin wax. 3 pm sections were taken from cooled blocks and floated on a water
bath (45 °C) to remove folds in sections. Sections were then transferred to
microscope slides coated with 3-Aminopropyltriethoxy-saline (TESPA, Sigma; see
Appendix). Once sections were dry, slides were transferred to an incubator (37 °C)
for 24 h to ensure complete adherence of tissues. Sections were de-waxed in xylene
(10 min), rehydrated through a descending alcohol series (100, 90 and 70% alcohol;
3 min each) and washed in water (15 min). Sections were then incubated with
Celestine Blue (Sigma) for 4 min to stain the nuclei. After washing in water (5 min)
sections were treated with van Gieson's collagen stain (see Appendix) for 3 - 5 min
and then rinsed with water. Sections were then dehydrated through an ascending
alcohol series (70, 90 and 100% alcohol; 3 min each) and xylene (10 min) before
mounting in DPX medium (BDH Laboratory Supplies, Poole, U.K.).
Infarct size was measured by a method previously described by Mulder et ai, (1998).
Briefly sections stained with van Gieson's collagen stain were placed under a CCD
video camera module (Sony, U.K.) attached to a microscope with a x20 lens. Images
were then electronically transferred to the computer for analysis (.Figure 2.3).
The endocardial and epicardial circumferences of the infarcted tissue and of the LV
free wall were determined with image analysis software (Imaging Associates, U.K.).
Infarct size was calculated as a percentage [endocardial + epicardial circumference of




Figure 2.3 Computer generated image oflongitudinal section ofa heartfrom a rat 6
weeks post coronary artery ligation. Images ofhearts were used to calculate infarct
size in relation to the left ventricular free wall. LV, left ventricle; I, infarct; S,
interventricular septum and RV, right ventricle.
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2.2 Functional pharmacological studies of isolated thoracic
aorta
2.2.1 Preparation of aortic rings
The thoracic aorta was pinned out in a silicone-coated (Sylgard, Dow-Corning, U.K.)
dissecting dish containing cold Krebs Henseleit solution. Using a blunt pair of
scissors, the aorta was carefully cleaned of adhering adipose and connective tissue.
The aorta was cut into transverse rings and mounted on two wires in an organ bath
(Model 700MO, Danish Myo Technology, Denmark) filled with 10 ml of warm (37
°C), oxygenated (95% O2, 5% CO2), Krebs Henseleit solution. To ensure that the
same size of segment of aorta was used in each experiment, rings were cut to fit the
length of the wires (~ 4 mm). Care was taken not to damage the endothelium during
mounting. Isometric tension was measured by a DSC6 strain gauge transducer,
linked to a MacLab data analysis system. Aortic rings were placed under 2 g of
tension and left for 60 min to equilibrate. During this equilibration period, rings were
periodically washed with Krebs Henseleit solution and tension readjusted to 2 g
when required.
2.2.2 General protocol
Before commencing experiments, the following protocol was performed on all aortic
rings. Rings were exposed to modified Krebs Henseleit solution containing 60 mM
potassium chloride (equimolar replacement of NaCl by KC1) to obtain maximal
contraction. Once contractions had stabilised (~ 5 min), responses were recorded on
an Apple Mac computer and rings washed with Krebs Henseleit solution (~ 10 min)
until the tension had returned to 2 g. Rings were exposed once more to modified
Krebs Henseleit solution to ensure maximal contraction. After washout with Krebs
Henseleit solution (~ 10 min) rings were exposed twice in succession, separated by
washout, to a supramaximal concentration of norepinephrine (NE; 10~5 M). In all
aortic rings the integrity of the endothelium was assessed by measuring acetylcholine
(ACh)-induced relaxation of NE-induced tone. A submaximal concentration of NE
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(~ EC<5o) was used to induce arterial tone. Once responses to NE were stable, rings
were exposed to a supramaximal concentration of ACh (1CT5 M). Aortic rings with
relaxations greater than 70% of NE-induced tone were classified as having an intact
endothelium and used in experiments. Rings failing to reach this criteria were
discarded. In some aortic rings the endothelium was removed prior to commencing
experiments. This was achieved by gently rubbing the intima of the rings with a pair
of fine forceps. As with endothelium-intact aortic rings, ACh-induced relaxation
(1CT5 M) of NE-induced tone (~ ECgo) was measured. Denudation of rings was
deemed successful in those rings where relaxations to ACh were less than 5% of NE-
induced tone. All aortic rings were washed with Krebs Henseleit solution and left to
re-equilibrate before commencing experimental protocol.
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2.3 Functional pharmacological studies of isolated small
mesenteric arteries using perfusion myograph
2.3.1 Introduction to technique
Until the mid-1970s, most of the information concerning the mechanical,
morphological and pharmacological properties of blood vessels was attained from in
vitro studies of large arteries, such as thoracic aorta. Information on smaller arteries
was limited to perfusion experiments and histological examination, with size and
fragility of smaller vessels discouraging investigators from undertaking mechanical
experiments. However, in 1976 wire myography was developed to allow
investigators to study blood vessels with internal diameters as small as 100 pm
(Mulvany & Halpern, 1976). In this technique segments of small arteries, are
mounted between two wires for measurement of isometric force (Figure 2.4). This
technique has been used extensively in vascular research. In 1991 Halpern & Kelley,
were the first to describe an adaptation of the wire myograph called the small vessel
arteriograph, or the perfusion myograph. In this technique, vessels are cannulated, in
a closed system, at both ends (Figure 2.4) and are exposed to a fixed transmural
pressure by infusing physiological salt solution into the vessel lumen. Therefore, in
contrast to the wire myograph, the perfusion myograph allows the blood vessel to
maintain its physiological shape and thus more of their physiological characteristics
than those used in the wire myograph. These include the development of myogenic
and spontaneous tone (VanBavel et al, 1991), which are rarely seen in the wire
myograph. Additionally, equal transmural pressure is achieved across the vessel wall,
contrasting with unequal stretch caused by the two wires. This is of paramount
importance in studies investigating the role of the endothelium in modulating
vascular tone, since transmural pressure within blood vessels in vivo is thought to
alter the release of endothelium-derived factors (for review see Shore, 1996).
Moreover, blood vessels are able to contract and relax as they would in vivo. Other
practical advantages of the perfusion myograph are given overpage:
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1. The endothelium is untouched during mounting and experimentation, in contrast
mounting on wires causes local damage to the endothelium.
2. The axial length of the vessel can be altered, thus preventing over stretching
during mounting.
3. Drugs can be added both luminally and abluminally.
The perfusion myograph does, however, have disadvantages. In the pressurised
system, blood vessels have to be free of holes or branches in order to maintain
pressure. This may prove difficult in some vessel types, such as coronary arteries,
where holes and branches are impossible to see even at high magnification.
Furthermore, although the axial length of vessels can be altered, it is difficult to
normalise the length in every vessel. However, because the perfusion myograph is
regarded as more a physiologically relevant model than the wire myograph, and for










Figure 2.4 A schematic diagram of wire and perfusion myograph. In the wire
myograph (a) blood vessels are mounted between two wires and changes in vessel
tension measured by isometric force exertion on the wires. In the perfusion
myograph (b) blood vessels are mounted on two cannulae (with distal cannulae
closed) and exposed to a fixed transmural pressure by infusing physiological salt
solution into the vessel lumen.
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2.3.2 Preparation of small mesenteric arteries
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The mesenteric bed was pinned out on a silicone-coated (Sylgard) dissecting dish
containing cold Krebs Henseleit solution. Care was taken not to over stretch the
vascular bed during pinning out. Mesenteric arteries with internal diameters of ~ 300
- 350 prn were selected for use in functional studies in this thesis. To achieve this it
was necessary to use third order branches of the mesenteric artery (Figure 2.5). The
artery of choice was selected by counting down the branches from the superior
mesenteric artery. The vascular bed is structured such that arteries and veins lie on
top of each other covered by adipose tissue. Therefore, with the use of a dissection
microscope (Zeiss, U.K.), fine forceps (World Precision Instruments, Inc., Sarasota,
U.S.A.) and vannas spring scissors (World Precision Instruments, Inc.), adipose
tissue surrounding the artery and vein was carefully removed. This was achieved by
gently teasing the adipose tissue away from the vessels and cutting the fine
membrane that attaches the adipose tissue to the artery or vein. The artery was
distinguished from the vein by examining the junction at the branch of the second
and third arteries. As shown in Figure 2.5, arteries have a distinct V shaped
junction in comparison with a 'u' shaped junction in veins. Additionally, arteries
have thicker, more defined walls than veins. Once the artery was identified,
remaining adipose tissue was removed as before. To enable identification of the
proximal and distal ends of the artery, and thus mimic blood flow direction when
mounting in the myograph, a small area of adipose tissue was left intact on the




Figure 2.5 Anatomical selection of 3rd order mesenteric arteries from the rat
mesenteric bed, (a) localisation of 3rd order arteries counting from the superior
mesenteric artery, (b) illustrates the differences between arteries and veins at the
junctions ofbranches.
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2.3.3 Mounting of arteries in the myograph
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Dissected arteries were transferred to the chamber of the perfusion myograph (Living
Systems Instrumentation Inc., Burlington, Vermont, U.S.A.) containing 10 ml of
warm (37 °C), oxygenated (95% 02, 5% C02), Krebs Henseleit solution. The artery
was then mounted onto fine glass cannulae (~ 100 - 150 |im tip diameter), and
secured by single-fibre silk threads. The procedure of mounting mesenteric arteries
was as follows: first the proximal end of the artery was gently pulled onto the
cannula tip until approximately 200 pm of the tip was inserted into the lumen of the
artery. The artery was then secured by two silk threads, which had already been
looped onto the cannula. Any blood present in the lumen of the artery was removed
by opening the stopcock to the proximal cannula and slowly infusing (1 ml/min)
Krebs Henseleit solution through the lumen by means of a miniature peristaltic pump
(PS/200, Living Systems Instrumentation Inc., Burlington, Vermont, U.S.A.). Care
was taken not to allow the intra-luminal pressure rise above 10 mmHg, in order to
prevent damage to the endothelium and vessel wall. After the blood was removed,
the stopcock was closed and the distal end of the artery wall tied onto the distal
cannula in the same way as described for the proximal end.
An intraluminal pressure of 60 mmHg was attained slowly by introducing Krebs
Henseleit solution into the vessel lumen using the miniature peristaltic pump,
connected to a pressure servo unit. A pressure of 60 mmHg was chosen because it
has been estimated that vessels of this size would experience pressures
approximately 50% of mean arterial pressure in vivo (Halpern & Kelley, 1991). As
the pressure increases, the artery usually developed a bend as a consequence of axial
lengthening. These buckles were removed by gently retracting the proximal cannula,
using the length transducer, to the original axial length prior to dissection. Care was
taken not to introduce any axial stretch. Once a pressure of 60 mmHg was reached
the pressure within the artery was maintained and regulated by switching the
pressure servo unit from manual to automatic mode. Before and during experimental
protocols, arteries were checked for any leaks by changing the pressure servo unit
back to manual mode. Under these conditions, any loss in pressure will not be
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compensated for by the pressure servo unit, resulting in a rapid drop in pressure. In
this case, the artery was discarded and another one mounted.
The myograph was placed on an inverted stage microscope (Nikon TMS-F, Japan)
which was connected to a monochrome television camera (Burle, U.S.A.), and the
vessel visualised on a television monitor. The lumen diameter and wall thickness
were measured using a video dimension analyser (Living Systems Instrumentation
Inc., Burlington, Vermont, U.S.A.), calibrated against a stage micrometer (resolution
= 1pm). The video dimension analyser senses changes in optical density of the artery
at a chosen scan line. The walls have a higher optical density that the rest of the
lumen and appear on the television screen as two thick bands. This allows continuous
measurement of both wall thickness and lumen diameter. Smaller lumen diameters
were measured by hand using a calibrated micrometer since the differences in the
optical density at diameters of less than 150 pm were not distinct enough for the
optical dimension analyser to detect.
After mounting and pressurisation, the arteries were continuously superfused with
warm (37 °C), oxygenated (95% O2, 5% CO2), Krebs Henseleit solution. The
temperature of the Krebs Henseleit solution was maintained at 37°C by passing it
through a glass-jacketed heated coil that was warmed with circulating water from a
water bath (Grant Systems, U.K.). The temperature in the chamber of the perfusion
myograph was checked regularly.
2.3.4 Protocol for addition of drugs to the perfusion myograph
In traditional organ bath experiments, such as those carried out on isolated aortic
rings, cumulative concentration response curves (CRC) are normally performed by
addition of increasing concentrations of drugs to the Krebs Henseleit solution bathing
the vessel. Unlike conventional organ baths, the chamber of the perfusion myograph
is not heated. Instead the temperature within the chamber is maintained by the
continuous perfusion of heated Krebs Henseleit solution. Therefore, addition of
drugs directly to the chamber itself would require switching off the pump, resulting
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in a fall in temperature within the chamber. To overcome this problem a 'reperfusion
circuit' was designed, which allowed cumulative CRCs to be performed. The
reperfusion circuit consisted of a closed system containing a total volume of 30 ml of
Krebs Henseleit solution, which was constantly superfused the artery at a low flow
rate (5 ml/min). All drugs used throughout the experiments were applied to this
reservoir. The reperfusion circuit was only used during preliminary and experimental
protocols; arteries were superfused with Krebs Henseleit solution in an open system
at all other times.
2.3.5 General protocol
Small mesenteric arteries were exposed to modified Krebs Henseleit solution
containing 60 mM KC1 (equimolar replacement of NaCl by KC1) to obtain maximal
constriction. Once constrictions had stabilised (~ 5 min), internal diameters of
arteries were recorded, and the superfusate replaced with Krebs Henseleit solution.
Small mesenteric arteries were exposed once more to modified Krebs Henseleit
solution to ensure maximal constriction. After sufficient washout with Krebs
Henseleit solution (~ 10 min), arteries were exposed twice in succession, separated
by washout, to a supramaximal concentration of phenylephrine (PE; 10" M). In all
arteries the integrity of the endothelium was checked by measuring ACh-induced
relaxation (10~5M) of PE-induced tone (1CT5M). As with thoracic aortae, mesenteric
arteries with relaxations greater than 70% of PE-induced tone were classified as
having an intact endothelium and included in experiments. Arteries failing to meet
this criteria were discarded.
In some experiments it was necessary to remove the endothelium. In larger arteries,
like the thoracic aorta, the endothelium is normally removed by mechanical
disruption. Indeed, in this thesis the endothelium of thoracic aortic rings was
removed by rubbing the intima of the ring with fine forceps. However, in the case of
small mesenteric arteries, mechanical disruption by such a method is not feasible
owing to the fragility and size of these arteries. Various methods have been
employed in the past to remove the endothelium from small arteries. These include
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perfusion of the arteries with detergents such as 3-[(3-cholamidopropyl)
dimethylammonio]-l-propane sulphonate (CHAPS) (Hiley et al., 1987; Takase et al.,
1995), dissolving the intracellular matrix with enzymes such as collagenase
(Carvalho & Furchgott, 1981) or rupturing endothelial cells osmotically with distilled
water (Criscione et al., 1984). Although these techniques are successful in removing
the endothelium, it is difficult to control the exposure time and shear rate through the
vessel lumen and as a result they carry the risk of not only damaging the endothelium
but also the underlying vascular smooth muscle (VSM) cells. Consequently, it is
difficult to ascertain if any changes in vessel response is due to disruption of the
endothelium or simply due to damage to the VSM cells. Mechanical disruption of the
endothelium in small arteries can be achieved by two methods. Osol et al., (1989)
demonstrated that introduction of a single human hair into the vessel lumen was an
effective method of removing the endothelium in small arteries. However, the most
commonly method used is that where an air bubble is passed through the vessel
lumen (Ralevic et al., 1989; Bjorling et al., 1992; Falloon et al., 1993). Previously
studies have demonstrated using confocal, scanning and transmission electron
microscopy that the use of an air bubble does not cause damage to the underlying
VSM cells (Smith, 1996). It is this method that is employed throughout the
experiments described in this thesis.
The method of endothelium denudation was as follows: firstly, the axial length of the
artery was noted by recording the setting on the length transducer, thus allowing the
vessel to be reset afterwards to its original length. The pressure servo unit was
switched to manual and the pressure within the artery slowly decreased. During this
decrease in pressure the axial length was decreased to prevent any axial stretch on
the artery. The distal stopcock was opened and an air bubble, approximately 2 cm in
length, introduced into the proximal tubing. This was achieved by disconnecting the
proximal tubing from the proximal stopcock and removing a small amount of Krebs
Henseleit solution. The proximal tubing was re-attached and the bubble passed
through the vessel lumen, the proximal cannula and artery by slowly increasing the
flow of Krebs Henseleit solution. Care was taken to ensure that the pressure within
the artery did not exceed 30 mmHg during the passage of the bubble. Once the
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bubble had passed through the distal stopcock was left open for a further 10 min to
ensure all endothelial cell debris was cleared from the lumen of the artery. After this
period the distal stopcock was closed, the flow increased slowly under manual mode
as before, and the vessel restored to its original axial length. Once a pressure of 60
mmHg was reached, the pressure servo unit was switched back to automatic mode
and the artery allowed time (~ 10 min) to re-equilibrate. As with endothelium-intact
mesenteric arteries, ACh-induced relaxation (10~5 M) of PE-induced tone (10~ M)
was measured. Denudation was deemed successful where relaxations to ACh were
less than 5% ofmaximal PE-constriction.
2.4 Drugs used in functional studies
Drug Source
Acetylcholine chloride Sigma (Poole, U.K.)
L-arginine hydrochloride Sigma
Catalase (bovine liver) Sigma
Mn [III] tetrakis [l-methyl-4-pyridyl] Alexis (Nottingham, U.K.)
porphyrin (MnTMPyP)














Over a relatively short period of time immunohistochemistry has become an
established routine histological technique for the identification of tissue and cellular
components. In essence, this technique relies on the interaction of antibodies with
antigens on the tissue of interest, with the site of antibody binding identified either by
direct labelling of the antibody or by using a secondary labelling method.
Antibodies are produced by terminally differentiated B cells, as part of the humoral
immune response to infection, with each antibody having specificity for one antigen.
There are five different classes of antibodies, all of which differ in structure and
function. The most common antibody found in the blood is called immunoglobulin
(Ig) G and is the predominant antibody produced in response to infection. IgG
consists of two light and two heavy polypeptide chains, joined by two disulphide
bridges. Antibodies are extremely variable in amino acid sequence at the ends of
these polypeptide chains. It is within these areas that the antibody gains affinity and
avidity for an antigen.
2.5.2 Production of Antibodies for Immunohistochemistry
Two types of antibody are used in immunohistochemistry; polyclonal and
monoclonal. Polyclonal antibodies are produced by immunisation of a host animal
with the antigen of interest. The introduced antigen mimics an invading pathogen,
and thus induces the humoral immune response. In simplified terms, B cells are
activated by the antigen resulting in the production and secretion of IgG antibodies
specific for that antigen. By purifying the serum, the antibody of interest can be
harvested. Although simple and cost effective, the use of polyclonal antibodies does
have disadvantages. Immunisation of the host animal with the antigen requires the
antigen to be extremely pure and even when pure there is the risk that different B
cells will produce antibodies against varying antigenic determinants on the antigen.
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Therefore, antibodies produced by this method may be highly variable with respect
to antigenic specificity. Moreover, when the serum is harvested it may contain
antibodies from the animal itself that are not specific for the antigen. Such antibodies
may cross-react with other molecules on the sample tissue and thus reduce the
reliability of the procedure.
The use of monoclonal antibodies in immunohistochemistry was made possible in
1975 when Kohler & Milstein described a method for immortalising B cells. As with
the production of polyclonal antibodies, the host animal is immunised with the
antigen of interest. Normal antibody-producing B cells are then isolated from the
host and fused with myeloma B cells, essentially immortalising the B cells.
Immortalised B cells that secrete the antibody of desired specificity for the antigen
can be isolated and cloned. Besides having an endless supply of antibodies, this
technique provides antibodies with absolute specificity for one antigenic determinant
on the antigen. Therefore, monoclonal antibodies are regarded as more reliable and
are the most commonly used antibodies in immunohistochemistry.
2.5.3 Methods used in Immunohistochemistry
As mentioned in Section 2.5.1 the site of antibody binding on the sample tissue can
be identified either by direct labelling of the antibody, or indirectly using a secondary
labelling method (Figure 2.6). Direct labelling of the antibody is the simplest and
shortest method for antigen detection; however, it is considered to be the least
sensitive (Robinson et al., 1988). The most common method of secondary labelling
is the use of a second antibody, which is specific for the Ig class of the primary
antibody. In this technique an unlabelled primary antibody is allowed to bind with its
antigen on the sample tissue. A second labelled antibody, raised in another animal
host and specific for the animal and Ig class of the primary antibody, is applied to the
tissue and allowed to bind to the primary antibody. It is acknowledged that the
indirect method for immunohistochemistry is a reliable and relatively sensitive




Enzymes are the most widely used labels for antibodies in immunohistochemistry,
and incubation with a substrate chromogen system produces a stable, coloured
reaction end product that can be detected by light microscopy. Horseradish
peroxidase is the most widely used enzyme and in combination with 3,3'-
diaminobenzidinetetrahydrochloride, it produces an insoluble, stable, dark brown
coloured end product. The most common alternative to horseradish peroxidase is
alkaline phosphatase. Incubation with an alkaline phosphatase substrate and red





Figure 2.6 Two methods used in immunohistochemistry, (a) direct method where
primary antibody is labelled with a marker and (b) indirect method where a second
labelled antibody is used to identify sites ofantigen-antibody binding. Modified from
Beltz & Burd: Immunocytochemical Techniques, Blackwell Scientific Publications,
1989.
2.5.4 Preparation of tissues for Immunohistochemistry
Fixing with formalin is thought to mask antigens within the tissue sample (Huang et
al., 1976) and therefore, before staining with antibodies can commence, it is
necessary to reverse this process. This is achieved by treating sections of tissues with
proteolytic enzymes, such as trypsin or pepsin. Unfortunately there is no universally
recommended time or enzyme and much depends on the tissue type and the method
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and duration of fixation. Therefore, experimental details given in Section 2.5.5 were
those optimised in-lab.
Despite the relative selectivity of antibodies used in immunohistochemistry, non¬
specific background staining can occur. The main cause of background staining is
non-immunological binding of the specific immune sera by hydrophobic and
electrostatic forces to certain sites within tissue sections (Kraehenbuhl & Jamieson,
1974). This form of background staining is often recognised as a uniform
background colour. To overcome this problem, tissues are treated with non-specific
Ig. This Ig will essentially bind to the sites that have non-specific affinity for
antibodies, without interfering with the binding of the primary antibody. In general,
serum (which will contain non-specific Ig) from the host of the secondary antibody is
used.
2.5.5 Protocol for Immunohistochemistry
The method of antibody detection used in this thesis was the indirect method, using a
monoclonal primary antibody and a secondary antibody conjugated to alkaline
phosphatase. Immunohistochemistry was used to investigate the expression of iNOS
in thoracic aortae from rats treated with LPS (see Section 2.1.1) and in the
cardiovascular system of CAL and sham-operated rats 6 weeks post-surgery (see
Section 2.1.2), The concentrations of antibodies used for individual tissues are given
in the appropriate chapters. Dilutions of antibodies were made in phosphate buffered
saline (PBS, pH 7.6; see Appendix) with 3% Bovine Albumin serum (Sigma). An
overview of the protocol used is given below.
Formalin fixed arteries and hearts were processed in alcohol (to replace the
formalin), infiltrated and embedded in molten paraffin wax. 3 pm sections were
taken from cooled blocks and floated on a water bath (45 °C) to remove folds in the
tissues. Sections were then transferred to microscope slides coated with TESPA
(Sigma). Once sections were dry slides were transferred to an incubator (37 °C) for
24 h to ensure complete adherence of tissues. Sections were dewaxed in xylene
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(10 min), rehydrated through a descending alcohol series (100, 90 and 70% alcohol;
3 min each), washed in water (15 min) and then placed in PBS for 5 min. Sections
were then incubated in tris-buffered saline (TBS; pH 7.8; see Appendix) for 15 min
at 37 °C before being treated with 0.1% trypsin (made in TBS). Incubation times for
trypsin on individual tissues were as follows; mesenteric arteries, 15 min; thoracic
aortae, 15 min and hearts, 45 min. After trypsinisation tissues were washed in PBS
for 15 min.
Tissues were treated with 1% goat serum (Diagnostics Scotland, Carluke, U.K.),
diluted in PBS for 30 min, at room temperature. Excess serum was removed from
microscope slides before treating sections with a rabbit anti-iNOS monoclonal
antibody (Affiniti Laboratories, Exeter, U.K.) for 24 h at 4 °C. Parallel tissues were
treated with an antibody of the same Ig class but not directed against the iNOS
epitope (Vector Laboratories, Peterborough, U.K.) again for 24 h at 4 °C. By doing
so we can eliminate the possibility that any binding of the anti-iNOS antibody is due
to non-specific binding due to the Ig class. After washing for 15 min in PBS, tissues
were treated with an alkaline phosphatase-conjugated goat anti-rabbit antibody
(Vector Laboratories) for 30 min at room temperature. Tissues were washed in PBS
for 15 min. To detect iNOS within the arteries, sections were treated with an alkaline
phosphatase substrate and red fuchsin as a chromogen for ~ 20 min (New Luchsin
Substrate System, Dako Corporation, Carpinteria, U.S.A.). Any positive sites of
antigen-antibody binding on the tissue were visualised as a crisp, red stain. A
summary of this protocol is given in Figure 2.7.
After detection of iNOS, tissues were briefly rinsed with distilled water and treated
with Harris' haematoxylin (BDH, Poole, U.K.) to counterstain nuclei of cells.
Tissues were rinsed again in distilled water and then mounted in Aquamount










Figure 2.7 Schematic diagram of immunohistochemistry method used in this thesis.
P; alkalinephosphatase, Ag; antigen.
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2.6.1 Introduction
NO production can be measured by a variety of methods in different types of
samples, including urine, plasma and whole cell preparations. The transient and
reactive nature of NO makes it unsuitable for most convenient detection methods.
However, since NO is rapidly oxidised to nitrite (N02") and predominantly nitrate
(NO3 ) (collectively termed NOx) these anions can be quantified and used as an
indirect measure of NO production. In cell culture systems NO will rapidly degrade
to NO2", however, in the presence of Fe2+haem, for example in the blood, NOT is
converted to the more stable product NO3". Therefore, the relative abundance of each
anion will depend on the sample type.
The most common and simplest of methods used to measure NO3" and N02" is the
conversion of NO3" to N02~ by nitrate reductase followed by the colorimetric
detection of N02~ as an azo dye product of the Greiss Reaction (Green et al., 1982;
Stuehr et al., 1989). Similarly, endogenous N02~ within the sample can be measured
using the Greiss Reaction, thus allowing both NO3" and N02" concentrations to be
quantified. Other methods used include measuring N02" by chemiluminescence
following reconversion to NO (Knowles et al., 1989; Bush et al., 1992). In this
thesis, plasma NO production was quantified by measuring total NOT (after
conversion of NO3" with nitrate reductase) by means of the Greiss Reaction, using a
Nitric Oxide Assay Kit (R&D systems, U.K.). The Greiss Reaction involves the
conversion of NOT to a diazonium ion with sulfanilic acid, this ion is then coupled to
A-(l-napthyl) ethylenediamine to form a chromophobe azo derirative, which absorbs
light at 540 nm. This simple assay is summarised in Figure 2.8. Endogenous N02"
within plasma samples was not measured because it was presumed that the majority













































Figure 2.8 Summary of assay for measurement of nitrite concentrations in plasma
samples. Step 1; nitrate is converted to nitrite by nitrate reductase. Step 2, nitrite is
converted to a diazonium ion which is then coupled to N-(l-Naphthyl)




Measurement of NOx is clearly a useful and straight forward index of NO generation,
however there are some important limitations of this technique that should be taken
into account when interpreting and extrapolating results. NOx is excreted by the
kidney into the urine, therefore, plasma NOx is not only an indirect index of systemic
NO production but also of renal function and plasma volume. In disease states where
renal function is impaired, and thus NOx excretion is decreased, plasma and urine
NOx measurements should be interpreted with caution. Ideally, NOx measurements
should coincide with an independent measurement of renal function. However,
difficulty in interpretation arises in those disease states where increased NO
production is thought to be responsible for renal dysfunction.
2.6.3 Experimental protocol
Assays were performed with duplicate samples and standards provided with the
assay kit.
All assay reagents were brought to room temperature before use. Plasma samples
were defrosted at room temperature and diluted 1.5 fold using the reaction buffer
provided. To eliminate proteins from the plasma, samples were ultrafiltered through
a 10,000 molecular weight filter (14 mm diameter, Amicon, Gloucestershire, U.K.).
50 pi of filtered samples were placed into labelled wells of a microplate. 50 pi of
N02" standards were similarly placed in labelled wells, with 50 pi of reaction buffer
used as zero standards. To each sample and standard well, 50 pi of reaction buffer
was added, followed by 50 pi of Greiss Reagent I and 50 pi of Greiss Reagent II.
Wells were mixed by gently tapping the side of the plate. The micropiter plate was
covered and left at room temperature for 10 min. The optical density of each well
was determined using a microplate reader (source) set at an absorbance of 540 nm.
Values for each duplicate standard and sample were averaged and the optical density
for the zero standards subtracted. A standard curve was created using the values from
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the standards provided and concentrations of NCA within the samples quantified
using this curve. An example of a standard nitrite curve, from which plasma sample
concentrations were extrapolated, is given in Figure 2.9. Plasma samples were
originally diluted, therefore, concentrations of N02" were corrected by multiplying
by the dilution factor (1.5).
N02" Concentration (fiM)
Figure 2.9 Example ofa standard nitrite curve for measurement ofplasma nitrite
concentrations.
2.7 Data Analyses
Data analysis for experiments described in this chapter are given in the method




Investigation of the pharmacological selectivity of the




Nitric oxide (NO) is a unique molecule involved in the regulation of diverse number
of physiological processes including vascular smooth muscle (VSM) contractility,
platelet reactivity, neurotransmission and the cytotoxic actions of immune cells (see
Section 1.3.2). However, excess production of NO has been linked to the
pathogenesis of a number of diseases. This has provided the rationale for designing
new therapies that modulate the synthesis of NO.
Expression of the inducible isoform of nitric oxide synthase (iNOS) in macrophages
and the subsequent production of large quantities of NO plays an important role in
the anti-pathogenic actions of these inflammatory cells (Nathan, 1992). However, it
is well established that iNOS can be expressed in almost any cell type including
VSM cells (Fleming et al., 1991) and cardiomyocytes (Brady et al., 1992; Balligand
et al., 1994) in response to bacterial lipopolysaccharide (LPS) and inflammatory
cytokines. The expression of iNOS within the cardiovascular system has been linked
to numerous diseases, including myocardial infarction (MI; Wildhirt et al., 1995),
chronic heart failure (CHF; Fukuchi et al., 1998; Vejlstrup et al., 1998) and septic
shock (Titheradge, 1999). However, due to the ubiquitous nature of endothelial NOS
(eNOS)-derived NO within the cardiovascular system and its pivotal role in the
regulation of vasomotor tone and arterial blood pressure (Moncada et al., 1991), non¬
selective inhibition of NO synthesis would be undesirable. It is clear, therefore, that
selective inhibitors of NOS may be of considerable therapeutic value. As a result,
considerable effort has been made recently to develop novel selective iNOS
inhibitors which would be useful pharmacological tools and, more importantly, as
possible therapeutic agents in the treatment of such diseases in which iNOS is
implicated.
A-(3-(Aminomethyl) benzyl) acetamidine dihydrochloride (1400W) has recently
been described as a slow, tight binding inhibitor of human iNOS (Garvey et al.,
1997). Using purified NOS, 1400W was shown to be at least 5000-fold more
selective for human iNOS than eNOS (Garvey et al., 1997). Furthermore, in a rat
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model of endotoxic shock, 1400W prevented the systemic hypotension as well as
rises in plasma nitrate levels in rats attributable to LPS-induced iNOS expression
(Wray et al., 1998). Despite this evidence, in vitro studies directly investigating the
effect of 1400W on the synthesis of NO by iNOS and eNOS are still lacking.
Therefore, the aim of experiments in this chapter was to test the hypothesis that




All procedures were carried out as described in Chapter 2.
3.2.1 Model of endotoxic shock
As discussed in Section 2.1.1, administration of LPS to rats reproduces many of the
symptoms associated with endotoxic shock in humans, including systemic
hypotension (Gray et al., 1991) and lack of responsiveness to vasoconstrictors
(Julou-Schaeffer et al., 1990). Induction of iNOS in the vasculature after LPS
administration, and the subsequent production of large amounts of NO, has been
implicated in the vascular dysfunction observed in rats with endotoxic shock (Julou-
Schaeffer et al., 1990; Weigert et al., 1995). Blood vessels isolated from rats treated
with LPS should provide an acceptable model to examine the pharmacological
selectivity of the novel iNOS inhibitor, 1400W, in vitro.
Therefore, preliminary experiments were designed to investigate the expression and
functional significance of iNOS in thoracic aortae from rats with endotoxic shock,
and to determine the suitability of this model for investigating the pharmacological
selectivity of 1400W in vitro.
3.2.1.1 Induction of endotoxic shock, plasma sampling and tissue
harvesting
Male Wistar rats were weighed (n=8; 250 - 350 g), injected with LPS (30 mgkg"1,
i.p.) and left for 5 h to develop endotoxic shock. Rats were anaesthetised with
sodium pentobarbitol (60 mgkg"1, i.p.) and blood collected (~ 5 ml) from the
abdominal aortae into a syringe pre-rinsed with heparin (100 U ml"1). Samples were
then immediately transferred into pre-chilled Eppendorph sample tubes containing 50
jllI of 10mmol/l EDTA. Samples were then immediately centrifuged as described in
Section 2.1.1.3. The cell free plasma was collected and stored at -20 °C prior to
nitrate/nitrite analysis (NOx, see Section 3.2.1.3).
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After exsanguination, thoracic aortae were removed and placed in cold, oxygenated
(95% 02, 5% C02) Krebs Henseleit solution. Blood samples and thoracic aortae were
also collected from healthy male Wistar rats (n=7, 250 - 350 g). Sections of the
thoracic aortae from both LPS-treated and control rats were removed and fixed in
10% neutral buffered formalin for 24 h prior to further processing and wax
embedding as described in Section 2.1.1.3.
3.2.1.2 Localisation of iNOS by immunohistochemistry
3 jam sections were taken from blocks and immunohistochemistry performed using
the indirect alkaline phosphatase method, with a rabbit anit-iNOS monoclonal
primary antibody (concentration; 1/250) and a goat anti-rabbit alkaline
phosphatase-conjugated secondary antibody (concentration; 1/50) as described in
Section 2.3.5, Negative controls were treated with an antibody of the same
immunoglobulin (Ig) class but not directed against the iNOS epitope (see Section
2.5.5), Thoracic aortae were then treated with Harris' haematoxylin to counterstain
nuclei.
3.2.1.3 Measurement of nitric oxide production
NO production was quantified by measuring nitrate/nitrite (NOx) plasma
concentrations by means of the Greiss Reaction using a 'Nitric Oxide Assay Kit'
(R&D systems, U.K.) as described in Section 2.6.3,
3.2.1.4 Functional studies in thoracic aortae
Thoracic aortae from both LPS-treated and control rats were cleaned of adhering
adipose and connective tissue and then cut into transverse rings. To ensure that same
size of aortic ring was used in each experiment, each ring was cut to the length of the
wires onto which the aortic ring was to be mounted (~ 4 mm). The endothelium was
removed by the method described in Section 2.2.2. Rings were mounted in a 10 ml
organ bath filled with warm (37 °C), oxygenated (95% 02, 5% C02) Krebs Henseleit
solution (see Section 2.2.1), placed under 2 g of tension and left to equilibrate for
60 min. The general protocol (see Section 2.2.2) was performed on all aortic rings
before commencing the experimental protocols described overpage.
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To investigate the effect of LPS treatment of rats on responsiveness of thoracic
aortae to adrenoceptor stimulation, cumulative concentration response curves (CRC)
to norepinephrine (NE; 1 x 10~9 to 3 x 10"5 M) were constructed in
endothelium-denuded rings from both LPS-treated (n=8) and control rats (n=7). On
completion of CRCs, rings were repeatedly washed and allowed to re-equilibrate for
at least 15 min before further experimentation.
To investigate the role of iNOS in modulating vascular responsiveness in thoracic
aortae from LPS-treated rats, endothelium-denuded rings were exposed to the
non-selective NOS inhibitor, A^-nitro-L-arginine methyl-ester (L-NAME; 2 x 1CT4
M; Rees et al., 1990) for 30 min prior to carrying out cumulative CRCs to NE
(1 x 10~9 to 3 x 10"5M).
3.2.2 Investigation of the pharmacological selectivity of 1400W
Endotoxic shock was induced in male Wistar rats (n=8, 250 -350 g) as described in
Section 3.2.1.1, Rats were killed by stunning and exsanguination, thoracic aortae
removed and placed in cold, oxygenated (95% O2, 5% C02) Krebs Henseleit
solution. Thoracic aortae were also collected from healthy male Wistar rats (n=8, 250
- 350 g). Aortic rings (~ 4 mm, see Section 3.1.2.4) from both LPS-treated and
control rats were mounted in a 10 ml organ bath filled with warm (37 °C),
oxygenated (95% 02, 5% C02) Krebs Henseleit solution. After a period of
equilibration of 60 min, the general protocol (see Section 2.2.2) was performed on all
aortic rings prior to carrying out the experimental protocols described below.
To establish whether 1400W inhibits the synthesis of NO by iNOS, cumulative
CRCs (1 x 10-9 to 3 x 10"5 M, rc=8) were constructed in endothelium-intact aortic
rings from LPS-treated rats in the presence and absence of A-(3-(Aminomethyl)
benzyl) acetamidine dihydrochloride (1400W). On the basis of previous studies
(Garvey et al., 1991; Wray et al., 1998) and preliminary data (n=4, data not shown)
three concentrations of 1400W were used, 10"6 M, 10"5 M and 10"4 M. Rings were
treated with 1400W for 30 min prior to commencing CRCs.
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Basal production of NO in endothelium-intact isolated rat aortic rings exerts a tonic
vasodilatory action, opposing the effects of vasoconstrictors (Martin et al., 1986).
Consequently, by measuring vasoconstrictor responses to NE basal production of NO
can be indirectly assessed. Therefore, to investigate whether 1400W has any non¬
selective effects on basal synthesis of NO by eNOS, CRCs to NE (1 x 10~9 to 3 x 10"5
M, n-8) were constructed in endothelium-intact aortic rings from control rats in the
presence and absence of 1400W. As before, rings were treated with 1400W (10~6M -
10"4M) for 30 min prior to commencing CRCs.
To investigate whether 1400W has on any non-selective effects on agonist-
stimulated synthesis of NO by eNOS, acetylcholine (ACh)-induced relaxations were
assessed in the presence and absence of 1400W (10~6 M - 10"4 M). A submaximal
concentration of NE (~ ECeo) was used to induce arterial tone. Once constrictions
were stable, cumulative CRCs to ACh (1 x 10~9 to 3 x 10'5M, n>6) were obtained. As
before, rings were treated with 1400W (10 6 M - 10"4 M) for 30 min prior to
commencing CRCs.
3.2.3 Preparation of drugs
Norepinephrine hydrogentartrate, acetylcholine chloride and A^-nitro-L-arginine
methyl-ester were diluted in Krebs Henseleit solution to give a stock solution of
10_1 M and frozen (-20 °C) in aliquots prior to use. Vitamin C (10-6 M) was added to
the stock solution of NE to prevent autoxidation. Further dilutions were made in
Krebs Henseleit solution. A-(3-(Aminomethyl) benzyl acetamidine dihydrochloride
(1400W) was diluted in saline (0.9% NaCl) under argon to give a stock solution of
10~3 M. Aliquots were then frozen (-20 °C) and stored under argon. Further dilutions
were made in Krebs Henseleit solution.
3.2.4 Data Analysis
All results were expressed as means ± s.e.mean. Cumulative CRCs to ACh were
measured as percentage relaxations of NE-induced tone. Where maximal values were
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obtained for cumulative CRCs to NE and ACh, the negative logarithm of the agonist
concentration that results in a half-maximal contraction or relaxation (pD2) was
calculated by nonlinear regression using GraphPad Prism software (Version 3.0).
Two-tailed r-tests, one-way analysis of variance (ANOVA) with Bonferroni post-test
for multiple comparisons and two-way repeated measure ANOVA were used as




3.3.1 Investigation of the expression of iNOS during endotoxic shock
3.3.1.1 Immunohistochemical localisation of iNOS
Immunoreactive iNOS was found in endothelial cells, VSM cells and in the
adventitia of thoracic aorate from LPS-treated rats (.Figure 3.1a). No
immunoreactivity was found in thoracic aortae from control rats or in negative
controls using IgG antibodies (Figure 3.1b, c).
3.3.1.2 Plasma nitrite concentrations
NOx concentrations in plasma samples from LPS-treated rats were significantly
higher than those from control rats (LPS-treated rats, 166.19 ± 5.79 pM; control,
25.61 ± 2.83 pM, PcO.OOl, two-tailed unpaired /-test).
3.3.1.3. Effect of lipopolysaccharide administration on vascular
responsiveness
Maximal contractions to KCl (60 mM) in endothelium-denuded aortic rings from
control rats were significantly greater than those in aortic rings from LPS-treated rats
(P<0.01, two-tailed unpaired /-test, Table 3.1). Interestingly, there were no
significant differences between LPS-treated and control rats with respect to
contractions to a supramaximal concentration of NE (10~5 M, Table 3.1). Relaxations
to ACh in aortic rings from both LPS-treated and control rats were all but abolished,
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Figure 3.1 Localisation of iNOS by immunohistochemistry in thoracic aortae
isolated from LPS-treated and control rats (n>7). Immunoreactive iNOS (red
staining) was detected in endothelial cells (E), vascular smooth muscle cells (V) and
in the adventitia (A) of thoracic aortae from lipopolysaccharide (LPS)-treated rats
(Panel a) but not in aortae from control rats (Panel b). No immunoreactive iNOS
was detected in thoracic aortae from LPS-treated rats treated with control IgG
antibodies (Panel c). Nuclei are counterstained with Harris' Haematoxylin (purple





60 mM KCl 2.1+0.2g l±0.1g*
10"5MNE 2.1±0.3g 1.7±0.2g
10"5M ACh 0.40±0.2% 0.46±0.1%
Table 3.1 Maximal contractions of endothelium-denuded thoracic aortic rings from
LPS-treated and control rats to KCl and norepinephrine (NE). Responses of NE-
contracted aortic rings to acetylcholine (ACh) are given as percentages of NE
(ECso)-induced tone. All values are given as means ±s.e.m. * P<0.05 compared with
respective responses in aortic rings from control rats (two-tailed unpaired t-test).
Endothelium-denuded aortic rings from LPS-treated rats were significantly less
responsive to NE when compared with responses in endothelium-denuded aortic
rings from control rats, as demonstrated by a right and downward shift ofNE CRCs
(P<0.01, two-way ANOVA, Figure 3.2). Indeed, maximal contractions for NE
CRCs were significantly lower in aortic rings from LPS-treated rats when compared
with those from control rats (LPS-treated, 1.3 ± 0.2; control, 2.7 ± 0.2 gram tension,
P<0.001, two-tailed unpaired t-test).
Treatment of endothelium-denuded aortic rings from LPS-treated rats with the
non-selective NOS inhibitor, L-NAME (2 x 10 4 M), increased responsivenss to NE
(P<0.001, two-way ANOVA, Figure 3.2). Treatment of aortic rings from control rats
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Figure 3.2 Cumulative concentration response curves (CRC) showing contractile
responses to norepinephrine (NE; 1 x 1CT9 to 3 x 10~5 M) in endothelium-denuded
thoracic aortic rings from LPS-treated (n=8) and control rats (n=7). Also shown are
CRCs to NE in the presence of the non-selective nitric oxide synthase inhibitor,
L-NAME (2 x 104 M). Values are given as means ± s.e.m. ** P<0.01 for CRCs in
untreated rings from LPS-treated rats compared with CRCs in untreated aortic rings
from control rats, ++ P<0.01 for CRCs in rings treated with L-NAME compared
with untreated aortic rings from LPS-treated rats, (two-way ANOVA).
100
Chapter 3
3.3.2 Investigation of the pharmacological selectivity of 1400W
3.3.2.1 KCI, norepinephrine maximal constrictions and endothelial
integrity
Maximal constrictions to KCI (60 mM) and a supramaximal concentration ofNE (10"
5
M) in endothelium-intact aortic rings from LPS-treated rats were significantly less
than those in endothelium-intact rings from control rats (P<0.05, two-tailed unpaired
/-test, Table 3.2). All aortic rings from LPS-treated and control rats had functional
endothelium (Table 3.2). However, relaxations to ACh were significantly smaller in
aortic rings from LPS-treated rats when compared with aortic rings from control rats
(P<0.05, two-tailed unpaired /-test).
Control LPS-treated
(«=:8) («=8)
60 mM KCI 4.6+0. lg 2.7±0. lg*
10"5M NE 5.7±0.2g 3.5±0.2g*
10~5M ACh 90±2% 74+4%*
Table 3.2 Maximal contractions (gram tension) ofendothelium-intact thoracic aortic
rings from lipopolysaccharide (LPS)-treated and control rats, to KCI and
norepinephrine (NE). Responses of NE-contracted aortic rings to acetylcholine
(ACh) are given as percentages ofNE (EC50)-induced tone. All values are given as
means ±s.e.m. * P<0.05 as compared with respective responses in aortic rings from
control rats (two-tailed unpaired t-test).
3.3.2.2 Effect of 1400W on vascular responsiveness in aortic rings from
LPS-treated rats
There were no significant differences between cumulative CRCs to NE performed in
aortic rings treated with 1400W at a concentration of 10~6 M when compared with
those in aortic rings in the absence of 1400W (P>0.05, two-way ANOVA; Figure
3.3, Table 3.3). In contrast, treatment of endothelium-intact aortic rings from LPS-
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treated rats with 10~5 M or 10"4M 1400W, significantly increased NE responsiveness
when compared with responsiveness of aortic rings in the absence of 1400W (P<0.05
for both, two-way ANOVA, Figure 3.4, 3.5, Table 3.3). pD2 values and maximal
contractions to NE were significantly increased in the presence of 10"4 M 1400W
when compared with untreated aortic rings (E<0.05, one-way ANOVA with
Bonferroni post-test, Table 3.3). There was no significant difference between pD2
values and maximal contractions to NE in aortic rings treated with 10~5 M or 10~4 M
1400W when compared with those in untreated rings from control rats (P>0.05, one¬
way ANOVA, Table 3.3) indicating that 1400W had effectively restored adrenergic

















Figure 3.3 Cumulative concentration response curves (CRC) to norepinephrine
(NE; 1 x 1CT9 to 3 x 10~5M) in endothelium-intact aortic rings from
lipopolysaccharide (LPS)-treated rats (n-8) in the presence of 10'6 M 1400W.
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Figure 3.4 Cumulative concentration
(NE; 1 x 1CT9 to 3 x I0'5 M)
lipopolysaccharide (LPS)-treated rats
Values are given as means ± s.e.mean.
aortic rings (two-way ANOVA).
response curves (CRC) to norepinephrine
in endothelium-intact aortic rings from
(n=8) in the presence of 10'5 M 1400W.
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Figure 3.5 Cumulative concentration response curves (CRC) to norepinephrine
(NE; 1 x 1CT9 to 3 x 10'5 M) in endothelium-intact aortic rings from
lipopolysaccharide (LPS)-treated rats (n-8) in the presence of 10'4 M 1400W.
Values are given as means ± s.e.mean. ** P<0.01 compared with CRCs in control
aortic rings (two-way ANOVA).
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Control (n=8) LPS-treated 6/7=8)
pD2 Max (g) pD2 Max (g)
Untreated 6.9+0.1 5.4±0.4 6.4±0.2* 2.8±0.7*
1400W 10"6M 7±0.1 6.4±0.6 6.6±0.1 3.3±0.7
1400W 10"5M 7.1 ±0.1 6.1 ±0.5 7.0±0.2 4.1±0.5
1400W lO^M 7.1 ±0.1 6±0.5 7.2±0.2t 4.6±0.7+
Table 3.3 pD? values and maximal contraction (Max) values to norepinephrine in
endothelium-intact aortic rings from LPS-treated and control rats in the presence
and absence of 1400W. Values are given as means ± s.e.mean. * P<0.05 compared
with respective values in untreated aortic rings from control rats (one-way ANOVA
with Bonferroni post-test). + P<0.05 compared with pD2 values and maximal
contractions in untreated aortic rings from LPS-treated rats (one-way ANOVA with
Bonferroni post-test).
3.3.2.3 Effect of 1400W on basal and agonist-stimulated release of nitric
oxide from eNOS
No concentration of 1400W (10~6 M - 10"4 M) had any significant effect on
cumulative CRCs to NE in endothelium-intact aortic rings from control rats (Figure
3.6, Table 3.3).
Following induction of NE-induced tone (untreated, 58.7 ± 11.1%; 10"6 M 1400W,
57.7 ±7%; 10"5M 1400W, 51.2 ±6.4%; 104M 1400W, 63.5 ± 4.6% ofmaximal NE
contractions, P>0.05, one-way ANOVA) in endothelium-intact aortic rings
cumulative additions of ACh (1 x 10 9 to 3 x 10"5 M) resulted in concentration-
dependent relaxations (Figure 3.7). No concentration of 1400W (10~6 M - 10"4 M)
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Figure 3.6 Cumulative concentration response curves to norepinephrine
(NE; 1 x 10~9 to 3 x 10~5M) endothelium-intact aortic rings from control rats (n=8)
in the presence of 10~6M 1400W, 10'5M 1400W and 10~4M 1400W. Values are given
as means ± s.e.mean. P>0.05 for CRCs in untreated aortic rings compared with
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Figure 3.7 Cumulative concentration response curves to acetylcholine
(ACh, 1 x 1CT9 to 3 x 10'5 M) in norepinephrine-contracted (~ ECeo) endothelium-
intact aortic rings from control rats (n=8) in the presence of 10'6 M 1400W, 10'5 M
1400W and 10' M 1400W. Values are given as means ± s.e.mean. P>0.05 for CRCs





Experiments in this chapter demonstrate that the novel iNOS inhibitor, 1400W
(1CT5 M to 1CT4 M), increased the responsiveness of endothelium-intact rat aortic
rings from LPS-treated rats, most likely as a consequence of decreased synthesis of
NO by iNOS. Furthermore, in endothelium-intact aortic rings from control rats,
1400W (KT6 M to 1CT4 M) had no significant effect on NE contractions or ACh-
mediated relaxations, suggesting that 1400W does not inhibit basal or agonist-
stimulated synthesis of NO by eNOS. These results provide convincing evidence that
1400W is a selective iNOS inhibitor in vitro.
Numerous studies have demonstrated that endothelium-intact and
endothelium-denuded blood vessels isolated from rats treated with LPS are
hyporesponsive to a variety of vasoconstrictors (Julou-Schaeffer et al., 1990;
Weigert et al., 1995). Furthermore, this hyporesponsiveness is reversed by
non-selective inhibitors of NOS irrespective of the presence or absence of the
endothelium, implying that enhanced NO formation from iNOS accounts for the
hyporeactivity. Indeed, studies have demonstrated that iNOS can be detected within
the vasculature from LPS-treated rats (Buttery et al., 1994; Sato et al., 1995).
Consistent with these findings, immunohistochemical studies in this chapter
demonstrated that iNOS was expressed in endothelial cells, VSM cells and in the
adventitia of thoracic aortae from LPS-treated rats but not in thoracic aortae from
control rats. Plasma NOx concentrations were significantly greater in LPS-treated rats
when compared with control rats. Therefore, in this model of endotoxic shock, LPS
administration results in the expression of iNOS within the thoracic aorta and also a
significant increase in the synthesis of NO, probably derived from iNOS. Isolated
endothelium-denuded aortic rings from LPS-treated rats were significantly less
responsive to NE when compared with responses in endothelium-denuded rings from
control rats. Furthermore, treatment of aortic rings with the non-selective NOS
inhibitor, L-NAME, reversed this hyperesponsiveness. Therefore, in accordance with
the aforementioned studies (Julou-Schaeffer et al., 1990; Weigert et al., 1995),
results here indicate that the expression of iNOS in the thoracic aortae as a
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consequence of LPS administration results in a profound hyporeactivity to NE. The
findings of these experiments are not novel, however, they confirm that this is a
reliable in vitro model for investigating the pharmacological properties of the novel
iNOS inhibitor, 1400W.
Besides its role in the vascular dysfunction associated with the pathogenesis of
endotoxic shock, excessive production of NO by iNOS has been linked to the
pathogenesis of a wide range of other diseases. These include cerebral ischaemia
(Iadecola et al., 1997), chronic inflammation (Moilamen et al., 1999) and
neurodegeneration (Okuda et al., 1995). Furthermore, recent studies reveal that iNOS
is expressed in the heart in experimental MI (Wildhirt et al., 1995) and in patients
with CHF (Fukuchi et al., 1998). However, investigations into the role of iNOS in
the pathogenesis of such diseases are limited by the lack of NOS inhibitors that can
distinguish between iNOS and eNOS.
Numerous compounds have been developed that are capable of inhibiting the
biological activity of NO. These include drugs which prevent the uptake of NOS
substrate, L-arginine, into cells (Bogle et al., 1992), agents which reduce the supply
of cofactors required for NO synthesis by NOS (Werner-Felmayer et al., 1990),
inhibitors of electron flow from nicotanamide adenine dinucleotide phosphate
(NADPH) to the flavins in the reductase domain of NOS (Kumagai et al., 1998;
Wolff et al., 2000) and drugs which prevent the binding of L-arginine to NOS
(reviewed by Hobbs et al., 1999). The most commonly used NOS inhibitors are the
L-arginine analogues, for example L-NAME and A^-monomethyl-L-arginine (L-
NMMA), whose main pharmacological action is to compete with L-arginine (Hobbs
et al., 1999). However, very little selectivity toward NOS isoforms is achieved with
this group of compounds, making them unsuitable for use in studies where selective
inhibition of iNOS is essential. There are some compounds available, however, that
demonstrate relative selectivity towards iNOS. Guanidines, in particular
aminoguanidine has been shown to be equipotent to L-NMMA in inhibiting iNOS in
vitro but significantly less potent in inhibiting NO synthesis by eNOS (Yen et al.,
1995). However, very high doses are required to elicit significant inhibition of iNOS
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in vivo (Wu et al., 1995). At such concentrations, aminoguanidine is likely to inhibit
eNOS as well as catalase and other iron- and copper-containing enzymes, resulting in
the accumulation of superoxide and other free radical species (Ou & Wolff, 1993).
The bisisothioureas are also reported to be potent and selective inhibitors of iNOS.
For example, the novel bisisothiourea, S\ S'-(l,3-phenylenebis (1,2-
ethanediyl))bisisothiourea (PBITU) was found to be 190-fold selective for human
purified iNOS compared with eNOS (Garvey et al., 1994). However, their lack of
passage across cell membranes and their high toxicity has meant that this group of
compounds are unlikely to become useful therapeutic agents (Garvey et al., 1994).
Recently, a derivative of PBITU, A-(3-(Aminomethyl) benzyl) acetamidine
dihydrochloride (1400W), has been described as a selective iNOS inhibitor (Garvey
et al., 1997). 1400W is reported to be at least 5000-fold more selective for human
iNOS than eNOS and was quoted at its time of discovery to be the most selective
inhibitor of human iNOS ever reported (Garvey et al., 1997). Furthermore, in a rat
model of endotoxic shock, 1400W has been shown to prevent systemic hypotension
as well increased plasma NOx levels attributable to LPS-induced iNOS expression
(Wray et al., 1998). Further to its selectivity for human iNOS, 1400W is active and
non-toxic in vivo (Garvey et al., 1997; Laszlo & Whittle, 1997; Wray et al., 1998).
Despite the evidence provided by these studies, somewhat surprisingly, in vitro
studies directly investigating the pharmacological selectivity of 1400W for iNOS
over eNOS are still lacking. Therefore, in view of these findings, experiments in this
chapter were designed to test the hypothesis that 1400W inhibits the activity of iNOS
in vitro without modifying the activity of eNOS. In endothelium-intact aortae from
rats treated with LPS, 1400W significantly increased responsiveness of endothelium-
intact thoracic aortae to NE in a concentration-dependent manner (10~5 M - 10"4M).
Indeed, in the presence of 1400W there were no significant differences between pD2
values and maximal contractions for NE CRCs in aortae from LPS-treated when
compared with responses in control aortic rings, indicating that 1400W had
effectively restored responsiveness to NE. To investigate the pharmacological
selectivity of 1400W for iNOS over eNOS, both basal and agonist-stimulated
synthesis of NO by eNOS were assessed in isolated aortic rings from control rats in
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the presence and absence of 1400W. Treatment of rings with 1400W had no
significant effect on responses to NE, suggesting that 1400W has no effect on basal
production of NO from eNOS. Similarly, 1400W did not modify relaxations to the
endothelium-dependent vasodilator ACh, suggesting that 1400W has no effect on the
agonist-stimulated synthesis of NO from eNOS. The findings of these experiments
provide convincing evidence that 1400W inhibits the activity of iNOS in aortic rings
from LPS-treated rats without modifying the activity of eNOS.
From the experiments presented in this chapter the mechanism by which 1400W
selectively inhibits the activity of iNOS is not clear. Garvey et al. (1997) demonstrate
that the binding of 1400W to purified human iNOS could be prevented by
pre-treatment with L-arginine, suggesting that 1400W may inhibit iNOS by
competiting with L-arginine for the substrate binding site on iNOS. Subsequent
experiments demonstrated that once 1400W was bound to the enzyme, L-arginine
was unable to reverse its inhibitory effects on NO synthesis. These findings suggest
that 1400W is either an irreversible inhibitor of iNOS, or one whose activities are
reversed very slowly. Although this data gives some insight into its mechanism of
action, it does not explain why 1400W is selective inhibitor of iNOS. Indeed, if it is
behaving like an L-arginine analogue one would expect, in a similar manner to other
L-arginine analogues, that it would readily inhibit the activity of eNOS. In the study
by Garvey et al., further experiments demonstrated that the kinetics of 1400W
binding to iNOS were time-dependent, and were described as a two-step mechanism.
Furthermore, it was suggested that selectivity of 1400W for iNOS was derived from
interactions that developed slowly. Indeed, recent observations have suggested that
this slow phase of inhibition involves a conformational change of NOS that is
thought to be specific to iNOS (Cooper et al., 2000, unpublished observations by
personal communication). In addition to the possible allosteric inhibitory properties
of 1400W, Garvey et al. (1997) found that the slow phase of its inhibition of iNOS
was dependent on the presence of NADPH. Because electrons from NADPH
oxidation are essential for the eventual reduction of haem (see Section 1.3,3), 1400W
binding may alter this flow of electrons and thus inactivate iNOS. Again it is not
obvious why 1400W would not alter electron flow in other isoforms of NOS. It is
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clear from this discussion that further experiments are needed to elucidate the precise
mechanism by which 1400W inhibits iNOS, in order to provide further avenues for
developing novel iNOS inhibitors with even greater selectivity than 1400W.
In conclusion, experiments in this chapter provide convincing evidence that the
recently described iNOS inhibitor, 1400W, inhibits the activity of iNOS in vitro
without modifying the activity of eNOS. These findings corroborate those of
biochemical studies and emphasise its potential as an important investigative and




Investigation of the superoxide dismutase properties




Endothelium-derived nitric oxide (NO) is rapidly inactivated by the oxygen-derived
free radical, superoxide, leading to a loss of its vasodilatory action (Gryglewski et
al., 1986). In eukaryotic cells, three isoforms of superoxide dismutase (SOD) exist;
an extracellular Cu/Zn-containing form, an intracellular Cu/Zn-containing form, and
an Mn-containing form present in the mitochondria (Fridovich, 1983), all of which
serve to dismutate endogenous superoxide. Studies involving the use of the copper
chelator, diethyldithocarbamate (DETCA), suggest that the Cu/Zn-containing
isoforms of SOD are of critical importance in protecting endothelium-derived NO
from inactivation by superoxide (Omar et al., 1991; Mian & Martin, 1995;
MacKenzie & Martin, 1998).
A loss of NO-mediated vasodilatation as a consequence of increased production or
decreased scavenging of superoxide has been linked to the pathogenesis of numerous
cardiovascular diseases. For example, atherosclerosis (Ohara et al., 1993),
hypertension (Bouloumie et al., 1997) and chronic heart failure (CHF; Belch et al.,
1991; Katz et al., 1993) are all associated with increased superoxide and impaired
endothelium-dependent relaxations. Elevation of the activity of endogenous SOD
might therefore form the basis of a strategy for therapeutic intervention in these
cardiovascular diseases. Elowever, it is unlikely that treatment with authentic
isoforms of SOD will be of benefit. This is because native isoforms of SOD are large
in size and are unlikely to penetrate cellular membranes to protect NO from
intracellular superoxide, furthermore, they have a very short half-life and are
therefore rapidly cleared from the circulation. To overcome these limitations, an
increasing number of low molecular weight, cell permeable compounds that exhibit
SOD-like activity have recently been developed. These include simple metal salts
(eg. MnCb; MacKenzie & Martin, 1998), free radical spin traps (eg. 4-hydroxy
2,2,6,6-tetramethylpiperidine, tempol; Mitchell et al., 1990) and metal-based SOD
mimetics (eg. metalloporphyrins; Patel & Day, 1999).
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The metalloporphyrins have emerged as an important class of novel SOD mimetics,
owing to them being stable, active, and non-toxic in vivo (Patel & Day, 1999) and
also due to their ability to permeate cell membranes (Liochev & Fridovich, 1995).
One compound belonging to this group is Mn [III] tetrakis [l-methyl-4-pyridyl]
porphyrin (MnTMPyP). MnTMPyP has been shown to facilitate the growth of SOD-
deficient Escherichia Coli. (Faulkner et al., 1994). Furthermore, MacKenzie &
Martin (1998) recently demonstrated that MnTMPyP protects agonist-stimulated
activity of NO from inactivation by superoxide in isolated rabbit aortae subjected to
intracellular and extracellular oxidative stress. Despite this evidence, recent studies
have suggested that MnTMPyP may actually scavenge NO itself by producing
superoxide (Gardner et al., 1996; MacKenzie et al., 1999), or it may interfere with
the NO/soluble guanylate cyclase (sGC) pathway (Pfeiffer et al., 1998). Furthermore,
it has been demonstrated that MnTMPyP may also inhibit the activity of endothelial
nitric oxide synthase (eNOS) and inducible NOS (iNOS; Pfeiffer et al., 1998).
In view of these findings, experiments in this chapter were designed to investigate
whether MnTMPyP can protect endothelium-derived NO from inactivation by
superoxide in an in vitro model of oxidative stress (Mian & Martin, 1995), without
having any non-selective inhibitory effects on the activity of eNOS or iNOS-derived




All procedures were carried out as described in Chapter 2.
4.2.1 Tissue harvesting and preparation of aortic rings
Male Wistar rats (rc=18, 250 - 350 g) were killed by stunning and exsanguination.
Thoracic aortae were removed and placed into cold, oxygenated (95% O2, 5% CO2)
Krebs Henseleit solution.
For experiments investigating the effect of MnTMPyP on the synthesis of NO by
iNOS, male Wistar rats («=6; 250 - 350 g) were injected with lipopolysaccharide
(LPS; 30 mgkg"1, i.p.) as described in Section 2.1.1.2 and left for 5 h to develop
endotoxic shock. Rats were then killed by stunning and exsanguination, thoracic
aortae removed and placed in into cold, oxygenated (95% 02, 5% CO2) Krebs
Henseleit solution.
Thoracic aortae were cleaned of adhering adipose and connective tissue and cut into
transverse rings (~ 4mm). In some aortic rings the endothelium was removed by the
method described in Section 2.2.2. Aortic rings were then mounted in a 10 ml organ
bath filled with warm (37 °C), oxygenated (95% 02, 5% CO2) Krebs Henseleit
solution (see Section 2.2.1). Aortic rings were placed under 2 gram of tension and
left to equilibrate for 60 min. The general protocol (see Section 2.2.2) was performed
on all aortic rings before commencing the experimental protocols described below.
4.2.2 Experimental protocols
4.2.2.1 Model of oxidative stress
Many compounds are capable of producing superoxide, or inducing its production
from the tissues themselves, and thus are suitable for inducing oxidative stress within
isolated tissues. These compounds include the copper chelator, DETCA (MacKenzie
& Martin, 1998), which inhibits Cu/Zn isoforms of SOD, xanthine
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oxidase/hypoxanthine (XO/HX), a superoxide generating system, and the superoxide
generating compound, pyrogallol (Halliwell & Gutteridge, 1989). Pyrogallol has
been used in numerous studies investigating the effects of superoxide on the activity
of both endogenous and exogenous NO (Ignarro et al., 1988; Mian & Martin, 1995).
Furthermore, pyrogallol has been shown to produce a profound decrease in the
magnitude of both basal and agonist-stimulated activity of endothelium-derived NO
in isolated rat aortic rings (Ignarro et al., 1988; Mian & Martin, 1995). It was for
these reasons that pyrogallol was used in experiments here to induce oxidative stress
in isolated rat aortic rings.
Pyrogallol is thought to oxidise spontaneously in solution with simultaneous
production of superoxide (Halliwell & Gutteridge, 1989). Hydrogen Peroxide (H202)
is formed whenever superoxide is generated by its rapid one electron reduction and
protonation, catalysed by SOD. Additionally superoxide can reduce transition metals
such as iron or copper that can, in turn, react with H202 to generate the highly
reactive hydroxyl radical (OH") in the metal catalysed Haber-Weiss reaction (Pal Yu,
1994). Both H202 and OH" have been shown to damage the endothelium and thus
may impair endothelial function (Beckman et al., 1990; Todoki et al, 1992).
Furthermore, H202 increases the liberation of NO (Rubanyi & Vanhoutte, 1986) and
there is evidence that it can mediate VSM relaxation directly (Burke & Wolin, 1987;
Zembowicz et al., 1993). Indeed, in preliminary experiments, treatment of
norepinephrine (NE)-contracted endothelium-intact rat aortic rings with pyrogallol
resulted in a delayed but rapid fall in arterial tone (data not shown). Furthermore, this
decrease in arterial tone was prevented when rings were pre-treated with catalase
(1000 U ml-1), which catalyses the decomposition of H202 to water and oxygen.
Consequently, to remove H202 and guard against the formation of OH', all
experiments described below were carried out in the presence of catalase. Aortic




To assess the effects of pyrogallol on the activity of eNOS-derived NO, and thus
establish whether this is a reliable model of oxidative stress, both basal and agonist-
stimulated activity of NO were assessed in endothelium-intact aortic rings in the
absence and presence of pyrogallol.
The activity of basal eNOS-derived NO was assessed indirectly by measuring
contractile responses to NE (Martin et al., 1986). To ensure that the amount of
superoxide generated throughout the duration of experimental protocols was
constant, instead of carrying out cumulative concentration response curves (CRC) to
norepinephrine (NE), which can take up to 50 min to complete, a submaximal
concentration of NE was chosen and the effect of pyrogallol on this NE-induced tone
examined. Therefore, endothelium-intact aortic rings were exposed to a submaximal
concentration of NE (~ EC6o)- Once responses had stabilised, rings were treated with
pyrogallol (3 x 10"4 M, n=8). At a concentration of 3 x 10"4 M, pyrogallol has
previously been shown to inhibit NO-mediated relaxations in isolated rat aortic rings
(Mian & Martin, 1995). Responses were recorded 5 min after addition of pyrogallol.
Agonist-stimulated activity of NO was assessed by measuring ACh-induced
relaxations. A submaximal concentration of NE (~ ECeo) was used to induce arterial
tone. Once contractions were stable, cumulative CRCs to ACh (1 x 1CT8 to 3 x 10"5
M, n=6) were obtained. On completion of CRCs, rings were repeatedly washed and
allowed to re-equilibrate for at least 15 min before further experimentation. Rings
were then treated with pyrogallol (3 x 10"4 M, n=6) for 5 min prior to inducing NE (~
EC60) tone and repeating cumulative CRCs to ACh (1 x 10"8 to 3 x 1CT5M).
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4.2.2.2 Effects of MnTMPyP on the activity of eNOS-derived nitric oxide
in pyrogallol-treated aortic rings
To investigate whether MnTMPyP can protect NO from destruction by superoxide,
experimental protocols described in Section 4.2.2.1 were repeated in the presence of
MnTMPyP (n>6). On the basis of a previous study, a concentration of ICC* M
MnTMPyP was used in these experiments (MacKenzie & Martin, 1998). Rings were
exposed to MnTMPyP for 30 min prior to and throughout the duration of the
experiments.
4.2.2.3 Effect ofMnTMPyP on the synthesis of nitric oxide by eNOS
To determine if MnTMPyP has any non-selective effects on the activity of NO
derived from eNOS or the enzyme itself, both basal and agonist-stimulated activity
of NO were assessed in endothelium-intact aortic rings in the absence and presence
of MnTMPyP.
To assess the effect of MnTMPyP on basal synthesis of NO by eNOS, cumulative
CRCs to NE (1 x 10"9 to 3 x 10"5 M, n-1) were constructed in endothelium-intact
aortic rings. On completion of CRCs rings were repeatedly washed and allowed to
re-equilibrate for at least 15 min before further experimentation. Aortic rings were
then exposed to MnTMPyP (10~4 M, n-1) for 30 min prior to repeating cumulative
CRCs to NE (1 x 10"9 to 3 x 10"5M).
To assess the effect of MnTMPyP on agonist-stimulated synthesis of NO by eNOS,
cumulative CRCs to ACh (1 x 10~8 to 3 x 10"5 M, /?=8) were constructed in
endothelium-intact aortic rings following induction of NE (~ EC6o)-induced tone. On
completion of CRCs, rings were repeatedly washed and allowed to re-equilibrate for
at least 15 min before further experimentation. Aortic rings were then exposed to
MnTMPyP (10~4 M, n=8) for 30 min prior to repeating cumulative CRCs to ACh
(1 x 10"8 to 3 x 10"5M).
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4.2.2.4 Effect ofMnTMPyP on the synthesis of nitric oxide by iNOS
In Chapter 3, experiments demonstrated that administration of LPS to rats resulted
in the expression of iNOS in thoracic aortae. Furthermore, as a consequence of
iNOS-derived NO, endothelium-intact and endothelium-denuded aortic rings from
LPS-treated rats were hyporesponsive to NE when compared with responses in aortic
rings from control rats. These findings support the use of thoracic aortae isolated
from LPS-treated rats in experiments here, investigating the effect of MnTMPyP on
the activity of NO derived from iNOS, and the activity of iNOS itself.
Therefore, to investigate the effect of MnTMPyP on the activity of NO derived from
iNOS and the activity of the enzyme itself, cumulative CRCs to NE (1 x 10~9 to 3 x
10"5 M, n-6) were constructed in endothelium-denuded aortic rings from rats treated
with LPS. On completion of CRCs, rings were repeatedly washed and allowed to re-
equilibrate for at least 15 min before further experimentation. Aortic rings were then
exposed to MnTMPyP (10~4 M, n-6) for 30 min prior to repeating cumulative CRCs
to NE (1 x 10~9 to 3 x 10"5 M). At the end of cumulative CRCs to NE, rings were
treated with the NOS substrate, L-arginine (10~3 M, n-5) to verify the expression of
iNOS within aortic rings (Julou-Schaeffer et al., 1990). A concentration of 10"3 M
was chosen, since this concentration has been shown to result in a 15-fold increase in
the EC50 concentration for NE in aortic rings from LPS-treated rats (Schott et al.,
1993). Responses were recorded 30 min after addition of L-arginine.
4.2.3 Preparation of drugs
Norepinephrine hydrogentartrate, acetylcholine chloride and L-arginine
hydrochlroride were diluted in Krebs Henseleit solution to give a stock solution of
10_1 M and frozen (-20 °C) in aliquots until use on day of experiment. Vitamin C
(10~6 M) was added to the stock solution of NE to prevent autoxidation. Catalase
(bovine liver), pyrogallol and Mn [III] tetrakis [1-methyl-4-pyridyl] porphyrin





All results were expressed as means ± s.e.mean. Cumulative CRCs to ACh and NE
were measured as percentage relaxations of NE-induced tone and percentages of
maximal contractions to KC1, respectively. The half-maximal relaxation {pD^) was
calculated for ACh CRCs by nonlinear regression using GraphPad Prism software
(Version 3.0) where indicated in the text. Two-tailed t-tests, one-way analysis of
variance (ANOVA) with Bonferroni multiple comparisons post-test and two-way
repeated measures ANOVA were used as indicated in the text. P<0.05 was




4.3.1 Effects of superoxide generation on the activity of eNOS-derived
nitric oxide
The endothelium was deemed intact in aortic rings as relaxations to ACh were
86.6 ± 4.4% of NE (~ EC6o)-induced tone (n=14).
4.3.1.1 Basal activity of nitric oxide
After induction of NE (~ EC6o) tone in endothelium-intact aortic rings
(1.6 ± 0.3 gram tension), addition of pyrogallol (3 x 10"4M) resulted in a rapid rise in
arterial tone (to 2.3 ± 0.3 gram tension, P<0.01, one-way ANOVA with Bonferroni
post-test; Figure 4.1, Figure 4.2). Indeed, the tension of aortic rings was increased
by 41.2 ± 6.7% in the presence of pyrogallol (Figure 4.5).
Figure 4.1 A representative experimental trace showing the effect of pyrogallol
(Pyr; 3 x 10'4 M) on norepinephrine (NE; ECfff-induced tone in endothelium-intact
rat aortic rings (n=8). All experiments were carried out in the presence of catalase
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Figure 4.2The effect of pyrogallol (Pyr; 3 x 10~4 M) on norepinephrine
(NE; EC6o)-induced tone in endothelium-intact rat aortic rings All
experiments were carried out in the presence of catalase (1000 U ml1). Values are
given as means ± s.e. mean. ** P<0.01 compared with gram tension in untreated
aortic rings (one-way ANOVA with Bonferronipost-test).
4.3.1.2 Agonist-stimulated activity ofnitric oxide
Following induction of NE tone (untreated, 65 ± 5.6 %; pyrogallol-treated, 69.3 ±
7.3% of maximal NE contraction) in endothelium-intact aortic rings, cumulative
additions of ACh (l x 10"8 to 3 x 10"5 M) resulted in concentration dependent
relaxations ( Figure4.3). Addition of pyrogallol (3 x 10"4 M) caused a marked
inhibition of ACh relaxations when compared with relaxations in untreated aortic
rings (PO.OOl, two way ANOVA, Figure 4.3). Indeed, maximal % relaxations to
ACh were significantly lower in rings treated with pyrogallol when compared with
untreated rings (untreated, 93.2 + 8; pyrogallol-treated, 59.4 ± 5.2% relaxations of
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Figure 4.3 Cumulative concentration response curves (CRC) to acetylcholine
(ACh; 1 x 10 s to 3 x 10~5 M) in norepinephrine (~ EC6o)-contracted endothelium-
intact rat aortic rings (n=6) in the presence and absence ofpyrogallol (3 x 10'4 M).
Values are given as means ± s.e.mean. All experiments were carried out in the
presence of catalase (1000 U ml'1). *** P<0.001 compared with cumulative CRCs in
untreated aortic rings (two-way ANOVA).
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4.3.2 Effects of MnTMPyP on the activity of eNOS-derived nitric oxide in
pyrogallol-treated aortic rings
The endothelium was deemed intact in aortic rings as relaxations to ACh were
81.2 ± 9% ofNE (~ EC6o)-induced tone (n=12).
4.3.2.1 Basal activity ofnitric oxide
Arterial tone (~ EC6o; 1.9 ± 0.3 gram tension) induced in endothelium-intact aortic
rings treated with MnTMPyP (10"4 M) did not differ from the tone induced in aortic
rings used in Section 4.3.1.1 (P>0.05, one-way ANOVA). Subsequent addition of
pyrogallol (3 x 10"4 M) to rings had no significant effect on arterial tone (to 2 ± 0.3
gram tension; Figure 4.4) Indeed, the tension of aortic rings was increased by only
8.8 ± 3.6%, contrasting with an increase of 41.2 ± 6.7% in the absence ofMnTMPyP











NE NE + Pyr
Figure 4.4 The effect of pyrogallol (Pyr; 3 x 10~4 M) on norepinephrine
(NE; EC6o)-inducedtone in endothelium-intact rat aortic rings (n=8) in the presence
ofMnTMPyP (10~4 M). All experiments were carried out in the presence of catalase
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Figure 4.5 Percentage increases in norepinephrine (NE; EC6o)-induced tone in
pyrogallol (Pyr; 3 x 10~4 M)treatedendothelium-intact rat aortic rings (n=16) in the
presence and absence ofMnTMPyP (10~4 M). All experiments were carried out in the
presence of catalase (1000 U ml ).Valuesare given as means s.e.mean.
** P<0.01 compared with percentage increases in arterial tone in rings treated with
pyrogallol in the absence ofMnTMPyP (two-tailed unpaired t-test).
4.3.2.2 Agonist-stimulated activity ofnitric oxide
In the presence ofMnTMPyP, pyrogallol had no significant effect on relaxations to
ACh (1 x 10~8 to 3 x 10"5 M) in NE-contracted (untreated, 61 ± 6%; pyrogallol-













Figure 4.6 Cumulative concentration response curves to acetylcholine
(ACh; 1 x 1CT8 to 3 x 10'5 M) in norepinephrine (~ EC6o)-contracted endothelium-
intact rat aortic rings (n-6) in the presence and absence ofpyrogallol (3 x 10'4 M)
andMnTMPyP (10'4M). All experiments were carried out in the presence of catalase
(1000 U mT1). Values are given as means ± s.e.mean. P>0.05, two-way ANOVA.
• Control
▼ + Pyrogallol (3 x 10-4 M)
+ MnTMPyP (10 4 M)
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4.3.3 Effect of MnTMPyP on eNOS-derived nitric oxide
The endothelium was deemed intact in aortic rings as relaxations to ACh were
74 ± 4.8% of NE (~ EC6o)-induced tone (n=15).
MnTMPyP (10~4 M) had no significant effect on cumulative CRCs to NE
(1 x 10~9 to 3 x 10"5 M) in endothelium-intact aortic rings (Figure 4.7). In the
presence of MnTMPyP (10~4 M) pTE values for cumulative CRCs to ACh
(1 x 10"8 to 3 x 10"5 M, Figure 4.8) were significantly increased (pD2 values;
untreated, 6.6 ±0.1; MnTMPyP-treated, 7.1 ± 0.1, P<0.05, two-tailed paired f-test),
indicating an increase in responsiveness to ACh. There were no significant
differences between maximal % relaxations to ACh in untreated and






















Figure 4.7 Cumulative concentration response curves to norepinephrine
(NE; 1 x 1CT9 to 3 x 10'5 M) in endothelium-intact rat aortic rings (n=7) in the






















Figure 4.8 Cumulative concentration response curves to acetylcholine
o c
(ACh; 1 x 10 to 3 x 10' M) in norepinephrine (~ EC6o)-contracted endothelium-
intact rat aortic rings (n-8) in the presence and absence of MnTMPyP (10~4 M).
Values are given as means ± s.e.mean. P>0.05, two-way ANOVA.
4.3.4 Effect of MnTMPyP on iNOS-derived nitric oxide
In endothelium-denuded aortic rings from LPS-treated rats, relaxations to ACh
(~ EC60) were less than 5% of NE-induced tone (2.3 ± 0.2%, n-6) indicating
successful denudation.
MnTMPyP (10" M) had no significant effect on cumulative CRCs to NE
(1 x 10"9 to 3 x 10"5 M) in endothelium-denuded aortic rings from LPS-treated rats
(Figure 4.9). Treatment of rings with L-arginine (10~3 M) at the end of CRCs to NE
resulted in a significant decrease in gram tension (without L-arginine, 1.1 ±0.3 gram
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tension; with L-arginine, 0.1 ± 0.1 gram tension, P<0.05, two-tailed paired t-test),













Figure 4.9 Cumulative concentration response curves to norepinephrine
(NE; 1 x 1CT9 to 3 x 10'5 M) in endothelium-denuded aortic rings (n-6) from
lipopolysaccharide-treated rats in the presence and absence ofMnTMPyP (10~4 M).




Experiments in this chapter demonstrate that the novel metalloporphyrin, MnTMPyP
(1CT4 M) prevents both the augmentation of NE-generated arterial tone and the
impairment of ACh-mediated relaxations in endothelium-intact rat aortic rings
induced by the superoxide-generating compound, pyrogallol (3 x 1CT4 M). These
findings suggest that MnTMPyP can protect both basal and agonist-stimulated
endothelium-derived NO from inactivation by superoxide. Under conditions of low
oxidative stress, ie. in the absence of pyrogallol, MnTMPyP (1CT4 M) increased
responsiveness of endothelium-intact rat aortic rings to ACh and had no significant
effect on NE responsiveness, implying that MnTMPyP (10^ M) does not inhibit
basal or agonist-stimulated activity of eNOS-derived NO or the activity of eNOS.
Similarly, MnTMPyP appears to have no effect on the activity of NO derived from
iNOS or the activity of the enzyme itself, since contractile responses to NE in
endothelium-denuded aortic rings from LPS-treated rats were unaffected by
MnTMPyP (KT4 M).
Endothelium-derived NO is rapidly inactivated by the oxygen-derived free radical,
superoxide, leading to a loss of its vasodilatory action (Gryglewski et al., 1986).
Treatment of isolated blood vessels with high concentrations of the
superoxide-generating compound, pyrogallol, has previously been shown to impair
both basal and agonist-stimulated activity of endothelium-derived NO as a
consequence of increased inactivation of NO by superoxide (Ignarro et al., 1988;
Mian & Martin, 1995). Experiments in this chapter demonstrate that treatment of
endothelium-intact rat aortic rings with pyrogallol (3 x 10~4 M) augmented
NE-induced tone and resulted in a profound decrease in ACh-mediated relaxations.
Therefore, in accordance with the aforementioned studies, results here imply that
both basal and agonist-stimulated activities of endothelium-derived NO are inhibited
by superoxide generated from pyrogallol. These findings confirm that this is a
reliable in vitro model of oxidative stress, with sufficient quantities of superoxide
being produced to impair endothelium-derived NO even when the endothelial-NO
pathway is maximally stimulated.
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The metalloporphyrins have emerged as a novel class of catalytic antioxidants that
scavenge a wide range of reactive oxygen species including superoxide (Patel &
Day, 1999). In this chapter, the SOD mimetic properties of one such compound,
MnTMPyP, were investigated. As with other compounds belonging to this class of
SOD mimetics, MnTMPyP consists of a metal redox active centre embedded in a
porphyrin ring (Patel & Day, 1999). Previously, MnTMPyP has been shown to
catalyse the dismutation of superoxide in the xanthine-oxidase cytochrome assay
with a rate constant of approximately 10~7 M"V and in SOD-deficient E.Coli with a
rate constant of approximately 10_9 M"V (Faulkner et al., 1994). Moreover,
MnTMPyP protected E.Coli against paraquat-induced oxidative stress (Liochev &
Fridovich, 1995) and facilitated the growth of SOD-deficient E.Coli (Faulkner et al,
1994). The precise mechanism by which this manganese-based metalloporphyrin
mediates its SOD-like activity is yet to fully defined, but, it is thought that the
manganese moiety functions in the dismutation of superoxide by alternate reduction
and oxidation, changing its valence state from Mn(III) to Mn(II) in a similar manner
to native Mn-containing SOD (Patel & Day, 1999).
In keeping with its SOD-like properties, experiments in this chapter demonstrate that
pre-treatment of endothelium-intact rat aortic rings with MnTMPyP (1CT4 M)
prevents the augmentation of NE arterial tone and the impairment of ACh-mediated
relaxations induced by pyrogallol (3 x 10"4 M). These results imply that MnTMPyP
can protect both basal and agonist-stimulated endothelium-derived NO under
conditions of high oxidative stress by acting as a SOD mimetic. Furthermore, these
findings are consistent with recent studies demonstrating that MnTMPyP (1CT M to
6 x 10"4 M) is capable of restoring endothelium-dependent relaxations in isolated
rabbit aortic rings subjected to both intracellular and extracellular oxidative stress
(MacKenzie & Martin, 1998; Fontana et al., 1999).
Despite the compelling evidence presented here, and from other studies (Faulkner et
al., 1994; Liochev & Fridovich, 1995; MacKenzie & Martin, 1998; Fontana et al.,
1999), that MnTMPyP is an effective SOD mimetic, recent studies provide evidence
that the prevailing redox environment may be of critical importance in determining
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its precise pharmacological profile. Interestingly, it has been suggested that in
contrast to situations of high oxidative stress, where MnTMPyP preferentially
scavenges superoxide, when levels of oxidative stress are low MnTMPyP may
participate in other redox reactions resulting in the paradoxical generation of
superoxide (Gardner et al., 1996; MacKenzie et al., 1999). In the aforementioned
study by MacKenzie et al. (1999), MnTMPyP was found to augment phenylephrine
(PE)-induced constrictions of endothelium-intact rat aortic rings under conditions of
low oxidative stress. Moreover, this augmentation was blocked when the
endothelium was removed or when aortic rings were treated with an inhibitor of
NOS, suggesting that MnTMPyP was inactivating rather than protecting basal
endothelium-NO activity. In subsequent experiments, MacKenzie et al. (1999)
demonstrated that the effect of MnTMPyP on PE-induced tone was also blocked by
pre-treatment of rings with authentic Cu/Zn SOD, implying that this augmentation in
constriction arose through inactivation of NO by superoxide derived from
MnTMPyP. Interestingly, they also demonstrated that this pharmacological property
of MnTMPyP was dependent on its concentration. In particular, increases in PE-
induced tone were only seen with concentrations of 10~8 M to 3 x 10~5 M MnTMPyP,
with concentrations greater than 3 x 10~5 M failing to increase in contractile
responses. From the experiments presented in their study, the mechanism by which
MnTMPyP generates superoxide under low levels of oxidative stress was unclear.
Furthermore, it is unclear why the concentration of MnTMPyP was so crucial in
determining whether it generates superoxide or not.
In addition to its possible pharmacological effect on the bioavailability of eNOS-
derived NO, MnTMPyP has also been shown to directly interfere with the NO/sGC
pathway in cultured endothelial cells, as well as purified sGC either activated with a
NO donor or reconstituted with NOS, under low levels of oxidative stress (Pfeiffer et
al., 1998). Specifically, in the presence of reducing agents such as glutathione,
MnTMPyP directly inhibited the activity of sGC and decreased the accumulation of
NO, as measured by the conversion of L-[3H]arginine to L-[3H]citrulline, as well as
the accumulation of cyclic guanosine 3', 5' monophosphate (cGMP). MnTMPyP was
also shown to inhibit the activities of recombinant eNOS and iNOS, possibly by
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interfering with the flow of electrons from NADPH to the haem moiety of the
oxygenase domain (Pfeiffer et al., 1998). In contrast with the findings of MacKenzie
et al. (1999), experiments in this study found that the inhibitory effects of MnTMPyP
on the NO pathway were not dependent on its concentration. Indeed, the inhibitory
effects of MnTMPyP were seen over a wide concentration range (10~9 M to 5 x 10~3
M).
It is clear from the discussion presented here that the use of MnTMPyP in situations
of high oxidative stress, may well serve its purpose, protecting endothelium-derived
NO from inactivation by superoxide. However, if MnTMPyP is used when levels of
superoxide in blood vessels are low, but at a sufficient level to modify NO
bioavailability, MnTMPyP may well generate superoxide rather than acting as a
scavenger, resulting in a paradoxical increase in vascular tone. Furthermore, it may
directly interfere with the NO signalling pathway. It is of paramount importance,
therefore, to determine the precise pharmacological properties of MnTMPyP in
situations of low oxidative stress. To address this issue, experiments were designed
in aortic rings from healthy and LPS-treated rats under conditions of low oxidative
stress, ie. in the absence of pyrogallol, to determine whether MnTMPyP, at a
concentration of 1CT4 M, modifies the activity of NO derived from either eNOS or
iNOS, or the activities of the enzymes themselves. Findings from these experiments
demonstrated that at a concentration of 10-4 M, MnTMPyP had no effect on
contractile responses of endothelium-intact rat aortic rings to NE and increased
responsiveness of rings to ACh. These results imply that at this concentration,
MnTMPyP does not inhibit the activity of basal or agonist-stimulated eNOS-derived
NO, nor does it inhibit the activity of the enzyme itself. Indeed, the sensitivity of
aortic rings to ACh was increased suggesting that MnTMPyP protected agonist-
stimulated activity of eNOS-derived NO from low levels of superoxide present in the
organ bath. In a similar manner to eNOS, MnTMPyP appears to have no effect on the
activity of NO derived from iNOS or the activity of iNOS, since contractile
responses to NE in endothelium-intact aortic rings from LPS-treated rats were
unaffected by MnTMPyP (1CT4 M). Therefore, in accordance with the study by
MacKenzie et al. (1999) findings from these experiments clearly suggest that in
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conditions of low oxidative stress and at a concentration of 10 M, MnTMPyP
appears not to generate superoxide. However, these findings contrast with those of
Pffefier et al. (1998) who show that at this concentration, MnTMPyP interferes with
the NO/sGC pathway in cultured endothelial cells and inhibits the activity of purified
isoforms of NOS. Differences between cultured cells and tissue preparations may
explain these discrepancies. In particular, one may expect levels of oxidative stress to
be much lower in cultured endothelial cells than those found in oxygenated organ
baths with segments of blood vessels, and thus MnTMPyP may be more prone to
participate in other redox reactions and thus interfere with the NO pathway. Indeed,
as previously mentioned, responsiveness of aortic rings to ACh were increased in the
presence of MnTMPyP, suggesting that superoxide production within the organ baths
was at a sufficient level to modify NO bioavailabilty.
In summary, experiments in this chapter clearly demonstrate that at a concentration
of 1CT4 M, MnTMPyP acts as an effective SOD mimetic, protecting
endothelium-derived NO from destruction by superoxide. Furthermore, at this
concentration MnTMPyP does not inhibit the activity of NO derived from either
eNOS or iNOS, or the activity of the enzymes themselves, under conditions of low
oxidative stress.
It is clear, however, that for MnTMPyP to emerge as a useful therapeutic tool in the
treatment of cardiovascular pathologies, further experiments are required to clarify
its precise pharmacological properties. In particular, experiments are required to
elucidate how and why it generates superoxide in conditions of low oxidative stress
and why its concentration is so crucial in determining this pharmacological property.
Furthermore, studies are required to determine if the effects of MnTMPyP on the
NO/sGC pathway and the activity of NOS would be a true pharmacological effect in
vivo, or whether these properties are unique to experiments using cultured




Investigation of the distribution of immunoreactive
inducible nitric oxide synthase in the cardiovascular




Although not constitutively expressed within the cardiovascular system, inducible
nitric oxide synthase (iNOS) can be induced in most cells, including cardiomyocytes
(Brady et al., 1992; Balligand et al., 1994), vascular endothelial and smooth muscle
cells (Schulz et al., 1991; Balligand et al., 1995; Fleming et al., 1991) in response to
inflammatory cytokines and pathogens. In isolated cardiomyocytes, induction of
iNOS by inflammatory cytokines and the subsequent production of large quantities
of NO inhibits myocyte contractility (Brady et al., 1992; Brady et al., 1993).
Furthermore, the expression of iNOS within the heart during endotoxic shock is
associated with depressed cardiac function (Schulz et al., 1995; Sun et al., 1997).
Intriguingly, the expression of iNOS in the heart has been linked to chronic heart
failure (CFIF). Some studies have reported the presence of calcium-independent NOS
activity within the myocardium from patients with CHF (de Belder et al., 1993;
Drexler et al., 1998). Other investigators have directly detected the presence of iNOS
mRNA and protein (Haywood et al., 1996; Fukuchi et al., 1998; Vejlstrup et al.,
1998). However, the cellular location of iNOS in the heart during CHF is not well
defined. Furthermore, previous studies have at times failed to define its anatomical
distribution throughout the heart.
There is abundant evidence demonstrating that endothelium-dependent relaxations in
both conductance and resistance arteries are impaired in CHF (Drexler & Lu, 1992;
Teerlink et al., 1994; Bauersachs et al., 1999; Bank et al., 1994; Carville et al.,
1998). In contrast, data on basal release of NO in CHF is controversial. Some studies
suggest that basal release of NO is preserved or may even be enhanced in CHF
(Drexler et al., 1992; Habib et al., 1994; Winlaw et al., 1994), while other studies
show that it is impaired (Eisner et al., 1991; Teerlink et al., 1994; Hirai et al., 1995;
Varin et al., 1999). The expression of iNOS in the peripheral vasculature during CHF
has not been directly investigated, but, it has been suggested that iNOS-derived NO
is responsible for the dissociation between basal and stimulated release of NO in
CHF (Carville et al., 1998; Bauersachs et al., 1999; Varin et al., 1999).
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The aims of experiments in this chapter were, therefore, to determine if iNOS is
expressed in hearts isolated from rats with CHF following coronary artery ligation
(CAL), and if so, investigate its spatial distribution throughout the heart.
Furthermore, experiments were carried out to determine if iNOS is expressed in




All procedures were carried out as described in Chapter 2.
5.2.1 Rat coronary artery ligation model of chronic heart failure
Myocardial infarction (MI) was induced in 5 week old male Wistar rats (250 -300 g)
by ligation of the left anterior descending coronary artery (CAL) as described in
Section 2.1.2.2,
5.2.2 Haemodynamic measurements and tissue harvesting
Six weeks post-surgery, CAL and sham-operated rats were anaesthetised with
sodium pentobarbitol (60 mgkg"1, i.p.). The right carotid artery was then located,
dissected free of extraneous tissue and then cannulated with a fluid filled catheter
attached to a pressure transducer, for measurement of mean arterial blood pressure
(MAP) and left ventricular end-diastolic pressures (LVEDP; see Section 2.1.2.3).
Following exsanguination, the mesenteric bed was excised, the gut removed and the
remaining vascular bed placed into cold, oxygenated (95% O2, 5% CO2), Krebs
Henseleit solution for functional studies (see Chapter 6). Sections of the mesenteric
bed and thoracic aortae from both CAL and sham-operated rats were placed in 10%
neutral buffered formalin for 24 h prior to further processing and wax embedding as
described in Section 2.1.2,4, The hearts and lungs were removed, rinsed in ice-cooled
saline (0.9%) then individually weighed. Hearts were bisected, fixed and processed
as before.
5.2.3 Measurement of infarct size
3 prn sections of hearts were taken from blocks and stained with van Gieson's
collagen stain for detection of collagen formation in left ventricular (LV) infarctions
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(see Section 2.1.2.5), Infarct size was then calculated by the method described in
Section 2.1.2.5,
5.2.4 Immunohistochemistry
3 pm sections of small mesenteric arteries, thoracic aortae and hearts were taken
from paraffin embedded blocks. Immunohistochemistry was then performed using
the indirect alkaline phosphatase method, with a rabbit anti-iNOS monoclonal
primary antibody (concentration; mesenteric arteries, 1/250; aortae, 1/250; hearts,
1/300) and a goat anti-rabbit alkaline phosphatase-conjugated secondary antibody
(concentration; mesenteric arteries, 1/50; aortae, 1/50; hearts, 1/100) as described in
Section 2.5.5, To verify selectivity of the primary antibody for iNOS,
immunohistochemistry was performed on sections of thoracic aortae from
lipopolysaccharide (LPS)-treated rats (E.Coli LPS, 30 mg kg"1 i.p. for 5 h, see
Chapter 3). Negative controls were treated with an antibody of the same
immunoglobulin (Ig) class but not directed against the iNOS epitope (see Section
2.5.5), Tissues were then treated with Harris' haematoxylin to counterstain nuclei.
5.2.5 Data Analysis
All results were expressed as means ± s.e.mean. Two-tailed unpaired t-tests were




5.3.1 Effect of left coronary artery ligation
All the animals that survived the first 24 h after CAL surgery (76%) were still alive 6
weeks later. There were no significant differences between rat weights for CAL and
sham-operated groups at 6 weeks after surgery (Table 5.1). Heart weights (corrected
for body weight) for CAL rats were significantly greater than those of sham-operated
rats (P<0.05, two-tailed unpaired t-test, Table 5.1). There were no significant
differences between groups with respect to lung weights (corrected for body weight,
P=0.1, unpaired t-test, Table 5.1) and MAPs (P=0.08, unpaired t-test, Table 5.1).
LVEDPs measured from CAL rats were significantly greater than those for sham-
operated rats (P<0.05, two-tailed unpaired t-test, Table 5.1).
Sham CAL
(n>8) (n>8)
Rat Weight (g) 495.7+22.3 473.9+9.7
Heart Weight (g kg ' body weight) 2.7+0.1 . 3.3+0.2*
Lung Weight (g kg 1 body weight) 3.3+0.1 4.3+0.5
LVEDP (mmHg) 6+1.1 15.4+1.5***
Mean arterial pressure (mmHg) 94.8+6.2 78.2+5.7
Table 5.1 Summary ofparameters measured from coronary artery ligation (CAL)
and sham-operated (Sham) rats 6 weeks post-surgery. All values are given as means
± s.e.m. * P<0.05, *** P<0.001 for CAL rats compared with respective values in
sham-operated rats (two-tailed unpaired t-test).
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Hearts from CAL rats had LV infarctions which averaged 60 ± 3% of the LV free
wall. Treatment of sections with van Gieson's collagen stain, stained LV infarctions
pink with a few remaining areas of viable myocytes staining yellow (Figure 5.1a).
These findings indicate that LV infarctions were principally composed of collagen.
In hearts from sham-operated rats, cardiomyocytes and all other cell types were
stained yellow, with only the collagenous adventitial layer of blood vessels and





Figure 5.1 Representative images of heart sections from coronary artery ligation
(CAL) and sham-operated rats (n=6) treated with van Gieson's collagen stain.
Collagen (pink staining) was detected in left ventricular infarctions of hearts from
CAL rats (Panel a; xlOO, scale bar = 200 jum). In hearts from sham-operated rats,
collagen (pink staining) was detected in the adventitia of blood vessels and
interstitial tissue (arrows) of the myocardium (Panel b; x200, scale bar = 45
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5.3.2 Localisation of inducible nitric oxide synthase in the heart
iNOS immunoreactivity was found in the cytoplasm of some but not all
cardiomyocytes in the interventricular septum in hearts from CAL rats 6 weeks post-
ligation (Figure 5.2a). Immunoreactive iNOS was found in the cytoplasm of viable
cardiomyocytes at the border of the infarct and within the infarct itself (Figure 5.2b,
5.3a). However, no iNOS immunoreactvity was detected within the infarcted
myocardium (.Figure 5.3a).
In contrast with the LV myocardium, no immunoreactive iNOS was detected in
cardiomyocytes within the right ventricular (RV) myocardium of hearts from CAL
rats (Figure 5.3b).
No immunoreactive iNOS was found in cardiomyocytes of the LV (Figure 5.4) and
RV myocardium nor in the interventricular septum (data not shown) in hearts from
sham-operated rats 6 weeks post-surgery.
Immunoreactive iNOS was found in endothelial cells, vascular smooth muscle
(VSM) cells and in the adventitia of thoracic aortae from rats treated with LPS
verifying the selectivity of the iNOS antibody (see Chapter 3, Figure 3.1a). No
immunoreactive staining was found in heart sections from CAL rats using an






Figure 5.2 Immunohistochemical localisation of iNOS in representative heart
sections from coronary artery ligation rats (n=6) six weeks post-ligation.
Immunoreactive iNOS (red staining) was localised to the cytoplasm of viable
cardiomyocytes within the interventricular septum (Panel a) and at the border of the
infarct (Panel b; I = infarcted myocardium). Nuclei are counterstained with Harris'





Figure 5.3Immunohistochemical localisation of iNOS in representative heart
sections from coronary artery ligation rats (n=6) six weeks post-ligation.
Immunoreactive iNOS (red staining) was detected in viable cardiomyocytes (V)
within the infarct (I; Panel a; scale bar = 30 However, no immunoreactive
iNOS was found in cardiomyocytes within the right ventricular myocardium (Panel




Figure 5.4 A representative image showing absence of iNOS immunoreactivity in the
left ventricular myocardium ofheartsfrom sham-operated rats (n=6) six weeks post-
surgery. Nuclei are counterstained with Harris' Haematoxylin (purple staining).
Magnification x200, scale bar = 40 pm.
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iNOS immunoreactivity was detected in endothelial cells of intramyocardial blood
vessels within the LV myocardium of hearts from CAL rats (Figure 5.5a). No
immunoreactivity was found, however, in VSM cells or in the adventitia (Figure
5.5a). Blood vessels within the RV myocardium of hearts from CAL rats showed no
iNOS immunoreactivity (Figure 5.5b). Similarly, no iNOS immunoreactivity was
found in intramyocardial blood vessels within hearts from sham-operated rats (data
not shown).
iNOS immunoreactivity was found in endocardial endothelial cells within the LV







Figure 5.5Immunohistochemical localisation of iNOS in intramyocardial blood
vessels in coronary artery ligation rats (n=6) six weeks post-ligation.
Immunoreactive iNOS (red staining) was located to endothelial cells (arrow) of
intramyocardial blood vessels within the left ventricular myocardium (Panel a; scale
bar = 20 pm).No iNOS immunoreactivity was detected in intramyocardial blood
vessels within the right ventricular myocardium (Panel b; scale bar = 45 pm). Nuclei




Figure 5.6Representative images of heart sections from coronary artery ligation
rats (n=6) six weeks post-ligation, showing immunoreactive iNOS (red staining) in
endocardial endothelial cells (arrow, x200, scale bar 25 ofthe left ventricular
myocardium. Nuclei are counterstained with Harris' Haematoxylin (purple staining).
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5.3.3 Localisation of inducible nitric oxide synthase in small mesenteric
arteries and thoracic aortae
Immunoreactive iNOS was found in endothelial cells, VSM cells and in the
adventitia of small mesenteric arteries from CAL rats (Figure 5.7a). No
immunoreactivity was found in small mesenteric arteries from sham-operated rats
(.Figure 5.7b) or in negative controls using IgG antibodies (data not shown).
Similarly, immunoreactive iNOS was found in endothelial cells, VSM cells and in
the adventitia of thoracic aortae from CAL rats (Figure 5.8a). No staining was found
in aortae from sham-operated rats (Figure 5.8b) or in negative controls using IgG





Figure 5.7 Images of representative sections of small mesenteric arteries from
coronary artery ligation (CAL) and sham-operated rats (n=6). Immunoreactive
iNOS (red staining) was detected in endothelial cells (E), vascular smooth muscle
cells (V) and in the adventitia (A) of arteries from CAL rats (Panel a), but not in
arteries from sham-operated rats (Panel b). Nuclei are counterstained with Harris'





Figure 5.8 Images ofrepresentative sections of thoracic aortae from coronary artery
ligation (CAL) and sham-operated rats (n=6). Immunoreactive iNOS (red staining)
was detected in endothelial cells (E),vascularsmooth muscle cells (V) and in the
adventitia (A) of aortae from CAL rats (Panel a), but not in aortae from sham-
operated rats (Panel b). Nuclei are counterstained with Harris' Haematoxylin




The salient finding of experiments described in this chapter is that iNOS is expressed
in both the heart and peripheral vasculature in rats with CHF. Using
immunohistochemistry, iNOS was found to be located to cardiomyocytes throughout
the non-infarcted LV myocardium and also in viable cardiomyocytes within the
infarct. Furthermore, iNOS was detected in coronary vascular and endocardial
endothelial cells within the LV myocardium. Interestingly, no iNOS was detected
within the RV myocardium. In small mesenteric arteries and thoracic aortae from rats
with CUF, iNOS was located to endothelial cells, VSM cells and to the adventitia.
LV infarct size is recognised to be a major determinant of the severity of CHF in rats
after CAL (Pfeffer et al., 1979). Pfeffer et al. (1979) revealed that the degree of
myocardial cell death after CAL is directly related to impaired LV function.
Furthermore, Pfeffer et al. demonstrated that rats with infarctions greater than 46%
of the left ventricle resulted in elevated diastolic pressures and reduced cardiac
outputs. In this chapter, six weeks after CAL, rats had infarctions averaging 60 % of
the LV free wall. Furthermore, LVEDPs were significantly elevated when compared
with those in sham-operated rats. Histological examination of hearts using van
Gieson's collagen stain revealed that a fibrous scar, composed mainly of collagen,
had replaced infarcted areas of hearts from CAL rats. Furthermore, heart weights,
corrected for body weight, were significantly greater than those for sham-operated
rats, indicating that hearts from CAL rats had undergone compensatory hypertrophy.
These results demonstrate that rats had developed CHF as a consequence of CAL.
This model resembles those of others who used rats with large infarcts and
significantly elevated LVEDPs in the context of severe CHF (Sakai et al., 1996a;
Sakai et al., 1996b; Kobayashi et al., 1999).
Experimental studies have demonstrated that iNOS is expressed in the myocardium
after CAL and subsequent MI. In rabbits, CAL resulted in a significant increase in
NO synthesis within the infarcted myocardium, which persisted for at least 14 days
post-MI (Dudek et al., 1995). Furthermore, immunohistochemical studies revealed
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that the induction of iNOS in infiltrating macrophages was responsible for this
increase in NO synthesis (Dudek et al., 1995; Wildhirt et al., 1995). From these
studies it would appear that the expression of iNOS in the heart is transient and
associated with injury to the heart and the subsequent inflammatory response.
However, there is now evidence that iNOS may be induced in the heart at later stages
during CHF (de Belder et al., 1993; Haywood et al., 1996; Fukuchi et al., 1998;
Vejlstrup et al., 1998). De Belder et al. (1993) reported that iNOS is expressed in
heart biopsies from patients with dilated cardiomyopathy and suggested that this was
the result of the specific inflammatory etiology of this condition (de Belder et al.,
1993b). However, some (Haywood et al., 1996; Fukuchi et al., 1998; Drexler et al.,
1998; Vejlstrup et al., 1998) but not all (Stein et al., 1998; Thoenes et al., 1996)
investigators have since detected the presence of iNOS mRNA and protein in
explanted hearts from patients with ischaemic and non-ischaemic end-stage CHF,
suggesting that iNOS expression might be a feature of the CHF condition per se.
Since the first report of iNOS induction in CHF, the in vivo anatomical distribution
of iNOS in the heart has been a matter for debate (Brady, 1993; Shah, 1993).
Invariably, iNOS has been located to the LV free wall and intraventricular septum
(Haywood et al., 1996; Fukuchi et al., 1998; Vejlstrup et al., 1998), of explanted
hearts from patients with ischaemic and non-ischaemic CHF, with only some
investigators detecting its presence within the RV myocardium (de Belder et al.,
1993; Haywood et al., 1996). Furthermore, the cell types in which iNOS is expressed
during CHF are not well defined. It has been suggested that the cardiomyocyte is the
predominant source of iNOS in CHF, however, this is not universally accepted.
Habib et al. (1996) and Haywood et al. (1996) reported immunohistochemical
evidence for cytoplasmic iNOS protein expression in cardiomyocytes of hearts from
patients with end-stage CHF. However, in a study of 22 explanted hearts from
patients with end-stage CHF, Vejlstrup et al. (1998) reported that iNOS was
expressed in cardiomyocytes in only a minority of patients. Furthermore, Fukuchi et
al. (1998) revealed that increased iNOS activity was intimately associated with
infiltrating macrophages and not with cardiomyocytes, in hearts from patients with
CHF of varying pathologies. Surprisingly, very little data is available regarding its
155
Chapter 5
expression within the coronary vasculature. Consequently, experiments in this
chapter were carried out to determine if iNOS was expressed in the heart in a rat
model of CHF, and if so, to investigate its spatial distribution within the heart.
Using immunohistochemistry, experiments in this chapter revealed that iNOS is
expressed in hearts from CHF rats but not in hearts from sham-operated rats. In
particular, iNOS was located to the LV free wall and interventricular septum. In
contrast, no iNOS was detected within the RV myocardium. These results
corroborate the findings of some (Haywood et al., 1996; Fukuchi et al., 1998) but not
all investigators (de Belder et al., 1993; Vejlstrup et al., 1998), and suggest that the
induction of iNOS in the failing heart during CHF might be specific to the LV
myocardium.
With respect to its cellular localisation, experiments revealed that in this model of
CHF, the cardiomyocyte is the predominant cell type expressing iNOS. In particular,
iNOS was localised to viable cardiomyocytes in both the infarcted and non-infarcted
myocardium. However, in this model of CHF, the expression of iNOS in the heart is
not exclusive to the cardiomyocyte. Indeed, examination of intramyocardial blood
vessels within the LV myocardium, revealed that iNOS is also expressed in vascular
endothelial cells. Interestingly, iNOS could not be detected in VSM cells or in the
adventitia. A recent study by Vejlstrup et al. (1998) demonstrated that iNOS was
expressed in the coronary vasculature in explanted hearts from patients with end-
stage CHF. However, in contrast with the findings in this chapter, Veljstrup et al.
revealed that iNOS was expressed in both vascular endothelial and smooth muscle
cells. In accordance with a recent study by Fukuchi et al. (1998), iNOS was detected
in endocardial endothelial cells of the interventricular septum, suggesting that iNOS
expression might not be exclusive to endothelial cells of the coronary vasculature.
The pathophysiological mechanisms underlying the induction of iNOS in the heart in
this model of CHF were not investigated. As discussed in Chapter 3 of this thesis,
inflammatory cytokines, such as TNF-a and interleukin-1 (IL-1) can induce the
expression of iNOS in cardiomyocytes (Brady et al., 1992; Balligand et al., 1994),
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and vascular endothelial and smooth muscle cells (Schulz et al., 1991; Balligand et
al., 1995; Fleming et al., 1991). Interestingly, there is evidence that inflammatory
cytokines are expressed in the heart during CHF. Torre-Amione et al. (1996b),
demonstrated that TNF-a mRNA and protein was expressed in the LV myocardium
from patients with both ischaemic and non-ischaemic end-stage CHF. In a more
recent study, Francis et al. (1998) established that IL-1 mRNA and protein was
expressed in cardiomyocytes and vascular endothelial cells within the LV
myocardium of explanted hearts from patients with ischaemic CHF. Furthermore, in
rats with CHF following CAL, mRNA for TNF-a, IL-1 and IL-6 was detected in the
non-infarcted LV myocardium (Ono et al., 1998). Therefore, inflammatory cytokines
may well serve a stimulus of iNOS expression in CHF.
Interestingly, a recent study by Kapadia et al. (1997), demonstrated that passive
mechanical stretch induced the expression of TNF-a in cardiomyocytes and non-
cardiomyocytes in the adult feline myocardium. Consequently, the authors of this
study suggested that passive mechanical stretch, such as that which occurs during the
progressive LV remodelling associated with CHF (see Section 1.5.5.1), might be a
sufficient stimulus to provoke the expression of TNF-a within the failing heart. If
this is indeed the case, it is conceivable that the induction of iNOS within the failing
heart may be ultimately dependent on the amount of mechanical stretch exerted on
the heart. Indeed, the findings from this chapter and from other studies (Haywood et
al., 1996; Fukuchi et al., 1998) suggest that iNOS induction in the failing heart might
be exclusive to areas of the heart, in particular the non-infarcted LV myocardium,
where mechanical stretch is likely to be high. Germane to this discussion is the
observation that the expression of TNF-a in the heart in response to other stimuli,
besides mechanical stretch, is self-limiting and occurs only in response to the
superimposed environmental stimuli (Giroir et al., 1992; Kapadia et al., 1995).
Therefore, the expression of TNF-a, and the subsequent induction of iNOS
throughout the heart might not be static but instead may vary considerably depending
on the levels of mechanical stretch present within the heart. This hypothesis may
explain why there is such disparity between studies regarding the cellular and
anatomical distribution of iNOS in the heart during CHF. The hypothesis presented
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here is provocative, however, it does represent an assumption based on correlations
rather than direct evidence. It is clear, therefore, that further studies are required to
fully address the relationship between inflammatory cytokines and mechanical
stretch in regulating the induction of iNOS in the heart during CHF. As discussed in
Section 1.5.5.1, mechanical stretch is thought to play a important role in the LV
remodelling associated with CHF. Studies suggest that mechanical stretch can
activate multiple signal transduction pathways, similar to those activated by growth
factors (Swynghedauw, 1999). Further to its possible role in the LV hypertrophy
associated with remodelling, mechanical stretch has been shown to induce apoptosis
of cardiomyocytes (Cheng et al., 1995; see Section 1.5.5.1). NO has been shown to
act as a bifunctional regulator of apoptosis. Physiological relevant levels of NO seem
to suppress the apoptotic pathway at multiple levels and by several pathways (Kim et
al., 1999; Li et al., 1999a). However, higher concentrations of NO may overwhelm
cellular protective mechanisms and exert proapoptotic and cytotoxic effects (Kim et
al., 1999). Indeed, cytokine-induced expression of iNOS has been shown to induce
cardiomyocyte apoptosis (Ing et al., 1999). Furthermore, the balance between the
apoptotic mediators, Bak and BcL-x, which respond specifically to individual
cytokines, was shown to modulate the extent of cardiomyocyte apoptosis (Ing et al.,
1999). There is some evidence that NO may have an anti-hypertrophic effect on the
heart. Ishigai et al. (1997), demonstrated in neonatal rat cardiomyocytes that both
bradykinin and the angiotensin converting inhibitor, perindoprilat, inhibited
phenylephrine-induced increases in protein and DNA content via an NO-dependent
mechanism. Furthermore, an anti-hypertrophic effect of NO is also suggested by
experimental and clinical studies (reviewed by Shah & MacCarthy, 2000). Taken
together these studies suggest an interesting relationship between mechanical stress,
inflammatory cytokines, NO and the LV remodelling associated with CHF.
However, it is clear that further studies are necessary to exploit this relationship and
to investigate further if NO contributes to LV remodelling by inducing apoptosis or if
it plays a counter-regulatory role in reducing hypertrophy.
In addition to their upregulation in the heart during CHF, plasma levels of
inflammatory cytokines are also elevated in patients with CHF (Levine et al., 1990;
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Torre-Amione et al., 1996a; Anker et al., 1997). Furthermore, in contrast with
impaired endothelium-dependent relaxations (Drexler et al., 1992; Teerlink et al.,
1994b) some studies suggest that basal NO synthesis of NO by the peripheral
vasculature may be preserved or even enhanced in CHF (Drexler et al., 1992; Habib
et al., 1994; Winlaw et al., 1994). Moreover, some investigators have hypothesised
that expression of iNOS is responsible for this dissociation (Carville et al., 1998;
Varin et al., 1999). In contrast with the heart, the expression of iNOS within the
peripheral vasculature during CHF has not been addressed. Experiments in this
chapter reveal that iNOS is expressed in endothelial cells, VSM cells and in the
adventitia of small mesenteric arteries and thoracic aortae from rats with CHF, but
not in arteries from sham-operated rats. This is the first study to demonstrate iNOS
expression in the peripheral vasculature in experimental CHF. These findings are,
however, contrast with the findings of a recent study, which failed to detect iNOS in
thoracic aortae from rats 8 weeks after CAL (Bauersachs et al., 1999). However, rats
used here had larger infarcts than those used in the aforementioned study, perhaps
suggesting that the severity of the model influences iNOS expression. The functional
significance if iNOS expression in the peripheral vasculature is addressed in
Chapters 6 and 7 of this thesis.
In conclusion, the findings of this chapter reveal for this first time that iNOS is
expressed in both the heart and peripheral vasculature in a rat model of CHF.
Furthermore, these experiments provide novel insight into its spatial distribution




Investigation of the role of inducible nitric oxide
synthase and superoxide in modulating vascular





Endothelium-derived nitric oxide (NO) plays a vital role in the regulation of
vasomotor tone and arterial blood pressure (see Section 1.4.1). Evidence is
accumulating to suggest that impaired NO-mediated vasodilatation of resistance
arteries contributes to increased peripheral vascular resistance (PVR) associated with
chronic heart failure (CHF). In clinical and experimental CHF, it has been
demonstrated that endothelium-dependent relaxations of peripheral resistance arteries
in response to acetylcholine are impaired (Drexler & Lu, 1992; Drexler et al., 1992;
Katz et al., 1992). In contrast, data on basal release of NO from resistance arteries in
CHF is controversial. Some studies suggest that basal release of NO from the
peripheral vasculature is preserved or may even be enhanced in CHF (Drexler et al.,
1992; Habib et al., 1994; Winlaw et al., 1994). Furthermore, there is evidence that
plasma concentrations of nitrate, the stable end product of NO, are increased in
patients with CHF (Kubo et al., 1994; Winlaw et al., 1994; Carville et al., 1998). In
contrast, other functional studies suggest that basal synthesis of NO is impaired in
CHF (Eisner et al., 1991; Hirai et al., 1995; Varin et al., 1999). The aetiology of
endothelial dysfunction associated with CHF is unclear and is likely to be complex.
In Chapter 5, immunohistochemical studies demonstrated that iNOS is expressed in
the hearts from rats with CHF following coronary artery ligation (CAE).
Furthermore, experiments revealed that iNOS was also expressed in small mesenteric
arteries from rats with CHF following CAE but not in those from sham-operated
control rats. It is possible that NO derived from iNOS may be responsible for
increased basal production of NO associated with CHF.
Irrespective of its source, increased basal production of NO should counteract
compensatory constrictor mechanisms and thus reduce PVR. Increased superoxide is
also associated with CHF (Belch et al., 1991; Diaz-Velez et al., 1996). Superoxide
scavenges NO (Gryglewski et al., 1986), and a therefore reduction in NO
bioavailability might explain why PVR remains elevated in CHF despite a preserved
or enhanced basal release of NO. Furthermore, increased scavenging of NO by
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superoxide may be responsible for impaired relaxations to endothelium-dependent
vasodilators.
The aims of the experiments in this chapter were, therefore, to determine the
functional significance of iNOS-derived NO on vascular responsiveness of isolated
small mesenteric arteries from rats with CHF following CAL, and to investigate the




All procedures were carried out as described in Chapter 2.
6.2.1 Tissue harvesting and preparation of arteries from mesenteric bed
The mesenteric bed was isolated from both CAL and sham-operated rats 6 weeks
post-surgery (see Chapter 5) and placed in cold, oxygenated (95% O2, 5% C02)
Krebs Henseleit solution.
Third order branches of the mesenteric artery (~ 3 mm long; internal diameter, ~ 300
- 350 pm) were dissected free of the mesenteric bed as described in Section 2.3.2,
Arteries were then mounted onto two fine glass microcannulae (~ 100 - 150 pm tip
diameter) in a small vessel pressure myograph (see Section 2.3.3), and were
continuously superfused with warm (37 °C), oxygenated (95% 02, 5% C02) Krebs
Henseleit solution. Intraluminal pressure of the artery was raised to 60 mmHg and
maintained at this level without further intraluminal perfusion. In some arteries the
endothelium was removed by the method described in Section 2.3.5, After an
equilibration period of 60 min, the general protocol (see Section 2.3.5) was
performed on all arteries prior to carrying out the experimental protocols described
below.
6.2.2 Experimental protocols
6.2.2.1 Vascular responsiveness of arteries from coronary artery
ligation and sham-operated rats
To assess vascular responsiveness of small mesenteric arteries from CAL and
sham-operated rats to adrenoceptor stimulation, cumulative concentration response
curves (CRC) to phenylephrine (PE; 1 x 10"9 to 3 x 10~5 M) were constructed in
endothelium-intact (n=8) and endothelium-denuded (n=6) arteries. Following
completion of CRCs, all vessels were repeatedly washed and allowed to re-
equilibrate for at least 15 min before further experiments.
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6.2.2.2 Effect of inducible nitric oxide synthase inhibition on vascular
responsiveness
To investigate the role of iNOS in modulating vascular responsiveness, endothelium-
intact mesenteric arteries were exposed to the selective iNOS inhibitor,
yV-(3-(Aminomethyl) benzyl) acetamidine dihydrochloride (1400W; 10~6 M, n=8) for
30 min prior to repeating cumulative CRCs to PE (1 x 10~9 to 3 x 10~5 M). In
Chapter 3, it was revealed in vitro that 1400W inhibits iNOS without modifying the
basal or agonist-stimulated activity of eNOS-derived NO. From these experiments,
however, concentrations greater than 10~6 M were required to achieve significant
inhibition of iNOS in thoracic aortae from rats with endotoxic shock. Thoracic aortae
are considerably larger in size than the mesenteric arteries used in this chapter. For
this reason, 1400W was used at a concentration of 10~6 M in experiments here.
1400W was present in the superfusate throughout the cumulative CRC.
6.2.2.3 Effect of superoxide quenching on vascular responsiveness
To investigate the role that superoxide plays in modulating vascular responsiveness,
endothelium-intact mesenteric arteries were exposed to the cell permeable
metalloporphyrin superoxide dismutase (SOD) mimetic, Mn [III] tetrakis [1-methyl-
4-pyridyl] porphyrin (MnTMPyP; 10"4 M, n-8) for 30 min prior to repeating
cumulative CRCs to PE (1 x 1CT9 to 3 x 10~5 M). In Chapter 4 of this thesis,
experiments demonstrate that at a concentration of 10~4 M, MnTMPyP protects
endothelium-derived NO from inactivation by superoxide in an in vitro model of
oxidative stress, without having any non-selective effects on the bioavailability of
eNOS or iNOS-derived NO, or the activity of the enzymes themselves. These
experiments provide convincing evidence that MnTMPyP is an effective SOD
mimetic, and support its use in experiments to investigate the role of superoxide in
modulating vascular function in small mesenteric arteries from rats following CAL.
MnTMPyP (10~4 M) was present in the superfusate throughout the cumulative CRC.
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6.2.2.4 Effect of combined inducible nitric oxide synthase inhibition and
superoxide quenching on vascular responsiveness
To further investigate the role of iNOS and superoxide in modulating vascular
responsiveness, endothelium-intact mesenteric arteries were exposed to the iNOS
inhibitor, 1400W (10 6 M) and the SOD mimetic, MnTMPyP (ICC1 M) for 30 min
prior to repeating cumulative CRC's to PE (1 x 10~9 to 3 x 10~5 M, n=8). Both drugs
were present in the superfusate throughout the CRC.
6.2.2.5 Effect of nitric oxide synthase substrate on vascular
responsiveness
To investigate the effect of the NOS substrate, L-arginine, on vascular
responsiveness, endothelium-denuded mesenteric arteries were exposed to L-arginine
(1CT3 M, 71=6) for 30 min prior to repeating cumulative CRCs to PE (1 x 10~9 to 3 x
10"5 M). A concentration of 10~3 M was chosen, since this concentration has been
shown to result in a 15-fold increase in the EC50 concentration for norepinephrine in
aortic rings from lipopolysaccharide-treated rats (Schott et al., 1993). L-arginine was
present in the superfusate throughout the CRC
6.2.2.6 Assessment of endothelium-dependent and endothelium-
independent vascular relaxations in arteries from coronary artery
ligation and sham-operated rats in the presence and absence of the
SOD mimetic, MnTMPyP
To assess endothelium-dependent relaxations, ACh-mediated relaxations were
measured in endothelium-intact PE-constricted small mesenteric arteries CAL and
sham-operated rats. A submaximal concentration of PE (~ EC50), as determined from
PE CRCs, was used to induce arterial tone. Cumulative CRCs to ACh (1 x 1CT10 to 3
x 10~6 M, 77=7) were then obtained in the presence and absence of the SOD mimetic
MnTMPyP (10^ M, 77=6).
To assess endothelium-independent relaxations, sodium nitroprusside (SNP)-
mediated relaxations were measured in endothelium-denuded PE-constricted small
mesenteric arteries CAL and sham-operated rats. As with ACh relaxations, a
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submaximal concentration of PE (~ EC5o), as determined from PE CRCs, was used to
induce arterial tone. Cumulative CRCs to SNP (1 x 1CT9 to 3 x 1CT5 M, n-1) were
then obtained in the presence and absence of the SOD mimetic MnTMPyP (10^ M,
n=l).
Arteries were treated with MnTMPyP for 30 min prior to and throughout the duration
of the experiments.
6.2.3 Preparation of drugs
Phenylephrine hydrochloride, acetylcholine chloride, sodium nitroprusside and
L-arginine were diluted in Krebs Henseleit solution to give a stock solution of
10_1 M and frozen (-20 °C) in aliquots until use on day of experiment.
A-(3-(Aminomethyl) benzyl acetamidine dihydrochloride (1400W) was diluted in
saline (0.9% NaCl) under argon to give a stock solution of 10-3 M. Aliquots were
then frozen (-20 °C) and stored under argon. Dilutions were made in Krebs Henseleit
solution. Mn [III] tetrakis [l-methyl-4-pyridyl] porphyrin (MnTMPyP) and diluted in
Krebs Henseleit solution immediately prior to experimentation.
6.2.4 Data Analysis
All results were expressed as means ± s.e.mean. Cumulative CRCs to PE were
measured as percentages of maximal constrictions to KC1. ACh and SNP cumulative
CRCs were measured as percentage relaxations of PE-induced tone. Where maximal
values were obtained for cumulative CRCs, the negative logarithm of the agonist
concentration that results in a half-maximal constriction or relaxation (pD2) was
calculated by nonlinear regression using GraphPad Prism software (Version 3.0).
Two-tailed t-tests, one-way analysis of variance (ANOVA) with Bonferroni post-test
for multiple comparisons and two-way repeated measures ANOVA were used as




6.3.1 Effect of left coronary artery ligation
As discussed in Section 5.3 of Chapter 5, CAL rats had significantly greater heart
weights than those of sham-operated rats, indicating that hearts from CAL rats had
undergone compensatory hypertrophy as a consequence of left ventricular (LV)
infarction. Furthermore, LV end-diastolic pressures were significantly elevated when
compared with sham-operated rats, which is an indicator of impaired LV function.
Infarct sizes for hearts from CAL rats averaged 60 ± 3 % of the LV free wall.
Furthermore, there was histological evidence for mature scar formation within the
infarcted zone (see Chapter 5, Figure 5.1a). These results suggest that rats had
developed CHF as a consequence of CAL.
6.3.2 KCI, phenylephrine maximal constrictions and endothelial
integrity
There were no significant differences between endothelium-intact and
endothelium-denuded small mesenteric arteries from CAL and sham-operated groups
with respect to internal diameters at rest and in response to KCI (60 mM, Table 6.1).
However, maximal constrictions to PE were significantly greater in
endothelium-denuded than in endothelium-intact small mesenteric arteries from both
CAL and sham-operated rats (P<0.05, one-way ANOVA with Bonferroni post-test,
Table 6.1). All endothelium-intact small mesenteric arteries studied had functional
endothelium (CAL, 101.3 ± 4%; sham-operated, 95.9 ± 3% ACh relaxation of PE-
induced tone) and no significant differences in maximal relaxations were found
between CAL and sham-operated groups (Table 6.1). Denudation of arteries was
deemed successful as relaxations to ACh were all but abolished (CAL, 3.8 ± 2%;




Internal diameter (pm) Internal diameter (pm)
+end -end +end -end
(n=8) (n=8) (17=11) (17=9)
Resting 319+15 310+13 330+9 310+10
60 mM KCl 118±15 105±10 125+9 110+10
10"5MPE 117+5* 88±10 120+5** 85+5
10~5M ACh 305±15 107±20 335+10 95+5
Table 6.1 Internal diameters (jam) of endothelium-intact (+end) and endothelium-
denuded (-end) small mesenteric arteries from coronary artery ligation (CAL) and
sham-operated (Sham) rats. Internal diameters ofarteries at rest, after exposure to
KCl, phenylephrine (PE) and acetylcholine (ACh) (arteries pre-contracted with 10 5
M PE) are given as mean values ± s.e. mean. * P<0.05 compared with respective
value in sham-operated endothelium-denuded arteries, ** P<0.01 compared with
respective values in CAL endothelium-denuded arteries (two-tailed unpaired t-test).
6.3.3 Assessment of vascular responsiveness to adrenoceptor
stimulation in coronary artery ligation and sham-operated rats
In both endothelium-intact and endothelium-denuded small mesenteric arteries from
CAL and sham-operated rats, cumulative additions of PE (1 x 10"9 to 3 x 10"5 M)
resulted in concentration-dependent constrictions (Figures 6.1, 6.2). In endothelium-
intact arteries from CAL rats, cumulative CRCs to PE were shifted significantly to
the left when compared with responses in sham-operated groups, indicating that
arteries from CAL rats were more responsive to PE than those from sham-operated
rats (P<0.05, two-way ANOVA, Figure 6.1). Indeed, pD2 values for PE CRCs in
arteries from CAL rats were significantly greater than those in sham-operated rats
(Table 6.2). Furthermore, maximal constrictions to PE were significantly greater in
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arteries from CAL rats when compared with constrictions in arteries from sham-
operated rats (Figure 6.1, Table 6.2). In endothelium-denuded arteries no significant
differences were found between CAL and sham-operated rats with respect to PE
CRCs (Figure 6.2). In addition, there were no significant differences between pD2



















Figure 6.1 Cumulative concentration response curves (CRC) showing contractile
responses to phenylephrine (PE; 1 x 10'9 to 3 x 10'5 M) in endothelium-intact (n=8)
small mesenteric arteries from coronary artery ligation (CAL) and sham-operated
rats (n=8) 6 weeks post-surgery. Values are given as means ± s.e.mean. ** P<0.01
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Figure 6.2 Cumulative concentration response curves showing contractile responses
to phenylephrine (PE; 1 x 10'9 to 3 x 10'5 M) in endothelium-denuded (n=6) small
mesenteric arteries from coronary artery ligation (CAL) and sham-operated rats 6




































Table 6.2 pD2 values and maximal (Max) percentage constrictionsfor phenylephrine
cumulative concentration response curves (CRC) in endothelium-intact (+end) and
endothelium-denuded (-end) small mesenteric arteries from coronary artery ligation
(CAL) and sham-operated (Sham) rats. Also shown are pD2 values and Max
constrictions for PE CRCs in endothelium-intact small mesenteric arteries in
presence of 1400W (10 6 M) andMnTMPyP (10 4 M) either on their own or together.
All values are given as mean values ± s.e.mean. * P<0.05 compared with pD2 value
in sham endothelium-intact arteries (one-way ANOVA with Bonferroni post-test),
# P<0.05 compared with max value in control endothelium-intact arteries from
sham-operated rats (two-tailed unpaired t-test), + P<0.05 as compared with pD2
values in control endothelium-intact arteries from coronary artery ligation rats (one¬
way ANOVA with Bonferroni post-test).
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6.3.4 Effect of 1400W and MnTMPyP on vascular responsiveness
Treatment of endothelium-intact arteries from CAL rats with 1400W (106 M) or
MnTMPyP (10"4 M) shifted PE CRCs to the right with respect to responses in
untreated arteries (P<0.05 for both, two-way ANOVA, Figure 6.3), indicating a
reduction in responsiveness to PE. Indeed, pD2 values were significantly decreased in
the presence of 1400W or MnTMPyP when compared with untreated arteries (Table
6.2). Responses to PE in arteries from CAL rats treated with 1400W or MnTMPyP
were not significantly different from those in sham-operated arteries (Figure 6.3,
Table 6.2). Responses to PE in endothelium-intact arteries from sham-operated rats
were unaffected by 1400W (10"6 M) or MnTMPyP (104 M) (Figure 6.4, Table 6.2).
In a similar fashion to those arteries treated with 1400W (106 M) or MnTMPyP
(104 M) alone, combined treatment with both drugs resulted in a significant
reduction in responsiveness of arteries from CAL rats to PE (PcO.Ol, two-way
ANOVA, Figure 6.3). Indeed, pD2 values were significantly decreased in the
presence of 1400W and MnTMPyP when compared with untreated arteries (Table
6.2). However, no differences were found when compared with responses in arteries
treated with 1400W alone. In arteries from sham-operated rats, combined treatment
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Figure 6.3 Effect of 1400W (10~6 M) and MnTMPyP (10~4 M), on their own or
together on cumulative concentration response curves (CRC) to phenylephrine
(PE; 1 x 10'9 to 3 x 10'5 M) in endothelium-intact small mesenteric arteries from
coronary artery ligation rats (CAL; n-8) 6 weeks post-ligation. Values are given as
means ± s.e.mean. ** P<0.01 for CRCs in untreated arteries compared with CRCs in
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Figure 6.4 Effect of 1400W (10~6 M) and MnTMPyP (10~4 M), on their own or
together on cumulative concentration response curves to phenylephrine
(PE; 1 x 10~9 to 3 x 10'5 M) in endothelium-intact small mesenteric arteries from




6.3.5 Effect of L-arginine on vascular responsiveness
Treatment of endothelium-denuded arteries from CAL rats with the NOS substrate,
L-arginine (10 3 M), for 30 min shifted PE CRCs to the right with respect to
untreated arteries (P<0.05, two-way ANOVA, Figure 6.5), indicating that
endothelium-denuded arteries are less responsive to PE in the presence of L-arginine.
pD2 values could not be calculated as maximal constrictions were not reached. L-
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Figure 6.5 Effect of L-arginine (10'3 M) on cumulative concentration response
curves (CRC) to phenylephrine (PE; 1 x 10'9 to 3 x 10 5 M) in endothelium-denuded
small mesenteric arteries from coronary artery ligation rats (CAL; n-6) 6 weeks
post-ligation. Values are given as means ± s.e.mean. ** P<0.01 compared with
CRCs in untreated arteries (two-way ANOVA).
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Figure 6.6 Effect of L-arginine (10' M) on cumulative concentration response
curves to phenylephrine (PE; 1 x 10'9 to 3 x 10'5 M) in endothelium-denuded small
mesenteric arteries from sham-operated rats (n-6) 6 weeks post-surgery. Values are
given as means ± s.e.mean. P>0.05, two-way ANOVA.
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6.3.6 Assessment of endothelium-dependent and endothelium-
independent vascular relaxations in coronary artery ligation and sham-
operated rats. Effect of superoxide quenching
Following induction of PE (~ ECscO-induced tone (CAL, 49.1 ± 2.3%; sham-
operated, 52.6 ± 2.4% of maximal PE constriction) in endothelium-intact arteries
from CAL and sham-operated rats, cumulative additions of ACh (1 x 10"10 to 3 x 10"6
M) resulted in concentration-dependent relaxations (Figure 6.7). pD2 values for
cumulative CRCs in arteries from CAL rats were significantly lower than those in
sham-operated rats, indicating that endothelium-dependent relaxations were blunted
in small mesenteric arteries from CAL rats (Table 6.3). Maximum relaxations to
ACh were achieved in most arteries at a concentration of 3 x 10~6 M and no
significant differences were found between CAL and sham-operated groups (Table
6.3).
Treatment of PE-constricted (57.5 ± 3.2% of maximal PE constriction) endothelium-
intact arteries from CAL rats with MnTMPyP (10~4 M) significantly increased pD2
values for ACh CRCs when compared with values in untreated arteries, indicating an
increase in responsiveness to ACh (Figure 6.8, Table 6.3). Treatment of PE-
contracted (53.9 ± 3.5% of maximal PE constriction) endothelium-intact arteries
from sham-operated rats with MnTMPyP had no significant effect on ACh CRCs


















Figure 6.7 Cumulative concentration response curves showing
endothelium-dependent relaxations to acetylcholine (ACh; 1 x 10~w to 3 x 10'6 M) in
phenylephrine (~ ECso)-constricted endothelium-intact small mesenteric arteries
from coronary artery ligation (CAL) and sham-operated rats (n-7) 6 weeks post-




pD2 Max (%) pD2 Max (%)
(n>6) (,n>6) (n>6) (n>6)
ACh Control 7.9±0.1 102.3±2.2 7.4+0.1* 104.1+3.5
ACh +MnTMPyP - 94.5+8.3 7.9+0. It 102.9+1.7
SNP Control - 97.1+1 1.3+0.2 104.9+1.4
SNP +MnTMPyP _ 98.9+1 7.4+3 102.8+3
Table 6.3 pD2 values and maximal (Max) percentage relaxations for acetylcholine
(ACh) and sodium nitroprusside (SNP) cumulative concentration response curves
(CRC) in phenylephrine (~ EC50) -constricted endothelium-intact and
endothelium-denuded small mesenteric arteries, respectively, from coronary artery
ligation (CAL) and sham-operated (Sham) rats, in the presence and absence of
MnTMPyP (10 4 M). pD2 values could not be calculated for CRCs to ACh in the
presence ofMnTMPyP orfor SNP CRCs in the absence andpresence ofMnTMPyP,
because maximal values were not reached. All values are given as mean values ±
s.e.mean. * P<0.05 compared with pD2 values for ACh CRCs in control
endothelium-intact arteries from sham-operated rats, + P<0.05 compared with pD2
values for ACh CRCs in control endothelium-intact arteries from CAL rats (one-way
ANOVA with Bonferroni post-test).
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Figure 6.8 Cumulative concentration response curves showing
endothelium-dependent relaxations to acetylcholine (ACh; 1 x 10~w to 3 x 10'6 M) in
phenylephrine (~ ECsoj-constricted endothelium-intact small mesenteric arteries
from coronary artery ligation rats (CAL; n>6) 6 weeks post-surgery, in the presence
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Figure 6.9 Cumulative concentration response curves showing
endothelium-dependent relaxations to acetylcholine (ACh; 1 x 10~'° to 3 x 10~6 M) in
phenylephrine (~ ECso)-constricted endothelium-intact small mesenteric arteries
from sham-operated rats (n>6) 6 weeks post-surgery, in the presence and absence of
MnTMPyP (1CT4 M). Values are given as means ± s.e.mean. P>0.05, two-way
ANOVA.
Following induction of PE (~ EC60)-induced tone (CAL, 57.3 ± 6.5%; sham-
operated, 53.8 ± 4.6% of maximal PE constriction) in endothelium-denuded arteries
from CAL and sham-operated rats, cumulative additions of SNP (1 x 10~9 to 3 x 10~6
M) resulted in concentration-dependent relaxations (Figure 6.10, Table 6.3). There
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(Figure 6.10). MnTMPyP had no significant effect on SNP cumulative CRCs in
PE-constricted (CAL, 53.4 ± 5.4%; sham-operated, 56.7 ± 5% of maximal PE

















Figure 6.10 Cumulative concentration response curves showing
endothelium-independent relaxations to sodium nitroprusside (SNP; 1 x 10~9 to 3 x
10'5 M) in phenylephrine (~ ECso)-constricted endothelium-intact small mesenteric
arteries from coronary artery ligation (CAL) and sham-operated rats (n=7) 6 weeks




In the previous chapter, immunohistochemical studies demonstrated that iNOS was
expressed in endothelial cells, VSM cells, and in the adventitia of small mesenteric
arteries from rats with CHF, but not in arteries from sham-operated rats. However,
despite the presence of iNOS, functional studies in the present chapter demonstrate
that endothelium-intact small mesenteric arteries from CHF rats were more
responsive to PE than those from sham-operated rats. Hyperesponsiveness of
endothelium-intact arteries from CHF rats was reversed by the selective iNOS
inhibitor, 1400W and by the cell permeable metalloporphyrin SOD mimetic,
MnTMPyP. Furthermore, supplementation of endothelium-denuded arteries from
CHF rats with the NOS substrate, L-arginine, resulted in a significant reduction in
responsivness to PE when compared with untreated arteries. Endothelium-dependent,
but not endothelium-independent relaxations, were impaired in arteries from CHF
rats when compared with relaxations in arteries from sham-operated rats.
Furthermore, MnTMPyP restored endothelium-dependent relaxations. These results
suggest that substrate deficient, iNOS-derived superoxide may be responsible for the
vascular dysfunction associated with this model of CHF.
During endotoxemia, expression of iNOS in the vasculature, and the subsequent
production of NO, plays an important role in the vascular hyporeactivity to
vasoconstrictors (see Chapter 3). Therefore, in this model of CHF, increased
production of NO from iNOS would be expected to reduce vascular responsiveness
to PE. Somewhat paradoxically, endothelium-intact small mesenteric arteries from
CHF rats were more responsive to PE than arteries from sham-operated rats. There
were no significant differences between responses to PE in endothelium-denuded
arteries from CHF or sham-operated rats, demonstrating that this vascular
dysfunction is dependent on the presence of the endothelium. Basal NO from eNOS
serves to dampen the effects of vasoconstrictors. One could speculate, therefore, that
decreased basal release of NO is responsible for the hyperesponsivness to PE.
Indeed, there is some evidence that basal release of NO from the endothelium may be
impaired in CHF. A recent study demonstrated that flow-mediated dilatation was
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abolished in peripheral resistance arteries in rats with CHF, suggesting that basal
release of NO was impaired (Varin et al., 1999). Similarly, Hirari et al. (1995) found
that the hyperaemic response of hindquarter resistance arteries were impaired in rats
with CHF.
To investigate the role that iNOS plays in modulating vascular function in this model
of CHF the selective iNOS inhibitor, 1400W, and the NOS substrate, L-arginine
were used. Garvey et al. (1997) demonstrated that 1400W is an irreversible inhibitor
of iNOS that is at least 5000-fold more selective for purified human iNOS than
eNOS. Furthermore, experiments in Chapter 3 demonstrated that 1400W inhibited
the activity of iNOS in isolated thoracic aortae from rats with endotoxic shock,
without modifying the activity of eNOS, providing convincing evidence that 1400W
is a selective inhibitor of iNOS. Experiments in this chapter show, somewhat
surprisingly, that inhibition of iNOS with 1400W reversed rather than potentiated the
hyperesponsiveness of small mesenteric arteries from CHF rats. These results
suggest that induction of iNOS does not result in the expected increase in NO
generation. Instead, expression of the enzyme appears to be a major contributory
factor in the hyperesponsive nature of endothelium-intact CHF arteries. In
experimental endotoxic shock, addition of the NOS substrate, L-arginine, to isolated
blood vessels increases NO production from iNOS and potentiates
hyporesponsiveness to vasoconstrictors (Julou-Schaeffer et al., 1990). Experiments
here demonstrate that supplementation of endothelium-denuded small mesenteric
arteries from CHF rats, but not sham-operated rats, with a supramaximal
concentration of L-arginine results in a reduction in responsiveness to PE, likely
through production of NO from iNOS. These results suggest that although iNOS is
present in small mesenteric arteries from CHF rats, it is unable to synthesise NO
because there is insufficient substrate. As discussed in Section 1.3.3, the synthesis of
NO by NOS requires a tightly coupled electron transfer from the flavin domain of
NOS to haem in the oxygenase domain, which in turn is tightly coupled with the
reduction of oxygen and subsequent oxidation of L-arginine. Uncoupled electron
transfer occurs in most oxygenase enzymes and refers to a diversion or loss of
electrons that would be otherwise used to generate a product from a substrate
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(Griffith & Stuehr, 1995). Oxygen is the usual acceptor of the stray electrons, giving
rise to superoxide. Therefore, with respect to NOS, the main product will certainly be
NO, however, some electrons may become uncoupled from its domains resulting in
the formation of superoxide. It has been demonstrated, however, that in the presence
of low concentrations of L-arginine or in its absence, nNOS catalyses the uncoupled
reduction of oxygen, leading to the production of large quantities of superoxide
(Klatt et al., 1993a). It has since been shown that iNOS can also produce superoxide
when deficient in L-arginine (Xia et al., 1998a). With no substrate to accept the
electrons from oxygen, the production of superoxide from NOS is self-explanatory.
Therefore, in this model of CHF, it is possible that a deficiency in L-arginine will not
only prevent iNOS from generating NO but will also result in the enzyme producing
superoxide. Increased scavenging of NO by superoxide would result in a reduction in
the bioavailability of basal endothelium-derived NO, which may explain the marked
increase in responsiveness of endothelium-intact arteries from CHF rats to PE.
Plasma malondialdehyde, a marker of oxidative stress, is increased in patients with
CHF (Belch et al., 1991; Diaz-Velez et al., 1996; Bauersachs et al., 1999). To
determine if increased superoxide production plays a role in modulating vascular
function in this model of CHF, the cell permeable metalloporphyrin SOD mimetic,
MnTMPyP (see Chapter 4), was used. In a similar fashion to 1400W, MnTMPyP
reversed the hyperesponsiveness of endothelium-intact small mesenteric arteries
from CFCF rats. This implies that mesenteric arteries from CHF rats are indeed
generating increased amounts of superoxide, which is responsible for the marked
elevation in responsiveness to PE. These findings are consistent with recent studies
demonstrating increased superoxide production by the peripheral vasculature from
rats with CHF following CAL (Bauersachs et al., 1999; Varin et al., 1999). Despite
evidence demonstrating increased levels of superoxide in CHF, the precise source is
unclear. Some studies suggest that a deficiency in antioxidant systems is responsible.
Several studies have demonstrated a reduction in antioxidants, such as glutathione
peroxidase, vitamin E, catalase and SOD, both in the failing heart (Hill & Singal,
1996; Prasad et al., 1996) and the systemic circulation (Nishiyama et al., 1998;
Yucel et al., 1998). Other studies suggest that increased synthesis of superoxide is
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responsible. In rats with CHF following CAL, thoracic aortae were shown to produce
increased amounts of superoxide that was probably derived from NADH/NADPH
oxidases (Bauersachs et al., 1999). Furthermore, autoxidation of catecholamines,
increased arachidonate metabolism and inflammatory cytokines have all been
suggested as possible sources of superoxide in CHF (Givertz & Colucci, 1998). In
the present study, however, both inhibition of iNOS and superoxide quenching
reverses the hyperesponsiveness to PE suggesting that iNOS is the source of
superoxide in these arteries. Indeed, there were no significant differences between
responses to PE in arteries treated with 1400W alone and those treated with both
1400W and MnTMPyP.
There is evidence that agonist-stimulated release of NO from the endothelium of the
peripheral vasculature is impaired in clinical and experimental CHF. In rats with
CHF following CAL, relaxations of isolated conductance arteries to ACh were
impaired when compared with sham-operated control (Ontkean et al., 1991; Teerlink
et al., 1994; Baggia et al., 1997; Bauersachs et al., 1999). In contrast, relaxations to
ACh in resistance arteries during experimental CHF appear to be normal (Baggia et
al., 1997; Prior et al., 1998). These studies suggest that NO-mediated relaxations
may not be universally impaired throughout the arterial circulation. However,
Drexler & Lu, (1992) demonstrated that hindquarter resistance arteries in rats with
large infarctions following CAL were less responsive to ACh than control rats.
Furthermore, impaired peripheral vasodilator responses to muscarinic agonists have
been observed extensively in the forearm resistance vessels of patients with CHF of
varying pathologies (Drexler et al., 1992; Kubo et al., 1991; Katz et al., 1992;
Nakamura et al., 1996; Carville et al., 1998). Consistent with these studies,
experiments in this chapter reveal that small mesenteric arteries from rats with CHF
are less responsive to ACh when compared with responses in arteries from sham-
operated rats, suggesting that agonist-stimulated activity of NO is impaired in these
arteries.
The underlying mechanisms responsible for impaired agonist-stimulated activity of
NO in CHF may be complex and have not yet been clarified. Some (Zelis et al.,
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1970; Nasa et al., 1996; Nakamura et al., 1996; Carville et al., 1998) but not all
studies (Drexler et al., 1992; Baggia et al., 1997; Bauersachs et al., 1999) have
demonstrated that endothelium-independent relaxations may also be impaired in
CHF, suggesting that abnormalities of the VSM may be responsible for impaired
relaxations to ACh. In this chapter, however, experiments reveal that endothelium-
independent relaxations to the NO donor, SNP, are not attenuated in small
mesenteric arteries from CHF rats, implying that endothelium-dependent relaxations
are selectively impaired in these arteries. Other potential mechanisms for impaired
agonist-stimulated activity of NO include down regulation of eNOS (Comini et al.,
1996; Smith et al., 1996; Wang et al., 1997; Varin et al., 1999), increased release of
endothelium-dependent constriction factors (Kaiser et al., 1989; Varin et al., 1999)
and impaired endothelial receptor-signal transduction pathways, ie. dysfunctional
muscarinic receptor (Hirooka et al., 1992). As discussed earlier, CHF is associated
with increased levels of superoxide. Furthermore, earlier experiments in this chapter
demonstrated that increased superoxide production might account for the marked
increase in vascular responsiveness of small mesenteric arteries, possibly as a
consequence of increased scavenging of basal endothelium-derived NO. Therefore,
increased scavenging of NO by superoxide may also account for impaired responses
to ACh. Indeed, subsequent experiments demonstrate that the SOD mimetic,
MnTMPyP restored responsiveness of small mesenteric arteries to ACh, suggesting
that increased superoxide is indeed responsible for impaired endothelium-dependent
relaxations.
In Chapter 4, the pharmacological properties of MnTMPyP were investigated. As
discussed in this chapter, recent studies have suggested that MnTMPyP may actually
scavenge NO itself and directly inhibit the activity of both iNOS and eNOS (Pfeiffer
et al., 1998, MacKenzie et al., 1999). However, experiments in Chapter 4 provided
convincing evidence that at a concentration of 1CT4 M, MnTMPyP acts a SOD
mimetic without modifying the activity of NO derived from iNOS or eNOS, or the
enzymes themselves. Consistent with these findings, experiments in the present study
demonstrate that MnTMPyP reduced responsiveness to PE in endothelium-intact
small mesenteric arteries from CHF rats and had no significant effect on responses in
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arteries from sham-operated rats. Furthermore, MnTMPyP increased responsiveness
of endothelium-intact small mesenteric arteries from CHF rats to ACh and had no
significant effect on responses in arteries from sham-operated rats. The findings of
the experiments in this chapter and those from Chapter 4 provide convincing
evidence that the effects of MnTMPyP in the present study are a direct consequence
of its SOD mimetic properties.
The findings of this chapter present an interesting new facet to the impact of iNOS in
CHF. In this model of CHF, instead of generating large quantities of NO, iNOS
appears to be generating superoxide, perhaps because of a deficiency in its substrate,
L-arginine. Moreover, this increase in superoxide production is responsible for the
hyperesponsive nature of endothelium-intact small mesenteric arteries from rats with
CHF. The precise mechanism and time course by which superoxide results in arteries
being hyperesponsive is unclear from these experiments alone. However, the fact that
the hypereactivity is dependent on the endothelium suggests that increased
scavenging of basal, eNOS-derived, NO by superoxide is responsible. In addition to
impaired basal release of NO, experiments also show that ACh-mediated
endothelium-dependent relaxations are impaired in arteries from rats with CHF.
Moreover, MnTMPyP increased responsiveness to ACh suggesting that increased
scavenging of agonist-stimulated NO by superoxide was responsible for this
dysfunction. While it remains to be established if this study mirrors clinical CHF,
these findings may represent an important mechanism for the endothelial dysfunction
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The elastic properties of conductance arteries are important in minimising both the
load on the left ventricle and the rise in arterial pressure during systole (see Section
1.2.3), Therefore, although conductance arteries play a minimal role in modulating
peripheral vascular resistance, they play an important role in the overall mechanical
efficiency of the cardiovascular system.
Vascular smooth muscle (VSM) tone plays a role in modulating the elastic properties
of conductance arteries (Dobrin & Rovick, 1969; Wilson et al., 1995; Bank, 1997,
Joannides et al., 1997). Furthermore, there is evidence that the release of
endothelium-derived nitric oxide (NO) increases arterial compliance (Ramsey, 1994;
Joannides et al., 1997). Therefore, endothelium-derived NO may play an important
role in reducing cardiac workload relative to peripheral needs by altering the
mechanical properties of conductance arteries.
Decreased compliance of conductance arteries has been demonstrated in many
cardiovascular diseases, including hypertension (Bella et al., 1999), atherosclerosis
(Hodes et al., 1995) and chronic heart failure (CHF; Arnold et al., 1991; Giannattasio
et al., 1995; Duprez et al., 1998). Maruyama et al. (1993) demonstrated using a
canine model of CHF that decreased arterial compliance results in a further decline in
left ventricular (LV) ejection. Furthermore, investigators have demonstrated that the
decreased arterial compliance associated with hypertension correlates with cardiac
hypertrophy (Girerd et al., 1991; Ohtsuka et al., 1996).
Numerous clinical and experimental studies have demonstrated that endothelium-
dependent relaxations to acetylcholine in conductance arteries are impaired in CHF
(Teerlink et al., 1994; Bank et al., 1994; Baggia et al., 1997; Bauersachs et al.,
1999). Furthermore, there is evidence that NO-mediated (Joannides et al., 1995)
flow-dependent dilatation is also impaired (Hornig et al., 1996; Mohri et al., 1997;
Homig et al., 1998). Teerlink et al. (1994) showed increased adrenergic
responsiveness of endothelium-intact but not endothelium-denuded thoracic aortic
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rings from rats with CHF. These studies suggest that agonist-stimulated and basal
release of NO from the endothelium in conductance arteries is impaired during CHF.
Experiments in Chapter 6 demonstrated that substrate deficient, inducible nitric
oxide synthase (iNOS)-derived superoxide was responsible for impaired relaxations
to acetylcholine in small mesenteric arteries from rats with CHF. Furthermore, it was
revealed that iNOS-derived superoxide plays a major role in the vascular
hyperesponsiveness to phenylephrine, possibly as a consequence of increased
scavenging of basal endothelium-derived NO. Immunohistochemical studies in
Chapter 5 revealed that iNOS is also expressed in thoracic aortae from rats with
CHF. Therefore, it is possible that iNOS-derived superoxide is responsible for the
vascular dysfunction of conductance arteries associated with CHF.
The aims of the experiments in this chapter were, therefore, to investigate the
functional significance of iNOS and superoxide in isolated thoracic aortae from rats
with CHF following coronary artery ligation (CAL), and to determine whether
substrate deficient iNOS-derived superoxide plays a role in the vascular dysfunction




All procedures were carried out as described in Chapter 2.
7.2.1 Rat coronary artery ligation model of chronic heart failure
Myocardial infarction was induced in 5 week old male Wistar rats (250 -300 g) by
ligation of the left anterior descending coronary artery as described in Section
2.1.2.2,
7.2.2 Haemodynamic measurements and tissue harvesting
Six weeks post-surgery, CAL and sham-operated rats were anaesthetised with
sodium pentobarbitol (60 mgkg1, i.p.) and the right carotid artery located, dissected
free of extraneous tissue and cannulated with a fluid filled catheter attached to a
pressure transducer, for measurement of mean arterial blood pressure (MAP) and LV
end-diastolic pressures (LVEDP; see Section 2.1.2.3).
Following exsanguination, thoracic aortae were removed and placed into cold,
oxygenated (95% O2, 5% CO2), Krebs Henseleit solution. The hearts and lungs were
removed, rinsed in ice-cooled saline (0.9%) then individually weighed. Hearts were
then bisected, placed in 10% neutral buffered formalin for 24 h prior to further
processing and wax embedding as described in Section 2.3.5.
7.2.3 Measurement of infarct size
3 pm sections of hearts were taken from blocks and stained with van Gieson's
collagen stain for detection of collagen formation in LV infarctions (see Section
2.1.2.4), Infarct size was then calculated by the method described in Section 2.1.2.5.
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Thoracic aortae from both CAL and sham-operated rats were cleaned of adhering
adipose and connective tissue and cut into transverse rings (~ 4mm). In some aortic
rings the endothelium was removed by the method described in Section 2.2.2, Aortic
rings were then mounted in a 10 ml organ bath filled with warm (37 °C), oxygenated
(95% O2, 5% CO2) Krebs Henseleit solution (see Section 2.2.1). Aortic rings were
placed under 2 gram of tension and left to equilibrate for 60 min. The general
protocol (see Section 2.2.2) was performed on all aortic rings before commencing the
experimental protocols described below.
7.2.5 Experimental protocols
7.2.5.1 Vascular responsiveness of aortic rings from coronary artery
ligation and sham-operated rats
To assess vascular responsiveness of aortic rings from CAL and sham-operated rats
to adrenoceptor stimulation, cumulative concentration response curves (CRC) to
norepinephrine (NE; 1 x 10~9 to 3 x 10~5 M) were constructed in endothelium-intact
(CAL, n-5; Sham-operated, n—8) and endothelium-denuded (CAL, 11=5; sham-
operated, n-6) aortic rings. Following completion of CRCs, all rings were repeatedly
washed and allowed to re-equilibrate for at least 15 min before further experiments.
7.2.5.2 Effect of inducible nitric oxide synthase inhibition on vascular
responsiveness
To investigate the role of iNOS in modulating vascular responsiveness, endothelium-
intact aortic rings were exposed to the selective iNOS inhibitor, A-(3-(Aminomethyl)
benzyl) acetamidine dihydrochloride (1400W; 10"5 M; CAL, n-5; sham-operated,
n=8) for 30 min prior to repeating cumulative CRCs to NE (1 x 10~9 to 3 x 10"5 M).
In Chapter 3, experiments demonstrated that at a concentration of 10"5 M, 1400W
inhibits iNOS without modifying the activity of either basal or agonist-stimulated




7.2.5.3 Effect of superoxide quenching on vascular responsiveness
To investigate the role that superoxide plays in modulating vascular responsiveness,
aortic rings were exposed to the superoxide dismutase (SOD) mimetic, Mn [III]
tetrakis [l-methyl-4-pyridyl] porphyrin (MnTMPyP; KT4 M, CAL, n=5; sham-
operated, n-1) for 30 min prior to repeating cumulative CRCs to NE (1 x 10~9 to 3 x
10"5 M). In Chapter 4 of this thesis, experiments demonstrated that at a
concentration of 10~4 M, MnTMPyP protected endothelium-derived NO from
inactivation by superoxide in an in vitro model of oxidative stress, without having
any non-selective effects on the activity of eNOS or iNOS-derived NO, or the
enzymes themselves. MnTMPyP (10~4 M) was present in the superfusate throughout
the cumulative CRC.
7.2.5.4 Effect of combined inducible nitric oxide synthase inhibition and
superoxide quenching on vascular responsiveness
To further investigate the role of iNOS and superoxide in modulating vascular
responsiveness, endothelium-intact aortic rings were exposed to the iNOS inhibitor,
1400W (1CT5 M) and the SOD mimetic, MnTMPyP (ICC1 M) for 30 min prior to
repeating cumulative CRC's to NE (1 x 10"9 to 3 x 10"5 M; CAL, n=5; sham-
operated, n=l). Both drugs were present in the superfusate throughout the CRC.
7.2.5.5 Effect of nitric oxide synthase substrate on vascular
responsiveness
To investigate the effect of the NOS substrate, L-arginine, on vascular
responsiveness, endothelium-denuded aortic rings were exposed to a supramaximal
concentration (Schott et al., 1993) of L-arginine (10~3 M, CAL, n=5; sham-operated,
n=6) for 30 min prior to repeating cumulative CRCs to NE (1 x 10~9 to 3 x 10~5 M).
L-arginine was present in the superfusate throughout the CRC
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7.2.5.6 Assessment of endothelium-dependent vascular relaxations in
aortic rings from coronary artery ligation and sham-operated rats in the
presence and absence of the SOD mimetic, MnTMPyP
To assess endothelium-dependent relaxations in aortic rings from CAL and sham-
operated rats, ACh-mediated relaxations were measured in endothelium-intact NE-
contracted aortic rings. A submaximal concentration of NE (~ EC60), as determined
from NE CRCs, was used to induce arterial tone. Cumulative CRCs to ACh (1 x 10~9
to 3 x 1CT5 M, CAL, n=6; sham-operated, n=8) were then obtained in presence and
absence of the SOD mimetic MnTMPyP (KT4 M). Aortic rings were treated with
MnTMPyP for 30 min prior to and throughout the duration of the experiments.
7.2.6 Preparation of drugs
Norepinephrine hydrogentartrate, acetylcholine chloride and L-arginine were diluted
in Krebs Henseleit solution to give a stock solution of 10~' M and frozen (-20 °C) in
aliquots until use on day of experiment. Vitamin C (10-6 M) was added to the stock
solution of NE to prevent autoxidation. 7V-(3-(Aminomethyl) benzyl acetamidine
dihydrochloride (1400W) was diluted in saline (0.9% NaCl) under argon to give a
stock solution of 10"3 M. Aliquots were then frozen (-20 °C) and stored under argon.
Dilutions were made in Krebs Henseleit solution. MnTMPyP (Mn [III] tetrakis [1-
methyl-4-pyridyl] porphyrin) and diluted in Krebs Henseleit solution immediately
prior to experimentation.
7.2.7 Data Analysis
All results were expressed as means ± s.e.mean. ACh and SNP cumulative CRCs
were measured as percentage relaxations of NE-induced tone. Where maximal values
were obtained for cumulative CRCs, the negative logarithm of the agonist
concentration that results in a half-maximal contraction or relaxation (pDi) was
calculated by nonlinear regression using GraphPad Prism software (Version 3.0).
Two-tailed t-tests, one-way analysis of variance (ANOVA) with Bonferroni post-test
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for multiple comparisons and two-way repeated measure ANOVA were used as




7.3.1 Effect of left coronary artery ligation
Survival rate during the first 24 h after CAL surgery was 60%. Two additional CAL
rats died before the six-week study period was completed. There were no significant
differences between rat weights for CAL and sham-operated groups 6 weeks post-
surgery (Table 7.1). Heart weights (corrected for body weight) for CAL rats were
significantly greater than those of sham-operated rats (P<0.05, two-tailed unpaired t-
test, Table 7.1). There were no significant differences between groups with respect to
lung weights (corrected for body weight) and mean arterial blood pressures (Table
7.1). LVEDPs measured from CAL rats were significantly greater than those for
sham-operated rats (P<0.05, two-tailed unpaired Mest, Table 7.1). Hearts from CAL
rats had visible infarctions, which averaged 45 ± 3 % of the LV free wall.




Rat Weight (g) 489.6+18 514121.9
Heart Weight (g kg 1 body weight) 3.2±0.1 . 3.710.1**
Lung Weight (g kg'1 body weight) 3.610.1 3.910.1
LVEDP (mmHg) 5.910.4 1310.6***
Mean arterial pressure (mmHg) 99.619 99.615.4
Table 7.1 Summary ofparameters measured from coronary artery ligation (CAL)
and sham-operated (Sham) rats 6 weeks post-surgery. All values are given as means
± s.e.m. ** P<0.01, *** P<0.001 for CAL rats compared with respective values in
sham-operated rats (two-tailed unpaired t-test).
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7.3.2 KCI, norepinephrine maximal constrictions and endothelial
integrity
Maximal constrictions to KCI were significantly lower in endothelium-intact aortic
rings from CAL rats when compared with sham-operated rats (PO.Ol, two-tailed
unpaired t-test; Table 7.2). There were no significant differences between
endothelium-intact and endothelium-denuded aortic rings from CAL and sham-
operated groups with respect to maximal constrictions to a supramaximal
concentration of NE (Table 7.2). All endothelium-intact aortic rings studied had
functional endothelium and no significant differences in maximal relaxations were
found between CAL and sham-operated groups (Table 7.2). Denudation of aortic
rings was deemed successful as relaxations to ACh were all but abolished (Table
7.2).
Treatment Sham C4Z,
+end -end +end -end
0=8) (if8) (17=6) 0=6)
60 mM KCI 4.3±0.4g 4.5+0.4g 3.5±0.2g** 3.8±0.5g
10"5MNE 4.1±0.3g 4.9±0.4g 3.7±0.3g 4.1±0.6g
10"5M ACh 83.1±1.9% 1±5.3% 79.8±6.2% 1.8±0.8%
Table 7.2 Maximal contractions of endothelium-intact (+end) and endothelium-
denuded (-end) arteries from coronary artery ligation (CAL) and sham-operated
(Sham) rats to KCI and norepinephrine (NE). Responses of NE-contracted aortic
rings to acetylcholine (ACh) are given as percentages ofNE (EC50)-induced tone. All
values are given as mean ± s.e.mean. ** P<0.01 compared with KCI responses in
sham-operated endothelium-intact aortic rings (two-tailed unpaired t-test).
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7.3.3 Assessment of vascular responsiveness to adrenoceptor
stimulation in coronary artery ligation and sham-operated rats
In both endothelium-intact and endothelium-denuded aortic rings from CAL and
sham-operated rats, cumulative additions of NE (1 x 10"9 to 3 x 10"5 M) resulted in
concentration-dependent contractions (Figures 7.1). In endothelium-intact aortic
rings from CAL rats, pD2 values and maximal contractions for NE CRCs were
significantly lower when compared with values in endothelium-intact aortic rings
from sham-operated rats (P<0.05, two-tailed unpaired Mest, Table 7.3), suggesting
that endothelium-intact aortic rings from CAL rats were less responsive to NE than
aortae from sham-operated rats. In endothelium-denuded aortic rings from CAL rats
there was a significant increase in responsiveness to NE (P<0.05, two-way ANOVA,
Figure 7.1). Indeed, pD2 values and maximal contractions for NE CRCs when
compared with responses in endothelium-intact aortic rings (P<0.05, one-way
ANOVA with Bonferroni post-test, Table 7.3). In contrast, there were no significant
differences between NE CRCs in endothelium-intact and -denuded aortic rings from




pD2 Max (g) pD2 Max (g)
(n>6) (n>6) (n=5) (n=5)
Control +end 6.3+0.2 5+0.3 5.8+0.2* 3.8+0.4*
Control -end 6.5+0.2 5.5+0.2 6.8+0.4# 4.6+0.6#
+ 1400W 6.3+0.2 5.1+0.4 6.1+0.3 4.2+0.7
+ MnTMPyP 5.9+0. It 3.7±0.6t 6.1+0.2 3.7+0.5
+1400W 6.1+0.3 3.9+0.5+ 6.0+0.2 4.4+0.4
+MnTMPyP
Table 7.3 pD2 values and maximal (Max) contractions (gram tension) for
norepinephrine cumulative concentration response curves (CRC) in endothelium-
intact (+end) and endothelium-denuded (-end) aortic rings from coronary artery
ligation (CAL) and sham-operated (Sham) rats. Also shown are pD2 values andMax
contractions for NE CRCs in endothelium-intact aortic rings in presence of 1400W
(10T6 M) and MnTMPyP (10 4 M) either on their own or together. All values are
given as mean values ± s.e.mean. * P<0.05 compared with respective values in
control endothelium-intact aortic rings from sham-operated rats, # P<0.05
compared with respective values in control endothelium-intact aortic rings from CAL
rats, + P<0.05 compared with respective values in control endothelium-intact aortic
























Figure 7.1 Cumulative concentration response curves (CRC) showing contractile
responses to norepinephrine (NE; 1 x 10'9 to 3 x 10'5 M) in endothelium-intact
(+end) and endothelium-denuded (-end) aortic rings from coronary artery ligation
(CAL; n-5) and sham-operated rats (n=6) 6 weeks post-surgery. Values are given as
means ± s.e.mean. ** P<0.01 compared with CRCs in -end aortic rings from CAL




7.3.4 Effect of 1400W and MnTMPyP on vascular responsiveness
Treatment of endothelium-intact aortic rings from CAL rats with 1400W (10"5 M) or
MnTMPyP (10-4 M), on their own or together had no significant effect on contractile
responses to NE (Figure 7.2, Figure 7.3, Table 7.3). Contractile responses to NE in
endothelium-intact aortic rings from sham-operated rats were unaffected by 1400W
(Figure 7.4, Table 7.3). However, treatment with MnTMPyP on its own or in
combination with 1400W resulted in a significant decrease in reponsiveness to NE
(,P<0.05, two-way ANOVA, Figure 7.5) Indeed, there was a significant decrease in
pD2 and maximal contractions for NE CRCs when compared responses in untreated





















Figure 7.2 Effect of 1400W (10~5M) on cumulative concentration response curves to
norepinephrine (NE; 1 x 10'9 to 3 x 10~5 M) in endothelium-intact aortic rings from
coronary artery ligation rats (CAL; n=5) 6 weeks post-ligation. Values are given as
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Figure 7.3 Effect ofMnTMPyP (10~4M) on its own or in combination with 1400W
(10~5M) on cumulative concentration response curves to norepinephrine (NE; 1 x 10'
9
to 3 x 10'5 M) in endothelium-intact aortic rings from coronary artery ligation rats
(CAL; n=5) 6 weeks post-ligation. Values are given as means ± s.e.mean. P>0.05,
for CRCs in untreated aortic rings compared with CRCs in 1400W, MnTMPyP as



















-9 -8 -7 -6
LOG[NE] M
-5
Figure 7.4 Effect of 1400W (10~5M) on cumulative concentration response curves to
norepinephrine (NE; 1 x 10'9 to 3 x 10~5 M) in endothelium-intact aortic rings from
sham-operated rats (n=8) 6 weeks post-surgery. Values are given as means ±
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Figure 7.5 Effect ofMnTMPyP (10~4 M) on its own or in combination with 1400W
(10~5M) on cumulative concentration response cur\>es to norepinephrine (NE; 1 x 10'
y
to 3 x 10 5 M) in endothelium-intact aortic rings from sham-operated rats (n=7) 6
weeks post-surgery. Values are given as means ± s.e.mean. * P<0.05 for CRCs in
untreated rings compared with CRCs in MnTMPyP and 1400W-treated rings, **




7.3.5 Effect of L-arginine on vascular responsiveness
Treatment of endothelium-denuded aortic rings from CAL rats with the NOS
substrate, L-arginine (10 3 M), resulted in a significant decrease in pD2 values for NE
CRCs (untreated; 6.8 ± 0.4; L-arginine-treated, 6.1 ± 0.1, P<0.05, two-tailed paired t-
test, Figure 7.6), indicating that in the presence of L-arginine arteries are less
responsive to NE. There were no significant differences between maximal
constrictions to NE in untreated and L-arginine-treated aortic rings (Figure 7.6). L-
arginine had no significant effect on NE responses in aortic rings from sham-
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Figure 7.6 Effect of L-arginine (10 ' M) on cumulative concentration response
curves (CRC) to norepinephrine (NE; 1 x 10'9 to 3 x 10'5 M) in endothelium-denuded
aortic rings from coronary artery ligation (CAL) rats (n=5) 6 weeks post-ligation.
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Figure 7.7 Effect of L-arginine (1()'3 M) on cumulative concentration response
curves to norepinephrine (NE; 1 x 10'9 to 3 x 10'5 M) in endothelium-denuded aortic
rings from sham-operated rats (n-6) 6 weeks post-surgery. Values are given as
means ± s.e.mean. P>0.05, two-way ANOVA.
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7.3.6 Assessment of endothelium-dependent vascular relaxations in
coronary artery ligation and sham-operated rats. Effect of superoxide
quenching
Following induction of NE (ECeoHnduced tone (CAL, 62.5 ± 4.8%; sham-operated;
60.3 ± 5.6% of maximal NE contractions) in endothelium-intact aortic rings from
CAL and sham-operated rats, cumulative additions of ACh (1 x 10~9 to 3 x 10~5 M)
resulted in concentration-dependent relaxations (Figure 7.8). Relaxations to ACh
were significantly greater in aortic rings from CAL rats when compared with sham-
operated rats (P<0.01, two-way ANOVA; Figure 7.8).
Treatment of NE-contracted (62.6 ± 8.9% of maximal NE contracted) endothelium-
intact aortic rings from CAL rats with MnTMPyP (10~4 M) tended to shift CRCs to
the left suggesting an increase in responsiveness to ACh in the presence of
MnTMPyP. However, these differences failed to reach statistical significance
(P>0.05, one-way ANOVA, Figure 7.9), furthermore, pTF values for ACh CRCs
could not be calculated as maximal relaxations were not achieved. In contrast,
treatment of NE-constricted (65.1 ± 6.6% of maximal NE contracted) endothelium-
intact aortic rings from sham-operated rats with MnTMPyP (10~4 M) significantly
increased responsiveness of aortic rings to ACh, as demonstrated by a leftward shift
of ACh CRCs (P<0.05, two-way ANOVA, Figure 7.10). pD2 values for ACh CRCs
















Figure 7.8 Cumulative concentration response curves (CRC) showing
endothelium-dependent relaxations to acetylcholine (ACh; 1 x 10~9 to 3 x 10'5 M) in
endothelium-intact aortic rings from coronary artery ligation (CAL; n=6) and sham-
operated (n-8) rats 6 weeks post-surgery. Values are given as means ± s.e.mean.



















Figure 7.9 Cumulative concentration response curves (CRC) showing
endothelium-dependent relaxations to acetylcholine (ACh; 1 x 10'9 to 3 x 10'5 M) in
endothelium-intact aortic rings from coronary artery ligation (CAL) rats (n—6) 6
weeks post-surgery, in the presence and absence ofMnTMPyP (1CT4 M). Values are
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Figure 7.10 Cumulative concentration response curves (CRC) showing
endothelium-dependent relaxations to acetylcholine (ACh; 1 x 10~9 to 3 x 10'5 M) in
endothelium-intact aortic rings from and sham-operated (n-8) rats 6 weeks post-
surgery, in the presence and absence ofMnTMPyP (10"4 M). Values are given as





In Chapter 6 of this thesis, experiments revealed that substrate deficient, iNOS-
derived superoxide plays a major role in the vascular hyperesponsiveness of small
mesenteric arteries from CHF rats. Furthermore, it was suggested that this is
probably as a result of increased inactivation of endothelium-derived NO.
Immunohistochemical studies in Chapter 5 revealed that, in addition to its
expression in small mesenteric arteries, iNOS is also expressed in thoracic aortae
from rats with CHF. Therefore, in view of these findings, experiments in the present
chapter were designed to investigate the functional significance of iNOS and
superoxide in these conductance arteries from rats with CHF. The main findings of
experiments in this chapter were that the selective iNOS inhibitor, 1400W, had no
significant effect on the vascular responsiveness of endothelium-intact aortic rings
from CHF rats. Supplementation of endothelium-denuded aortic rings from CFLF but
not sham-operated rats with the NOS substrate, L-arginine, resulted in a significant
reduction in responsiveness to NE. However, the metalloporphyrin SOD mimetic,
had no significant effect on contractile responses in endothelium-intact aortic rings
from CHF rats. These results suggest that superoxide deficient iNOS plays no role in
modulating vascular responsiveness in conductance arteries in this model of CFEF.
Six weeks after CAL, rats had infarctions averaging 45% of the LV free wall.
Furthermore, LVEDPs were significantly elevated when compared with those in
sham-operated rats. Histological examination of hearts using van Gieson's stain
revealed that a fibrous scar, composed mainly of collagen, had replaced infarcted
areas of hearts from CAL rats. Furthermore, heart weights were significantly greater
than those for sham-operated rats, indicating that hearts had undergone compensatory
hypertrophy as a consequence of LV infarction. These results demonstrate that rats
had developed CFEF as a consequence of CAL. However, in contrast with the model
used in Chapters 5 and 6 of this thesis, this model resembled a more moderate form
of CHF (Fraccarollo et al., 1997; Mulder et al., 1998), as evidenced by smaller
infarct sizes and lower LVEDPs.
212
Chapter 7
In contrast with small mesenteric arteries (see Chapter 6), endothelium-intact aortic
rings from rats with CHF were less responsive to NE when compared with responses
in endothelium-intact aortic rings from sham-operated rats. This hyporeactivity
would suggest that, in contrast with small mesenteric arteries, where iNOS-derived
superoxide was responsible for the hyperesponsive nature of these arteries, the
expression of iNOS in thoracic aortae results in the expected increase in NO
generation. Immunohistochemical studies in Chapter 5 revealed that iNOS was
located to all cell types in thoracic aortae from CHF rats, therefore, one might expect
endothelium-denuded aortic rings to also be hyporesponsive to NE. However,
somewhat surprisingly, there were no significant differences between responses to
NE in endothelium-denuded aortic rings from CHF and sham-operated rats. These
results suggest that this vascular hyporeactivity is dependent on the presence of the
endothelium. Furthermore, they suggest that iNOS-derived NO might not play an
active role in modulating vascular function in these arteries.
As discussed in previous chapters, basal production of NO in endothelium-intact
isolated rat aortic rings exerts a tonic vasodilatory action, opposing the effects of
vasoconstrictors (Martin et al., 1986). Indeed, in the present chapter, denudation of
aortic rings from CHF rats resulted in a significant increase in responsiveness to NE,
implying that endothelium-derived relaxing factors, including NO play an active role
in modulating vascular responsiveness in these arteries. In contrast, however,
denudation of aortic rings from sham-operated rats had no significant effect on
responsiveness to NE. It is unclear from these experiments alone why this disparity
between CHF and sham-operated rats exists. What is clear from this finding,
however, is that the observed hyporeactivity of endothelium-intact aortic rings from
CHF rats should be interpretated with caution. Indeed, it is possible that
endothelium-intact aortic rings from CHF rats appear hyporeactive when compared
with aortae from sham-operated rats simply because in aortic rings from sham-
operated rats endothelium-derived NO is playing no tonic vasodilatory role in
modulating vascular responsiveness. Consistent with this hypothesis, endothelium-
intact aortic rings from sham-operated rats were significantly less responsive to ACh
than aortic rings from CHF rats. Taken together these results would suggest that the
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release of NO from the endothelium in aortic rings from sham-operated rats is
impaired. While it remains to be established if this is indeed the case, it is clear that
comparisons between CHF and sham-operated rats should be approached with
caution.
To establish if iNOS plays a role in modulating vascular responsiveness in thoracic
aortae from rats with CHF, the selective iNOS inhibitor, 1400W (see Chapter 3),
and the NOS substrate, L-arginine were used. 1400W had no significant effect on the
responsiveness of endothelium-intact aortic rings from CHF or sham-operated rats to
NE. Therefore, as proposed earlier, these results suggest that the induction of iNOS
in thoracic aortae does not play an active role in modulating vascular responsiveness
in these arteries. In experimental endotoxic shock, addition of the NOS substrate,
L-arginine, to isolated blood vessels increases NO production from iNOS and
potentiates hyporesponsiveness to vasoconstrictors (Julou-Schaeffer et al., 1990).
Experiments here demonstrate that supplementation of endothelium-denuded aortic
rings from CHF rats, but not sham-operated rats, with a supramaximal concentration
of L-arginine resulted in a significant reduction in responsiveness to NE. These
results confirm the presence of iNOS within thoracic aortae from CHF rats.
Furthermore, they suggest that, in a similar fashion to small mesenteric arteries (see
Chapter 6), iNOS may be unable to synthesize NO because there is insufficient
substrate.
In Chapter 6 of this thesis, experiments suggested that a deficiency in L-arginine not
only prevented iNOS from generating NO, but also resulted in the enzyme producing
superoxide. Moreover, as previously mentioned, this source of superoxide was
deemed responsible for the hyperesponsive nature of endothelium-intact small
mesenteric arteries, possibly as a consequence of increased scavenging of eNOS-
derived NO. Experiments here suggest that in aortic rings from CHF rats, iNOS may
also be deficient in L-arginine. However, as discussed, the endothelium appears to
play an active tonic vasodilatory role in modulating vascular responsiveness in these
arteries. Therefore, if iNOS is generating superoxide it is unlikely that this source of
superoxide has a significant effect on the bioavailability of endothelium-derived NO.
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Consistent with this hypothesis, treatment of endothelium-intact aortic rings from
CHF rats with the cell permeable metalloporphyrin, MnTMPyP (see Chapter 4), on
its own or in combination with 1400W had no significant effect on responsiveness to
NE. Furthermore, MnTMPyP had no significant effect on relaxations to ACh in
endothelium-intact aortic rings from CHF rats. Therefore, these findings suggest that
either iNOS is not generating superoxide or the superoxide generated by iNOS has
no effect on the bioavailability of endothelium-derived NO and hence vascular
function in these arteries from CHF rats.
Interestingly, in contrast with aortic rings from CHF rats, treatment of endothelium-
intact aortic rings from sham-operated rats with MnTMPyP resulted in a significant
reduction in responsiveness to NE when compared with responses in untreated rings.
In Chapter 4, MnTMPyP was shown to increase responsiveness of endothelium-
intact aortic rings to ACh by protecting endothelium-derived NO from inactivation
by low levels of endogenous or exogenous superoxide generated within the organ
bath. Therefore, in sham-operated aortic rings treated with MnTMPyP, an increase in
the bioavailability of endothelium-derived NO is probably responsible for the
marked decrease in responsiveness to NE. As discussed, earlier experiments
suggested that basal release of NO from the endothelium in aortic rings from sham-
operated rats was impaired. Increased inactivation of endothelium-derived NO by
superoxide generated within the organ bath may well explain this finding. Indeed,
MnTMPyP, significantly increased the responsiveness of endothelium-intact aortic
rings to ACh. More importantly, however, these findings highlight important
differences between endothelium-intact aortic rings from CHF and sham-operated
rats with respect to the susceptibility of basal endothelium-derived NO to
inactivation by superoxide. In particular, these results suggest that in aortic rings
from CHF rats, endothelium-derived NO is less prone to inactivation by superoxide
than in aortic rings from sham-operated rats. This hypothesis is provocative,
however, it is based on correlations rather than direct evidence. However, if this
hypothesis is proven, it may explain why earlier studies using MnTMPyP suggest
that, despite being substrate deficient, iNOS expressed in aortic rings from CHF rats
is not generating superoxide. Indeed, it may be that iNOS is generating superoxide,
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however, because these arteries from CHF rats are less susceptible to inactivation by
superoxide, it has no significant effect on the bioavailability of endothelium-derived
NO, and thus vascular responsivenss.
It is clear from this discussion that the experiments in this chapter present a complex
story regarding the role of iNOS and superoxide in modulating vascular function in
conductance arteries from rats with CHF. In particular, interpretation of the results
presented in this chapter are complicated by the finding that in aortic rings from
sham-operated but not CHF rats, the release of endothelium-derived NO is impaired,
probably as a consequence of increased scavenging by superoxide. However, there
are some important conclusions that can be drawn from this study. In a particular,
experiments provide convincing evidence that iNOS plays no role in modulating
vascular responsiveness of thoracic aortae from CHF rats. Experiments also suggest
that, as in small mesenteric arteries from CHF rats (see Chapter 6), iNOS expressed
in thoracic aortae might be substrate deficient. However from the data presented here
it is unclear if iNOS is generating superoxide or not. In conclusion, therefore, this
study presents some interesting differences between small mesenteric arteries and
thoracic aortae from CHF rats with respect to the role of iNOS and superoxide in
modulating vascular function. However, it is clear that further studies are required to








Chronic heart failure (CHF) is a major cause of cardiovascular mortality and
morbidity, accounting for 5% of acute hospital admissions in the UK (Sutton et al.,
1997). In CHF, a complex interplay of haemodynamic and neurohormonal
mechanisms are activated to maintain arterial blood pressure in the face of reduced
cardiac output. Increased peripheral vascular resistance (PVR), as a consequence of
these compensatory mechanisms plays an important role in the progression of CHF,
contributing to increased internal left ventricular (LV) stress and LV remodelling
(see Section 1.5.5).
Resistance arteries are know to be the most important blood vessels in the body in
determining PVR (see Section 1.2.3). There is evidence to suggest that impaired
nitric oxide (NO)-mediated vasodilatation of resistance arteries contributes to the
increased PVR associated with CHF. However, there is some evidence that basal
synthesis of NO may be preserved or even enhanced in CHF, perhaps due to the
expression of inducible NO synthase (iNOS). Increased superoxide production has
been demonstrated in CHF and, since superoxide inactivates NO, a reduction in NO
bioavailability may be responsible for impaired NO-mediated relaxations and may
also explain why PVR remains elevated despite increased NO production. Increased
basal production of NO, contrasting with impaired NO-mediated vasodilatation, has
also been demonstrated in conductance arteries during CHF. Although conductance
arteries play a minimal role in modulating PVR, they do play an important role in the
overall mechanical efficiency of the cardiovascular system (see Section 1.2.3), At the
onset of this thesis, the expression of iNOS in the cardiovascular system in CHF and
its role in modulating vascular function had not been investigated. Furthermore, the
role of superoxide in modulating the bioavailability of the vascular NO system in
CHF had not been fully addressed.
The ultimate goal of this thesis was to investigate the role of iNOS and superoxide in
modulating vascular function in rats with CHF following coronary artery ligation
(CAL) and subsequent myocardial infarction (MI). Therefore, the primary aim of
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experiments was to determine whether iNOS was expressed in the cardiovascular
system in this model of CHF. In particular, its expression within the heart, small
mesenteric arteries (internal diameters, 300 - 350 |im) and thoracic aortae was
investigated. After establishing whether iNOS was expressed in small mesenteric
arteries and thoracic aortae from rats with CHF, the aim of future experiments was to
investigate the functional significance of iNOS on vascular function. The final aim of
this thesis was to examine the role of superoxide in modulating vascular NO
bioavailabiltiy in this model of CHF. In summary, therefore, experiments in this
thesis set out to attain a more comprehensive understanding of the role of the NO
system in modulating vascular function during CHF, with the ultimate goal of
evaluating its potential as a viable target for future drug therapy.
To investigate the role of iNOS and superoxide in modulating vascular function in
this model of CHF, the pharmacological properties of the novel iNOS inhibitor, N-
(3-(Aminomethyl) benzyl) acetamidine dihydrochloride (1400W), and the cell
permeable superoxide dismutase mimetic, Mn [III] tetrakis [l-methyl-4-pyridyl]
porphyrin (MnTMPyP) were investigated. Experiments in Chapter 3 provided
convincing evidence that 1400W inhibits the activity of iNOS in vitro without
modifying the activity of eNOS and thus supported its use in furture experiments to
investigate the role of iNOS in modulating vascular function of arteries from CHF
rats. In Chapter 4, experiments provided convincing evidence that MnTMPyP was
an effective SOD mimetic and thus was suitable for use in future experiments
investigating the role of superoxide in modulating NO bioavailability in the
peripheral vasculature from CHF rats.
The primary finding of this thesis was that iNOS was detected in both the heart and
peripheral vasculature in rats with CHF six weeks post-ligation. Furthermore, no
iNOS was detected within the heart and peripheral vasculature in sham-operated rats,
providing convincing evidence that the expression of iNOS in the cardiovascular
system was specific to the induction of CHF per se. iNOS immunoreactivity was
detected in all cell types of both small mesenteric arteries and thoracic aortae from
rats with CHF. Previous functional studies have suggested that iNOS-derived NO is
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responsible for the increased basal NO production associated with CHF (Drexler et
al., 1992; Habib et al., 1994; Winlaw et al., 1994). However, this is the first time
iNOS has been detected in the peripheral vasculature in CHF. Therefore, these
findings complement and extend functional studies in suggesting that iNOS-derived
NO may be responsible for the increased basal NO production associated with CHF.
In contrast with the peripheral vasculature, previous clinical studies have detected
iNOS mRNA and protein in hearts from patients with CHF, providing convincing
evidence that CHF is associated with iNOS expression in the heart. However, as
discussed in Chapter 5, the spatial distribution of iNOS in the human failing heart
remains a matter for debate. In the model of CHF used in this thesis,
immunohistochemical studies revealed that iNOS was exclusively expressed within
the LV free wall and interventricular septum. These results corroborate the findings
of some (Haywood et al., 1996; Fukuchi et al., 1998) but not all investigators (de
Belder et al., 1993; Vejlstrup et al., 1998), and suggest that the induction of iNOS in
the heart during CHF might be specific to the LV myocardium. With respect to its
cellular localisation, iNOS could be detected in viable cardiomyocytes, coronary
vascular and endocardial endothelial cells. Therefore, besides complementing
previous clinical studies, the findings from these experiments extend these studies by
providing some novel information regarding the possible spatial distribution of iNOS
within the failing heart.
Experiments in Chapter 6 were designed to investigate the functional significance of
iNOS and superoxide in isolated small mesenteric arteries (300 - 350 pm) from rats
with CHF. Despite the presence of iNOS in these arteries, in vitro studies in this
chapter revealed that endothelium-intact but not endothelium-denuded small
mesenteric arteries from CHF rats were more responsive to phenylephrine (PE) than
those from sham-operated rats. The hypereponsiveness of endothelium-intact arteries
from CHF rats was reversed by the selective iNOS inhibitor, 1400W and by the
metalloporphyrin SOD mimetic, MnTMPyP. Supplementation of endothelium-
denuded arteries from CHF but not sham-operated rats with the NOS substrate, L-
arginine, resulted in a significant reduction in responsivness to PE when compared
with untreated arteries. Endothelium-dependent, but not endothelium-independent
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relaxations, were impaired in arteries from CHF rats when compared with relaxations
in arteries from sham-operated rats. Furthermore, MnTMPyP restored endothelium-
dependent relaxations.
The findings of this chapter may present an interesting new facet to the impact of
iNOS in modulating vascular function of resistance arteries in CHF. iNOS
expression in blood vessels is normally associated with the production of large
quantities of NO and a subsequent decrease in vascular responsiveness (see Chapter
3). However, in this model of CHF, instead of generating large quantities of NO,
iNOS appears to be generating superoxide, perhaps because of a deficiency in its
substrate, L-arginine. Furthermore, results suggested that this source of superoxide
was responsible for the hyperesponsive nature of these arteries, possibly as a
consequence of increased scavenging of eNOS-derived NO. Moreover, iNOS-
derived superoxide was deemed responsible for impaired endothelium-dependent
relaxations. All three isoforms of NOS have been shown to generate superoxide
rather than NO when deficient in substrate and/or cofactors (Klatt et al., 1993b; Xia
et al., 1998a; Xia et al., 1998b). Furthermore, there is evidence to suggest that
tetrahydrobiopterin deficient eNOS-derived superoxide may contribute to the
endothelial dysfunction associated with atherosclerosis (reviewed by Wever et al.
1998). Therefore, the concept of NOS generating superoxide under conditions of low
substrate and/or cofactor is not novel. However, the findings of this thesis are the
first to implicate a pathophysiological role for substrate deficient iNOS-derived
superoxide. While the clinical significance of this finding remains to be established,
they may represent an important mechanism for the endothelial dysfunction and
raised PVR associated with CHF.
The next finding in this thesis indicated that, in contrast to small mesenteric arteries,
substrate deficient iNOS played no role in modulating function of thoracic aortae
from rats with CHF. Initial experiments suggested that endothelium-intact aortic
rings from CHF rats were less responsive to norepinephrine (NE) when compared
with responses in aortic rings from sham-operated rats. This hyporeactivity would
suggest that iNOS is generating NO in these arteries from CHF rats. However, as
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discussed in Chapter 7, subsequent experiments in endothelium-denuded aortic
rings revealed that this apparent hyporeactivity was probably because the release of
NO from the endothelium in aortic rings from sham-operated rats was impaired.
Despite being unable to make comparisons between responses in aortic rings from
CHF and sham-operated rats, there are some important conclusions that can be drawn
from the experiments in this chapter. In particular, inhibition of iNOS and/or
scavenging of superoxide in endothelium-intact aortic rings from CHF rats had no
significant effect on NE responsiveness, providing convincing evidence that iNOS
and superoxide play no role in modulating vascular function of these arteries.
Subsequent experiments using L-arginine, however, revealed that in a similar manner
to small mesenteric arteries, there might be insufficient substrate available for iNOS
in thoracic aortae to generate NO. The experiments in this thesis fail to provide a
comprehensive explanation for why in these arteries substrate deficient iNOS is not
generating superoxide. In the discussion of Chapter 7, it was suggested that iNOS
might be generating superoxide, but because endothelium-derived NO in these
arteries was less prone to destruction by superoxide then this source of superoxide
had no significant effect on vascular responsiveness. This hypothesis was based on
the finding that in endothelium-intact aortic rings from sham-operated but not CHF
rats endothelium-derived NO was destroyed by endogenous or exogenous superoxide
production within organ bath.
8.2 Future studies
Having considered the results, there are now additional studies that should be carried
out to exploit the findings of this thesis and to further enhance the understanding of
the role of iNOS and superoxide in the cardiovascular system in CHF. The crucial
finding here is that in small mesenteric arteries from rats with CHF, iNOS generates
superoxide rather NO, perhaps because of a deficiency in its substrate. These
conclusions are based on pharmacological observations and are substantiated by
previous biochemical studies showing that iNOS generates superoxide when
deficient in L-arginine (Xia et al., 1998a). Despite this compelling evidence, direct
measurement of superoxide generation by iNOS in the presence and absence of
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1400W and L-arginine would clearly enhance the impact of this hypothesis.
Similarly, experiments directly measuring L-arginine levels within these arteries
could strengthen this hypothesis. The most obvious progression from this thesis
would be to establish if the findings presented in this thesis using a rat model of CHF
are mirrored in clinical CHF. One viable option would be to isolate resistance
arteries from gluteal biopsies from patients with CHF and perform functional
experiments using the perfusion myograph.
As discussed, this thesis presents some important differences between small
mesenteric arteries and thoracic aortae in this model of CHF with respect to the roles
of iNOS and superoxide in modulating vascular function. Additional studies are
warranted to substantiate these differences. In particular, experiments are required to
elucidate why substrate deficient iNOS is generating superoxide in small mesenteric
arteries but not in thoracic aortae. Furthermore, future studies are necessary to
investigate and substantiate the finding that endothelium-derived NO in thoracic
aortae from CHF rats appears to be less susceptible to destruction by superoxide than
thoracic aortae from sham-operated rats.
In this model of CHF, it is unclear why iNOS is substrate deficient. A recent study
observed a 76% reduction in mRNA expression for the cationic amino acid
transporter responsible for the transportation of L-arginine into cells, in peripheral
mononuclear cells from patients with CHF (Kaye et al., 2000). This finding suggests
that the uptake of L-arginine into cells may be impaired in CHF. In contrast,
however, a more recent study demonstrated that L-arginine uptake into thoracic
aortae was enhanced in rats with CHF when compared with sham-operated rats
(Stathopulos et al., 2001). Future experiments should encompass measuring the
uptake of L-arginine into the vasculature in this model of CHF and/or measuring
mRNA or protein levels of the membrane transporter.
The pathophysiological mechanisms underlying the induction of iNOS in the
peripheral vasculature in this model of CHF were not investigated. As discussed in
Chapter 5, plasma levels of inflammatory cytokines are elevated in patients with
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CHF, and thus may serve as a stimulus for iNOS in the vasculature. To determine if
indeed, cytokines are responsible for the expression of iNOS in this model of CHF,
future studies should include measuring plasma levels of inflammatory cytokines.
As discussed in Section 1.3.6.3, under conditions where NO and superoxide are
generated, a diffusion-limited, essentially irreversible reaction between equimolar
amounts of NO and superoxide results in the formation of peroxynitrite (ONOO";
Beckman & Koppenol, 1996). Low levels of ONOO" can have beneficial effects on
vascular function, mediated via stimulation of guanylate cyclase and generation of
cyclic guanosine monophosphate (cGMP; Nossuli et al., 1997). However, at high
concentrations ONOO" is cytotoxic (Crow & Beckman, 1995), causing lipid
peroxidation and DNA damage. Moreover, ONOO" induces apoptosis in cultured
cells (Lin et al., 1998) and has been implicated vascular injury associated with
endotoxic shock (Szabo et al., 1996) and atherosclerosis (Stroes et al., 1998). In this
model of CHF, increased scavenging of endothelium-derived NO by superoxide was
deemed responsible for vascular dysfunction, therefore, it is possible that ONOO" is
being formed in these arteries and thus may result in vascular injury. To substantiate
this hypothesis, future studies should investigate whether ONOO" levels are increased
in the peripheral vasculature in this model of CHF. This could be achieved by
detecting nitrated tyrosine residues, which is widely accepted as a marker for ONOO"
formation, within isolated arteries.
The main bulk of this thesis concentrated on investigating the role of iNOS and
superoxide in modulating vascular function in rats with CHF. However, experiments
in Chapter 5 provided some additional information regarding the distribution of
iNOS in the heart in this model of CHF. The findings of these experiments provide
the impetus for a wealth of future studies, which would hopefully expand the
understanding of the role of iNOS and superoxide in modulating the cardiovascular
system in CHF. As discussed, immunohistochemical studies in Chapter 5 revealed
that iNOS was exclusively expressed within the LV myocardium in this model of
CHF. In the discussion of this chapter, it was hypothesised that mechanical stretch,
such as that which occurs during the progressive LV remodelling associated with
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CHF, might be a sufficient stimulus to provoke the gene expression of the
inflammatory cytokine, tumour necrosis factor-a (TNF-a) within the failing heart.
Inflammatory cytokines can induce the expression of iNOS, and therefore it was
suggested that mechanical stretch might be the ultimate regulatory factor in inducing
iNOS expression within the failing heart. Though provocative this hypothesis
requires confirmation. It is clear, therefore, that further studies are required to fully
address the relationship between inflammatory cytokines and mechanical stretch in
regulating the induction of iNOS in the heart during CHF. By doing so these studies
may explain why iNOS expression in the heart is not uniform throughout the heart.
Another important aim of future experiments would be to investigate the functional
significance of iNOS expression in the failing heart. As discussed in Section 1.4.2,
the physiological significance of NO on the functioning of the heart is not fully
understood. In isolated cardiomyocytes, induction of iNOS by inflammatory
cytokines and the subsequent production of large quantities of NO inhibits myocyte
contractility (Brady et al., 1992; Brady et al., 1993). Furthermore, the expression of
iNOS within the heart during endotoxic shock is associated with depressed cardiac
function (Schulz et al., 1995; Sun et al., 1997). There is some evidence that NO may
inhibit the positive inotropic response to (3-adrenergic stimulation (Balligand et al.,
1993). Furthermore, increased NO production by iNOS has been implicated in the
hyporesponsiveness of the myocardium to (3-adrenergic stimulation in patients with
LV dysfunction (Hare et al., 1998). Taken together these results may suggest,
therefore, that iNOS expression in the failing heart may play a pathological role in
modulating cardiac function. However, it has been demonstrated that endogenous
eNOS-derived NO released during diastole results in a faster onset of LV relaxation.
Indeed, as discussed in Section 1.4.2.4 it has been postulated that the release of NO
during diastole serves to increase diastolic distensibility during the cardiac cycle. On
the basis of this hypothesis, therefore, increased NO production in the failing heart
may play a beneficial role in LV dysfunction associated with CHF by maintaining
the Frank-Starling mechanism. Indeed, a recent study revealed that in patients with
CHF, an increase in iNOS gene expression augmented LV stroke volume and LV
stroke work because of a NO-mediated rightward shift of the diastolic LV pressure-
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volume relation and a concomitant increase in LV preload reserve (Heymes et al.,
1999). This hypothesis remains an intriguing possibilty, however, experiments
presented in this thesis should not be ignored when evaluating whether iNOS plays
an overall beneficial or detrimental role in modulating cardiac function in CHF. In
particular, it may be that as with the peripheral vasculature, iNOS expressed in the
failing heart is substrate deficient. If so, then, iNOS expression in the heart may be
associated with increased generation of superoxide. This could in turn reduce the
bioavailability of eNOS-derived NO and result in a worsening of LV function. It is
clear, therefore, that extensive studies are necessary to address the role of iNOS and
superoxide in modulating cardiac function.
8.3 Clinical Implications
The findings of this thesis present evidence that iNOS may play an important role in
the endothelial dysfunction and raised PVR associated with CHF. Although further
studies are necessary to determine if these experimental findings are mirrored in
clinical CHF, the findings reported here suggest that dysfunctional iNOS may be a
viable target for future drug therapies in CHF.
Inhibition of iNOS may be a viable therapeutic option, particular so, with the
emergence of an increasing amount of compounds that offer selectivity for iNOS
over eNOS (Garvey et al., 1997; McMillan et al., 2000). Another option may be to
increase the amount of substrate available to iNOS. Increasing the availability of L-
arginine may prevent the production of superoxide by iNOS in resistance arteries and
thus increase the bioavailability of eNOS-derived NO. Furthermore, L-arginine
supplementation may facilitate the synthesis of NO by iNOS, which may in turn
reduce PVR further. In addition to its potential benefits in lowering PVR, increasing
the generation of NO from iNOS in conductance arteries may increase the elasticity
of these arteries. This may in turn, have beneficial effects on the overall mechanical
efficiency of the cardiovascular system. Recent studies investigating therapeutic
options to restore endothelial function in CHF revealed that L-arginine
supplementation may be beneficial. In clinical CHF, intravenous infusion of
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L-arginine increased cardiac output (Goumas et al., 2001) and increased NO-
mediated relaxations to acetylcholine (Prior et al., 2000). Furthermore, chronic
administration of L-arginine increased forearm blood flow during exercise, improved
functional status and arterial compliance (Rector et al., 1996). Larger clinical studies
are required to substantiate the findings of these clinical studies and to further
evaluate the benefit of L-arginine supplementation in the treatment of CHF.
As discussed, the underlying mechanisms responsible for the induction of iNOS in
the cardiovascular system in this model of CHF were not investigated. However,
compelling evidence suggests that inflammatory cytokines, such as TNF-a, may be
responsible. Therapies directed against this cytokine may represent a novel approach
to CHF management, particular so since TNF-a has been implicated in a number of
other pathophysiological processes that are thought important to the progression of
CHF (see Section 1.5.6.2), Anti-TNF-a strategies may target the mechanisms of
immune activation, the intracellular pathways regulating TNF-a production or the
fate of TNF-a once released into the circulation (Torre-Amione et al., 2000). A
recent study demonstrated that treatment of transgenic mice overexpressing TNF-a
with an adenoviral vector expressing soluble TNF-a receptor type 1 preserved
myocardial function (Li et al., 2000). Furthermore, Deswal et al. (1997) reported
preliminary results from a phase I study of a recombinant human TNF-receptor-
fusion protein, which binds to TNF-a and inactivates it, in patients with functional
class III CHF. In this study, circulating concentrations of TNF-a were reduced on the
first day of therapy and remained low for 2 weeks. Moreover, the treatment was well
tolerated and was associated with an improvement in symptoms. These encouraging
results have led to phase II placebo-controlled studies, which are underway and are
expected to be complete in the next two years (Torre-Amione et al., 2000).
The findings presented here and from other studies suggest a role for increased
superoxide production in the pathogenesis of CHF (see Section 1.5.6.3). Raising
endogenous levels of superoxide dismutase may therefore prove beneficial in the
treatment of CHF. There have been some studies evaluating the potential of
conenzyme Q10 (CQ10), a natural cofactor in mitochondrial respiration and
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superoxide scavenger. Anecdotal reports and uncontrolled studies (Langsjoen &
Folkers, 1990) have shown beneficial effects of CQ10 in patients with CHF.
However, there have been only limited controlled studies. A recent study, however,
demonstrated that CQ10 had no effect on ejection fraction or exercise capacity in
patients with class III CHF (Khatta et al., 2000). Similar studies have been carried
out to evaluate the benefit of Vitamin C and E in the treatment of CHF. Eilis et al.
(2000) revealed that both chronic and acute administration of Vitamin C reduced
oxidative stress and increased flow-dependent vasodilation in patients with CHF. A
recent clinical study, revealed that supplementation of Vitamin E did not result in
any significant improvement in prognostic or functional indexes of CHF or in the
quality of life of patients with CHF (Keith et al., 2001). Notably, however, some
drugs that have been found to be effective in the treatment of CHF may have
important antioxidant properties. For example, the (3-adrenergic antagonist carvediol
and one of its metabolites exert potent antioxidant properties in vitro that may be
realised at therapeutic concentrations in patients with CHF (Yue et al., 1992).
Furthermore, there is evidence that carvediol can reduce oxidative stress in patients
with CHF. Angiotensin-converting inhibitors have also been shown to scavenge free
radicals in vitro (Suzuki et al., 1993a). From this discussion, it is clear that further
studies are warranted to further evaluate the benefit of antioxidant therapy in the
management of CHF.
8.4 Conclusion
In conclusion, this thesis presents an interesting new facet to the role of iNOS in
modulating vascular function in CHF. In particular, findings of this thesis reveal that
substrate deficient iNOS-derived superoxide may play an important role in the
endothelial dysfunction and raised PVR associated with CHF. Although further
research is required at both an experimental and clinical level to substantiate these
findings, this thesis suggests that targeting the NO system, in particular the activity






All salts were purchased from BDH, U.K.
Krebs Henseleit solution
Composition in mM:
sodium chloride, 118; potassium chloride, 4.7; calcium chloride, 2.5, magnesium
sulphate, 1.2, potassium di-hydrogen orthophosphate, 1.2; sodium carbonate, 25 and
glucose 5.5
Phosphate Buffered Saline (PBS) pH 7.6
1. Dissolve 12.7g di-sodium hydrogen orthophosphate in 80 ml deionised H2O.
Microwave for 30 seconds.
2. In a separate container, dissolve 1.7g of sodium di-hydrogen orthophosphate in
80 ml deionised H2O.
3. Add both solutions to 800 ml deionised H20 and pH to 7.6 with concentrated
HC1.
Make up final volume to 1L with deionised H2O.
Tris-Bujfered Saline (TBS) pH 7.8
1. Dissolve 6.04g of tris in 80 ml deionised H20. Add 2.77 ml of concentrated HC1.
2. In a separate container, dissolve 8.1 g of sodium chloride in 900 ml deionised
H20.
Mix the 2 solutions, adjust to pH 7.8 using concentrated HC1 and make up to 1L
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Aminopropylethoxysaline (TESPA) slide coating
Appendix
Bathe slides for 10 seconds in each of the following:
1. 10% HC1 in 70% ethanol
2. deionised H2O
3. 100% acetone
Air dry the slides, then 10 seconds in each of the following:
4. 2% TESPA in acetone
5. 100% acetone
6. 100% acetone
Slides are air dried again, can be stored for one month in airtight containers
Stains
van Gieson 's collagen stain
To 50 ml of deionised H2O, add:
1. 50 ml of saturated aqueous picric acid solution (BDH, U.K)
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Inducible nitric oxide synthase-derived superoxide contributes to
hypereactivity in small mesenteric arteries from a rat model of
chronic heart failure
'Alyson A. Miller, 'Ian L. Megson & *'Gillian A. Gray
'Endothelial Cell Biology and Molecular Cardiology Section, Centre for Cardiovascular Science, Department of Biomedical
Sciences, University of Edinburgh, Hugh Robson Building, George Square, Edinburgh, EH8 9LD
1 The aims of this study were to (a) determine whether inducible nitric oxide synthase (iNOS) is
expressed in small mesenteric arteries from rats with chronic heart failure (CHF), (b) investigate the
functional significance of this potential source of nitric oxide (NO) on vascular responsiveness and
(c) investigate the role that superoxide plays in modulating vascular function in these arteries.
2 CHF was induced in male Wistar rats by coronary artery ligation (CAL). In sham-operated rats
the ligature was not tied but pulled under the artery. Six weeks after surgery CAL rats had left
ventricular (LV) infarctions and elevated LV end-diastolic pressures.
3 Immunoreactive iNOS was found in endothelial cells, vascular smooth muscle cells and in the
adventitia of small mesenteric arteries from CAL rats but not those from sham-operated rats.
4 Third order mesenteric arteries (300-350 fim) were mounted in a small vessel pressure
myograph. Endothelium-intact arteries from CAL rats were more responsive to phenylephrine
(PE) than arteries from sham-operated rats (pD, value, CAL, 6.2 + 0.1; sham-operated, 5.9 + 0.1,
P<0.05).
5 Both the selective iNOS inhibitor, N-(3-(Aminomethyl) benzyl) acetamidine dihydrochloride
(1400W; 10~6 m) and the superoxide dismutase mimetic, Mn [III] tetrakis [l-methyl-4-pyridyl]
porphyrin, (MnTMPyP; 10"4 M) reversed the hyperesponsiveness (pD2 values, 1400W, 5.9 + 0.1;
MnTMPyP, 5.81 ±0.1, P<0.05). The NOS substrate, l-arginine (10~3 m), reduced responsiveness of
endothelium-denuded small mesenteric arteries from CAL rats (PcO.Ol). None of these drugs
altered responses to PE in arteries from sham-operated rats.
6 In summary, this study demonstrates that iNOS is expressed in mesenteric arteries from rats with
CHF. However, instead of generating large quantities of NO, iNOS appears to be generating
superoxide, perhaps because of a deficiency in its substrate, L-arginine. Increased superoxide
generation from iNOS contributes to the hyperesponsive nature of endothelium-intact small
mesenteric arteries from rats with CHF.
British Journal of Pharmacology (2000) 131, 29-36
Keywords: Nitric oxide; inducible nitric oxide synthase; superoxide; L-arginine; endothelium; rat mesenteric arteries; heart
failure
Abbreviations: ANOVA, analysis of variance; CAL, coronary artery ligation; CHF, chronic heart failure; CRC, concentration
response curve; eNOS, endothelial nitric oxide synthase; iNOS, inducible nitric oxide synthase; LV, left ventricle;
LVEDP, left ventricular end-diastolic pressure; MnTMPyP, Mn [III] tetrakis [l-methyl-4-pyridyl] porphyrin; N-
(3-(Aminomethyl) benzyl) acetamidine dihydrochloride; NO, nitric oxide; PE, phenylephrine; SOD, superoxide
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Introduction
Endothelium-derived nitric oxide (NO) plays a vital role in the
regulation of vasomotor tone and arterial blood pressure (for
review see Moncada et al., 1991). Evidence is accumulating to
suggest that impaired NO-mediated vasodilatation contributes
to increased peripheral vascular resistance associated with
chronic heart failure (CHF). In clinical and experimental CHF
it has been established that endothelium-dependent relaxation
in response to acetylcholine is impaired (Drexler et al., 1992;
Ramsey & Jones, 1994; Bauersachs et ah, 1999). In contrast,
data on basal release of NO in CHF is controversial. Some
studies suggest that basal release of NO is preserved or may
even be enhanced in CHF (Drexler et al., 1992; Habib et al.,
1994; Winlaw et al., 1994), while other studies show that it is
impaired (Eisner et al., 1991; Teerlink et al., 1994). The
aetiology of endothelial dysfunction associated with CHF is
unclear and is likely to be complex.
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The inducible isoform of nitric oxide synthase (iNOS) is
expressed in the vasculature in response to inflammatory
cytokines and pathogens (Moncada et al., 1991). Inflamma¬
tory cytokines such as tumour necrosis factor-a are elevated
in the plasma of patients with CHF (Katz et al., 1994).
Furthermore, iNOS has been reported by some investigators
to be present in the myocardium (Fukuchi et al., 1998;
Vejlstrup et al., 1998) and skeletal muscle (Adams et al.,
1997) of patients with CHF. The role of iNOS in the
vasculature has not been directly addressed in CHF. It has
been suggested, however, that iNOS may be responsible for
increased basal production of NO in CHF (Carville et al.,
1998).
Irrespective of its source, increased basal production of NO
should counteract compensatory constrictor mechanisms and
thus reduce peripheral vascular resistance. Increased super¬
oxide production is associated with CHF (Belch et al., 1991).
Superoxide scavenges NO (Gryglewski et ah, 1986), therefore,
a reduction in NO bioavailability may well explain why
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peripheral vascular resistance remains elevated in CHF despite
a preserved or enhanced basal release of NO.
The aims of the present study were to determine if iNOS is
expressed in isolated small mesenteric arteries from a rat model
of CHF, to determine the functional significance of this
potential source of NO on vascular responsiveness and to
investigate the role that superoxide plays in modulating
vascular function in these arteries.
Methods
Coronary artery ligation model of CHF
All experiments were carried out in accordance with the
Animals (Scientific Procedures) Act 1986. Myocardial infarc¬
tion was induced in 5 week old male Wistar rats (250-300 g,
Charles River) by coronary artery ligation (CAL), as
previously described (Pfeffer et al., 1979). In brief, rats were
anaesthetized (sodium pentobarbitol; 60 mg kg-1, i.p.), the
thoracic cavity was opened and the heart exteriorized. Using a
silk ligature, the left anterior descending coronary artery was
tied. In control sham-operated rats, the ligature was not tied
but pulled through under the coronary artery. After closure of
the chest, animals were allowed to recover and were
maintained on standard chow and water ad libitum.
Six weeks after surgery, rats were anaesthetized (sodium
pentobarbitol; 60 mg kg-1, i.p.), the right carotid artery was
isolated and a Millar pressure transducer-tipped catheter (2F,
model SPR 407, Millar Instruments, Inc., Houston, TX,
U.S.A.) introduced into the artery for measurement of arterial
blood pressure. The catheter was then advanced into the left
ventricle (LV) for measurement of left ventricular end-diastolic
pressure (LVEDP) as an index of left ventricular function.
Following exsanguination, the mesenteric bed was excised,
the gut removed and the remaining vascular bed placed into
cold, oxygenated (95% 02, 5% C02), Krebs-Henseleit solution
(composition, in mm: NaCl 118, KC1 4.7, CaCl2 2.5, MgS04
1.2, KH2 P04 1.2, NaHC03 25 and glucose 5.5) for functional
studies. Sections of the mesenteric bed from both CAL and
sham-operated rats were placed in 10% neutral phosphate
buffered formalin for fixation. The hearts and lungs were
removed and weighed. Hearts were bisected, fixed in formalin
as above for detection of mature collagen in the infarcted zone
and measurement of infarct size.
Immunohistochemistry
Formalin fixed mesenteric arteries from both CAL and sham-
operated rats were processed in ethanol and embedded in
paraffin wax. Three-/(m sections were taken from blocks,
dewaxed in xylene (10 min), rehydrated through a descending
alcohol series (100, 90 and 70% alcohol; 3 min each) and
washed in water (15 min). To expose antigenic sites, arteries
were treated with 0.1% trypsin (diluted in Tris-buffered
saline; pH 7.8; 15 min). Arteries were then treated with anti-
iNOS monoclonal antibody for 24 h (4°C), washed in
phosphate buffered saline (PBS; pH 7.6; 10 min) and treated
with alkaline phosphatase-conjugated goat anti-rabbit IgG
for 30 min (room temperature). To detect iNOS within
arteries, sections were treated with an alkaline phosphatase
substrate and red fuchsin as a chromogen (~ 20 min).
Negative controls were treated with an antibody of the same
immunoglobulin class but not directed against the iNOS
epitope. Tissues were counterstained with Harris' haematox-
ylin (BDH, Poole, U.K.).
Measurement of infarct size
Hearts were processed as above and 3 /im sections taken from
paraffin blocks. After dewaxing and rehydration, hearts were
treated with Van Gieson's stain for detection of collagen
formation in infarctions. Infarct size was measured in sections
as previously described (Mulder et al., 1998). Sections were
placed under a CCD video camera module (Sony, U.K.)
attached to a microscope with a x 20 lens. The endocardial
and epicardial circumferences of the infarcted tissue and of the
LV were determined with image analysis software (Imaging
Associates, U.K.). Infarct size was calculated as a percentage
[endocardial + epicardial circumference of the infarcted LV
(mm)/endocardial + epicardial circumference (mm)] of the
whole LV.
Preparation of arteries from mesenteric bed
Third order branches of the mesenteric artery (~3 mm length,
internal diameter; 300-350 ^m) were dissected free of the bed
and mounted between two microcannulae in a small vessel
pressure myograph (Living Systems Instrumentation Inc.,
Burlington, U.S.A.). Arteries were constantly superfused with
warm (37°C), oxygenated (95% 02, 5% C02) Krebs-Henseleit
solution. The intraluminal pressure of the vessel was raised to
60 mmHg and maintained at this level with a pressure servo
unit without further intraluminal perfusion. A pressure of
60 mmHg was chosen because it has been estimated that
vessels of this size would experience pressures approximately
50% of mean arterial pressure in vivo (Halpern & Kelley,
1991). Luminal diameter was measured using a video
dimension analyser (Living Systems Instrumentation Inc.,
Burlington, U.S.A.) and a calibrated hand micrometer, when
the optical dimension analyser was unable to detect differences
in optical density at smaller lumen diameters.
After an equilibration period of 60 min, arteries were
exposed twice in succession, separated by washout, to modified
Krebs-Henseleit solution containing 60 mm KC1 (equimolar
replacement of NaCl by KC1) to obtain maximal constriction.
Arteries were then exposed twice to a supramaximal
concentration of phenylephrine (PE; 10~5 m). In all arteries
the endothelial integrity was tested by measuring ACh-induced
relaxation (ICC5 m) of PE-induced tone (10~5 m), with
maximal relaxation indicating the presence of an intact
endothelium. In some arteries, the endothelium was removed
by passing an air bubble through the vessel lumen by a method
previously described (Falloon et al., 1993), and successful
denudation verified by loss of ACh-induced relaxation
(10~5 m). After sufficient washout and re-equilibration,
arteries were constantly superfused in a closed system with a
total volume of 30 ml warm (37°C), oxygenated (95% 02, 5%
C02) Krebs-Henseleit solution. All drugs used throughout this
study were applied to this 30 ml reservoir, removing 1 ml of
Krebs-Henseleit solution and replacing with the drug being
added (as previously described, Mickley et al., 1997).
Responses were recorded 5 min after addition of drug in order
to allow time for responses to reach equilibrium. Four arteries
were isolated from each CAL and sham-operated rat and the
following experiments carried out in a random order.
Experimented protocols
Vascular responsiveness ofarteries from coronary artery ligation
and sham-operated rats To assess vascular responsiveness of
small mesenteric arteries from CAL and sham-operated rats to
adrenoceptor stimulation, cumulative concentration response
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curves (CRC) to PE (1 x 10~9 to 3 x 10"5 M) were constructed
in endothelium-intact (n = 8) and endothelium-denuded (n = 6)
arteries. Following completion of CRCs all vessels were re¬
peatedly washed and allowed to re-equilibrate before further
experiments.
Effect of iNOS inhibition on vascular responsiveness To
investigate the role of iNOS in modulating vascular respon¬
siveness, endothelium-intact mesenteric arteries were exposed
to the iNOS inhibitor, N-(3-(Aminomethyl) benzyl) acetami-
dine dihydrochloride (1400W; 10~6 M, n = 8) for 30 min prior
to repeating cumulative CRCs to PE (1 x 10~9 to 3 x 10~5 M).
At this concentration. 1400W has been shown to inhibit the
activity of iNOS in isolated rat aortic rings treated with
lipopolysaccharide, without modifying the release of NO from
endothelial NOS (eNOS) (Garvey et al., 1997). 1400W was
present in the superfusate throughout the CRC.
Effect of superoxide quenching on vascular responsiveness To
investigate the role that superoxide plays in modulating
vascular responsiveness, endothelium-intact mesenteric arteries
were exposed to the superoxide dismutase (SOD) mimetic, Mn
[III] tetrakis [l-methyl-4-pyridyl] porphyrin (MnTMPyP;
10~4 M, n = 8) for 30 min prior to repeating cumulative CRCs
to PE (1 x 10~9 to 3 x 1CD5 M). At a concentration of ICC4 M,
MnTMPyP has been shown to protect endothelial-derived NO
from destruction by superoxide in an in vitro model of
oxidative stress (MacKenzie & Martin, 1998). MnTMPyP was
present in the superfusate throughout the CRC.
Effect of combined iNOS inhibition and superoxide quenching on
vascular responsiveness To further investigate the role of
iNOS and superoxide in modulating vascular responsiveness,
endothelium-intact mesenteric arteries were exposed to the
iNOS inhibitor, 1400W (10~6 M, n = 8) and the SOD mimetic,
MnTMPyP (10"4m, n = 8) for 30 min prior to repeating
cumulative CRC's to PE (1 x ICC9 to 3 x ICC5 M). Both drugs
were present in the superfusate throughout the CRC.
Effect of NOS substrate on vascular responsiveness To
investigate the effect of the NOS substrate, L-arginine, on
vascular responsiveness, endothelium-denuded mesenteric
arteries were exposed to a supramaximal concentration (Schott
et al., 1993) of L-arginine (10 3 M, n = 6) for 30 min prior to
repeating cumulative CRCs to PE (1 x ICC9 to 3 x ICC5 M). L-
arginine was present in the superfusate throughout the CRC.
Assessment of endothelium-dependent relaxations in arteries
from coronary artery ligation and sham-operated rats in the
presence and absence of the SOD-mimetic, MnTMPyP To
assess endothelium-dependent relaxations in mesenteric ar¬
teries from CAL and sham-operated rats ACh-mediated
relaxations were measured in PE-constricted arteries. A
submaximal concentration of PE (~EC50), as determined
from PE CRCs, was used to induce arterial tone. Cumulative
CRCs to ACh (lxlCC10 to 3x1CC6m, n = T) were then
obtained in the absence and presence of the SOD-mimetic
MnTMPyP (10 -1 M, n = 6).
Materials
Anti-iNOS monoclonal antibodies were obtained from Affiniti
Laboratories (Exeter, U.K.) and alkaline phosphatase-con-
jugated goat anti-rabbit IgG from Vector Laboratories
(Peterborough, U.K.). IgG antibodies were purchased from
Vector Laboratories (Peterborough, U.K.). New Fuchsin
Substrate System was purchased from Dako Corporation
(Carpinteria, U.S.A.).
Phenylephrine hydrochloride, acetylcholine chloride and L-
arginine were obtained from Sigma (Poole, U.K.), were diluted
in Krebs-Henseleit solution to give a stock solution of ICC1 M
and frozen (— 20°C) in aliquots until use on day of experiment.
1400W (N-(3-(Aminomethyl) benzyl acetamidine dihy¬
drochloride) was obtained from Calbiochem (Nottingham,
U.K.) and subsequently diluted in saline (0.9% NaCl) under
argon to give a stock solution of ICC3 M. Aliquots were then
frozen (—20°C) and stored under argon. Further dilutions
were made in Krebs-Henseleit solution. MnTMPyP (Mn [III]
tetrakis [l-methyl-4-pyridyl] porphyrin) was obtained from
Alexis (Nottingham, U.K.) and diluted in Krebs-Henseleit
solution immediately prior to experimentation.
Analysis of data
All results were expressed as means+ s.e.mean. Where
maximal values were obtained for cumulative CRCs, the
negative logarithm of the agonist concentration that results in
a half-maximal constriction or relaxation (pD2) was calculated.
Two-tailed /-tests, one-way analysis of variance (ANOVA)
with Bonferroni multiple comparisons post-test and two-way
repeated measures ANOVA were used as indicated in the text.
R<0.05 was considered to be statistically significant.
Results
Effect of left coronary artery ligation
All the animals that survived the first 24 h after CAL surgery
(76%) were still alive 6 weeks later. There were no significant
differences between rat weights for CAL and sham-operated
groups at 6 weeks after surgery (Table 1). Heart weights
(corrected for body weight) for CAL rats were significantly
greater than those of sham-operated rats despite the presence
of large infarcts (P< 0.05, two-tailed unpaired /-test, Table 1),
indicating that hearts from CAL rats had undergone
compensatory hypertrophy as a result of left ventricular
infarction. There were no significant differences between
groups with respect to lung weights and arterial blood
pressures (Table 1). LVEDPs measured from CAL rats were
significantly greater than those for sham-operated rats
(P<0.05, two-tailed unpaired /-test, Table 1). CAL rats had
left ventricular infarctions averaging 60 + 3% of the LV free
wall. Additionally there was histological evidence for mature
collagen scar formation within the infarcted zone (not shown).
Table 1 Summary of all parameters measured from
coronary artery ligation (CAL) and sham-operated (SHAM)
rats
CAL SHAM
Parameter («> 8) (n>8)
Rat weight (g) 473.9 + 9.7 495.7 + 22.3
Heart weight (g kg 1 body weight) 3.3 + 0.2* 2.7 + 0.1
Lung weight (g kg ' body weight) 4.3 + 0.5 3.3 + 0.1
Left ventricular end-diastolic 15.4+1.5** 6 + 1.1
Pressure (mmHg)
Arterial pressure (mmHg) 78.2 + 5.7 94.8 + 6.2
All values are given as mean ±s.e.mean. *P<0.05,
**P< 0.001 for CAL rats compared with sham-operated
rats (two-tailed unpaired /-test).
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Immunohistochemistry
Immunoreactive iNOS was found in endothelial cells, vascular
smooth muscle (VSM) cells and in the adventitia of small
mesenteric arteries from CAL rats (Figure 1). No immunor-
eactivity was found in mesenteric arteries from sham-operated
rats (Figure 1) or in negative controls using IgG antibodies
(not shown).
KCl, PE maximal constrictions and endothelial integrity
There were no significant differences between endothelium-
intact and endothelium-denuded small mesenteric arteries
from CAL and sham-operated groups with respect to internal
diameters at rest and in response to KCl (60 mm; Table 2).
However, maximal constriction to PE was significantly greater
in endothelium-denuded than in endothelium-intact mesenteric
arteries from both CAL and sham-operated rats (P<0.05,
one-way ANOVA with Bonferroni post-test, Table 2). All
endothelium-intact small mesenteric arteries studied had
functional endothelium (CAL, 101.3 + 4%; sham-operated,
95.9 + 3% relaxations to ACh) and no significant differences in
maximal relaxations were found between CAL and sham-
operated groups (Table 2).
Assessment of vascular responsiveness to adrenoceptor
stimulation in coronary artery ligation and
sham-operated rats
In both endothelium-intact and endothelium-denuded small
mesenteric arteries from CAL and sham-operated rats,
cumulative additions of PE (1 x 10~9 to 3 x 10"5 m) resulted
in concentration-dependent constrictions (Figure 2a,b). In
endothelium-intact arteries from CAL rats, cumulative CRCs
to PE were shifted significantly to the left when compared with
responses in sham-operated groups, indicating that arteries
from CAL rats were more responsive to PE than those from
sham-operated rats (P<0.05, two-way ANOVA, Figure 2a).
Indeed, pD2 values for PE CRCs in arteries from CAL rats
were significantly greater than those in sham-operated rats
(CAL, 6.2 + 0.1; sham-operated, 5.9 + 0.1, P<0.05, two-tailed
unpaired Mest). There was no significant difference between
maximal constrictions observed in arteries from CAL and
sham-operated rats (Figure 2a).
In endothelium-denuded arteries no significant differences
were found between CAL and sham-operated rats with respect
to PE CRCs (Figure 2b). In addition, there were no significant
Table 2 Internal luminal diameters of endothelium-intact
( + end) and -denuded (-end) arteries from coronary artery
ligation (CAL) and sham-operated (SHAM) rats
CAL (^m) SHAM Qmi)
+ end -end + end -end
(«=H) (n = 9) (n = 8) (n = 8)
Resting 330 + 9 310+10 319+15 310+13
60 mm KCl 125 + 9 110+10 118+15 105 + 10
10"5 m PE 120 + 5** 85 + 5 117 + 5* 88+10
1(T5 m ACh 335+10 95 + 5 305 + 15 107 + 20
Internal diameters of arteries at rest, after exposure to KCl,
phenylephrine (PE) and acetylcholine (ACh) (arteries pre¬
contracted with 1(T5 m PE) are given as mean values ±s.e.
mean. *P<0.05 as compared with sham-operated endothe¬
lium-denuded arteries, **P<0.01 as compared with CAL
endothelium-denuded arteries (one-way ANOVA with
Bonferroni post-test).
Figure 1 Localization of iNOS by immunohistochemical staining in mesenteric arteries from coronary artery ligation and sham-
operated rats, (a) Showing immunoreactive iNOS (pink staining) in endothelial cells, vascular smooth muscle cells and in the
adventitia of mesenteric arteries from rats following coronary artery ligation, (b) Showing absence of immunoreactive iNOS in
arteries from sham-operated rats. Nuclei are stained with Harris' Haematoxylin (purple staining). Magnification x400, scale
bar = 30 ^m.
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differences between pD2 values (CAL, 6.3 + 0.3; sham-
operated, 5.9 + 0.2) and maximal % constrictions (Figure 2b).
Effect of 1400W and MnTMPyP on vascular
responsiveness
Treatment of endothelium-intact arteries from CAL rats with
1400W (10"6 M) or MnTMPyP (10~4 M) shifted PE CRCs to
the right with respect to responses in untreated arteries
(P<0.05 for both, two-way ANOVA, Figure 3a), indicating
a reduction in responsiveness to PE. pD2 values were
significantly decreased in the presence of 1400W or MnTMPyP
when compared with untreated arteries (untreated, 6.3 + 0.1;
1400W, 5.9 + 0.1; MnTMPyP, 5.8 + 0.1, P<0.05, one-way
ANOVA with Bonferroni post-test). Responses to PE in
arteries from CAL rats treated with 1400W or MnTMPyP
were not significantly different from those in sham-operated
arteries (Figure 3a). Responses to PE in endothelium-intact
arteries from sham-operated rats were unaffected by 1400W
(10"6 M) or MnTMPyP (1(T4 M) (Figure 3b).
In a similar fashion to those arteries treated with 1400W
(10~6 M) or MnTMPyP (10~4 M) alone, combined treatment
with both drugs resulted in significant reduction in respon¬
siveness of arteries from CAL rats to PE (P<0.01 two-way
ANOVA, Figure 3a). pD2 values were significantly decreased
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Figure 2 Cumulative concentration response curves (CRC) showing
tontractile responses to phenylephrine (PE; 1 x 10-9 to 3 x 10~5 m)
n (a) endothelium-intact (n = 8) and (b) endothelium-denuded (n = 6)
>mall mesenteric arteries from coronary artery ligation (CAL) and
;ham-operated rats 6 weeks post-surgery. Values are given as
neans + s.e.mean. *P<0.01 as compared with CRCs in sham-
3perated arteries (two-way ANOVA).
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Figure 3 Effect of 1400W (10~6 m) and MnTMPyP (10~4 m), on
their own or together on cumulative concentration response curves
(CRC) to phenylephrine (PE; 1 x 10"9 to 3x10~5m) in endothe¬
lium-intact small mesenteric arteries from (a) coronary artery ligation
(CAL; n = 8) and (b) sham-operated (n = 8) rats 6 weeks post-surgery.
Values are given as means + s.e.mean. *P<0.01 for CRCs in
untreated arteries compared with CRCs in 1400W, MnTMPyP
treated arteries from CAL rats (two-way ANOVA).
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untreated arteries (untreated, 6.3 ±0.1; 1400W +MnTMPyP,
5.7 + 0.2, P<0.01, one-way ANOVA with Bonferroni post-
test). However, no differences were found when compared with
responses in arteries treated with 1400W alone. In arteries
from sham-operated rats, combined treatment had no
significant effect on responses to PE (Figure 3b).
Effect of L-arginine on vascular responsiveness
Treatment of endothelium-denuded arteries from CAL rats
with the NOS substrate, L-arginine (1CD3 m) for 30 min shifted
PE CRCs to the right with respect to untreated arteries
(P<0.05, two-way ANOVA, Figure 4a), indicating that in the
presence of L-arginine arteries are less responsive to PE. pD2








































Figure 4 Effect of L-arginine (10~3 M) on cumulative concentration
response curves (CRC) to phenylephrine (PE; 1 x 10~9 to 3 x 10~5 M)
in endothelium-denuded small mesenteric arteries from (a) coronary
artery ligation (CAL; n = 6) and (b) sham-operated (n = 6) rats 6
weeks post-surgery. Values are given as means±s.e.mean. *P<0.01
as compared with CRCs in untreated arteries (two-way ANOVA).
not reached. L-arginine had no significant effect on PE
responses in arteries from sham-operated rats (Figure 4b).
Endothelium-dependent relaxations: effect of superoxide
quenching
Following induction of PE-induced tone (CAL, 49.1+2.3%;
sham-operated, 52.6 + 2.4% of maximal PE constriction) in
endothelium-intact arteries from CAL and sham-operated
rats, cumulative additions of ACh (1 x 10_1° to 3 x 10~6 m)
resulted in concentration-dependent relaxations. pD2 values for
cumulative CRCs in arteries from CAL rats were significantly
lower than those in sham-operated rats, indicating that
endothelium-dependent relaxations were blunted in small
mesenteric arteries from CAL rats (CAL, 7.4+ 0.1; sham-
operated, 7.9 + 0.2, P<0.05, two-tailed unpaired /-test).
Maximum relaxations to ACh were achieved in most arteries
at a concentration of 3 x 10-6 M and no significant differences
were found between CAL and sham-operated groups (CAL,
104.1+3.5%; sham-operated, 102.4+ 2.4%).
In the presence of MnTMPyP (10~4 m), relaxations to ACh
in arteries from CAL rats were significantly enhanced, with a
significant increase in pD2 values (untreated 7.4 + 0.1;
MnTMPyP, 7.9 + 0.2, P<0.05, two-tailed paired /-test).
Treatment of arteries from sham-operated rats with
MnTMPyP had no significant effect on ACh CRCs.
Discussion
The salient finding of this study is that iNOS is expressed in
mesenteric arteries from rats with CHF. However, despite the
presence of iNOS, endothelium-intact small mesenteric arteries
from CHF rats were found to be more responsive to
phenylephrine that those from sham-operated rats. Hyper-
esponsiveness of endothelium-intact arteries from CAL rats
was reversed by the iNOS inhibitor, 1400W and by the SOD-
mimetic, MnTMPyP. Furthermore, supplementation of en¬
dothelium-denuded arteries from CAL rats with the NOS
substrate resulted in a significant reduction in responsiveness
to phenylephrine. These results suggest that substrate deficient,
iNOS-derived superoxide may be responsible for the vascular
dysfunction associated with this model of CHF.
Increased cytokine levels may serve as a stimulus for iNOS
expression in CHF (Katz et al., 1994). Indeed, iNOS is
expressed in the myocardium (Fukuchi et al., 1998; Vejlstrup et
al., 1998) and skeletal muscle (Adams et al., 1997) in clinical
CHF. In the present study, iNOS was expressed in endothelial
cells, VSM cells and in the adventitia in small mesenteric
arteries from rats with CHF, but not in arteries from sham-
operated rats. This is the first study to demonstrate iNOS
expression in the peripheral vasculature in experimental CHF.
These findings are in contrast to a recent study, which failed to
detect iNOS in thoracic aortae from rats 8 weeks after
myocardial infarction (Bauersachs et al., 1999). Differences in
vessel type may explain this discrepancy. Moreover, rats used
in the present study had larger infarcts than those used in the
aforementioned study, perhaps suggesting that the severity of
the model influences iNOS expression.
During endotoxemia, expression of iNOS in the vascula¬
ture, and the subsequent production of NO, plays an
important role in the vascular hyporeactivity to vasoconstric¬
tors (for review see Thiemermann, 1994). Therefore, in this
model of CHF, increased production of NO from iNOS would
be expected to reduce vascular responsiveness to phenylephr¬
ine. Somewhat paradoxically, endothelium-intact small me-
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senteric arteries from CHF rats were more responsive to
phenylephrine than arteries from sham-operated rats. There
was no significant difference between responses to phenylephr¬
ine in endothelium-denuded arteries from CHF or sham-
operated rats, demonstrating that this vascular dysfunction is
dependent on the presence of the endothelium. Basal NO from
eNOS serves to dampen the effects of vasoconstrictors. One
could speculate, therefore, that decreased basal release of NO
is responsible for the hyperesponsiveness to phenylephrine.
Teerlink et al. (1994) showed increased adrenergic responsive¬
ness of thoracic aortic rings from rats with CHF, which was
dependent on the presence of the endothelium. Furthermore,
their study demonstrated that impaired basal release of NO
from the endothelium was responsible for this vascular
dysfunction.
To investigate the role that iNOS plays in modulating
vascular function in this model of CHF we used a novel
selective iNOS inhibitor, 1400W, and the NOS substrate, L-
arginine. 1400W is an irreversible inhibitor of iNOS that is at
least 1000 fold more selective for iNOS than eNOS in rats
(Garvey et al., 1997). Furthermore, 1400W is effective in
abolishing iNOS activity and attenuating hypotension asso¬
ciated with endotoxemia in rats (Wray et al., 1998). In the
present study we show, somewhat surprisingly, that inhibition
of iNOS with 1400W reversed, rather than potentiated, the
hyperesponsiveness of small mesenteric arteries from CHF
rats. These results suggest that induction of iNOS does not
result in the expected increase in NO generation. Instead,
expression of the enzyme appears to be a major contributory
factor in the hyperesponsive nature of endothelium-intact
CHF arteries. In experimental endotoxemia addition of the
NOS substrate, L-arginine, to isolated blood vessels increases
NO production from iNOS and potentiates hyporesponsive-
ness to vasoconstrictors (Julou-Schaeffer et al., 1990). Here we
show that supplementation of endothelium-denuded small
mesenteric arteries from CHF rats, but not sham-operated
rats, with a supramaximal concentration of L-arginine results
in a reduction in responsiveness to phenylephrine, presumably
through production of NO from iNOS. These results suggest
that although iNOS is present in small mesenteric arteries from
CHF rats, it is unable to synthesize NO because there is
insufficient substrate. Recent studies have shown that iNOS,
when deficient in its substrate/cofactors, produces superoxide
rather than NO (Xia & Zweier, 1997; Xia et al., 1998).
Therefore, in this model ofCHF, it is possible that a deficiency
in L-arginine will not only prevent iNOS from generating NO
but will also result in the enzyme producing superoxide.
Increased scavenging of NO by superoxide would result in a
reduction in the bioavailability of endothelium-derived NO,
which may explain the marked increase in responsiveness of
endothelium-intact arteries from CHF rats to phenylephrine.
To determine if increased superoxide production plays a
role in modulating vascular function in this model of CHF, we
used the cell permeable metalloporphyrin SOD mimetic,
MnTMPyP. In a similar fashion to 1400W, MnTMPyP
reversed the hyperesponsiveness of endothelium-intact small
mesenteric arteries from CHF rats. This implies that
mesenteric arteries from CHF rats are indeed generating
superoxide, which is responsible for the marked elevation in
responsiveness to phenylephrine. Numerous studies have
demonstrated increased superoxide production in CHF
(McMurray et al., 1990; Belch et al., 1991; Bauersachs et al.,
1999). NADH/NADPH oxidases (Bauersachs et al., 1999),
autoxidation of catecholamines, increased arachidonate
metabolism and inflammatory cytokines have all been
suggested as possible sources of superoxide in CHF (for
review see Givertz & Colucci, 1998). In the present study,
however, both inhibition of iNOS and superoxide quenching
reverses the hyperesponsiveness to phenylephrine suggesting
that iNOS is the source of superoxide in this model of CHF.
Indeed, there were no significant differences between responses
to phenylephrine in arteries treated with 1400W alone and
those treated with both 1400W and MnTMPyP.
Although MnTMPyP has been shown to protect SOD-null
E. coll against oxidant stress (Faulkner et al., 1994), recent
studies provide evidence that MnTMPyP may actually
scavenge NO itself and directly inhibit the activity of eNOS
(Pfeiffer et al., 1998; Mackenzie et al., 1999). Mackenzie et al.
demonstrated an augmentation of phenylephrine-induced
constrictions by MnTMPyP in isolated rat aortic rings that is
reversed by inhibition of eNOS. However, in the present study
MnTMPyP reduced responsiveness to phenylephrine in
endothelium-intact small mesenteric arteries from CHF rats
and had no significant effect on responses in arteries from
sham-operated rats. We are convinced, therefore, that the
effects of MnTMPyP in the present study are a direct
consequence of its SOD-mimetic properties.
This study presents an interesting new facet to the impact of
iNOS in CHF. In this model of CHF, instead of generating
large quantities of NO, iNOS appears to be generating
superoxide, perhaps because of a deficiency in its substrate,
L-arginine. Moreover, this increase in superoxide production is
responsible for the hyperesponsive nature of endothelium-
intact small mesenteric arteries from rats with CHF. The
precise mechanism and time course by which superoxide
results in arteries being hyperesponsive is unclear from these
experiments alone. However, the fact that the hypereactivity is
dependent on the endothelium suggests that increased
scavenging of basal, eNOS-derived NO by superoxide is
responsible. In addition to impaired basal release of NO, we
also show that ACh-mediated endothelium-dependent relaxa¬
tions are impaired in arteries from rats with CHF. Moreover,
relaxations to ACh were improved in the presence of
MnTMPyP.
In summary, the present study suggests that substrate
deficient, iNOS-derived superoxide is responsible for increased
responsiveness of endothelium-intact mesenteric arteries,
possibly as a result of impaired release of endothelial-derived
NO. While it remains to be established if this study mirrors
clinical CHF, our findings may represent an important
mechanism for the endothelial dysfunction and raised
peripheral resistance associated with CHF.
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